

Ranjana H. Advani, M.D.

Stanford University Medical Center

Stanford Cancer Institute
875 Blake Wilbur Drive, CC-2338
Stanford, CA94305-5821

Telephone: 650-725-6456

Fax: 650-725-8222

Email: radvani@stanford.edu

Affiliated Institution:

Stanford Hospital and Clinics
300 Pasteur Dr.
Stanford, CA 94305

Professional Licensure: California Medical License / A44422

Specialization: Oncology

PROFESSIONAL / ACADEMIC APPOINTMENTS

12/1/1996-3/31/2004	Clinical Instructor, Staff Physician Oncology, Stanford University Medical Center
4/1/2004-2/28/2007	Assistant Professor of Medicine Oncology, Stanford University Medical Center
3/1/2007-10/31/2011	Associate Professor of Medicine Oncology, Stanford University Medical Center
11/1/2011-Present	Professor of Medicine Oncology, Stanford University Medical Center
12/21/2012-Present	Saul Rosenberg Professor of Lymphoma

TRAINING

1981-1985	Internal Medicine Residency: TN Medical College and Nair Hospital, Bombay University, Bombay, India
1985-1986	Research Assistant, Hematology: Stanford University Medical Center
1986-1987	Internship/Residency in Internal Medicine: Santa Clara Valley Medical Center and Stanford University Medical Center
1987-1991	Fellowship in Hematology: Stanford University Medical Center

- 1991-1993 Visiting Physician: Division of Oncology/Hematology, University of Tübingen Medical Center, Tübingen, Germany
- 1994-1996 Fellowship in Oncology: Stanford University Medical Center

EDUCATION

- 1973-1976 Premed (Intermediate Science): Bombay University, Bombay, India
- 1976-1981 Bachelor of Medicine and Surgery (M.B.B.S): TN Medical College, Bombay University, India
- 1981-1984 Doctor of Medicine (M.D.): TN Medical College, Bombay University, India

BOARD CERTIFICATION

- 1985 Board Certification in Internal Medicine (Bombay University, India)
- 1991 Board Certification in Internal Medicine, American Board of Internal Medicine (ABIM)
- 1994 Board Certification in Hematology (ABIM)
- 1995 Board Certification in Oncology (ABIM)
- 2001 Recertification in Internal Medicine (ABIM)
- 2009 Recertification in Oncology (ABIM)

PROFESSIONAL SOCIETIES

- 1994-1995 American Association for Cancer Research (AACR)
- 1992-present American Society of Hematology (ASH)
- 1995-present American Society of Clinical Oncology (ASCO)
- 2009 American Association for Cancer Research (AACR)
- 2009-present International Society for Cutaneous Lymphoma (ISCL)

PROFESSIONAL APPOINTMENTS

- 2000-2003 ASCO Bylaws Committee
- 2001-2007 American Cancer Society (ACS) Board: Santa Clara Unit
- 2002-present Eastern Cooperative Oncology Group (ECOG): Lymphoma Core Committee
- 2004-present National Comprehensive Cancer Network (NCCN) Guidelines Committee: Hodgkin Lymphoma (HL)
- 2004-present NCCN Guidelines Committee: Non-Hodgkin's Lymphoma (NHL)
- 2005-2008 ASCO International Affairs Committee
- 2008-present American College of Radiology Appropriateness (ACR) Criteria: ASCO Representative to HL and NHL Subcommittee

2009-2010	United States Cutaneous Lymphoma Consortium: Education Committee
2010-2013	ASH Committee on Educational Affairs
2010-present	Lymphoma Research Foundation (LRF): Scientific Advisory Board (SAB)
2010-present	National Cancer Institute (NCI) Lymphoma Steering Committee: T-Cell Working Group
2011-2012	Peripheral T-Cell Lymphoma (PTCL) Advisory Board: Cutaneous Lymphoma Foundation
2011-2014	ASCO Cancer Education Committee
2011-present	Lunenburg Lymphoma Biomarker Consortium (LLBC) member
2011-present	LRF Mantle Cell Lymphoma (MCL) Research Initiative
2013-present	NCCN Hodgkin Lymphoma Guidelines Committee (Vice-Chair)
2013-present	College of American Pathologists Biomarker Review Panel (ASCO representative)
2013-present	NCCN International Program Steering Committee
2014-2016	World Health Organization (WHO) Classification of Haematopoietic and Lymphoid Tumors Clinical Advisory Committee: U.S. Clinical Co-Chair
2014-2017	American Joint Committee on Cancer (AJCC) Hematologic Malignancies Expert Panel Member, AJCC Cancer Staging System, 8th Edition
2014-2016	Member, T-Cell Lymphoma subcommittee, Clinical Trials Planning Meeting (CTPM) held by the NCI Lymphoma Steering Committee (LYSC)
2014-2017	ASCO Scientific Program Committee on Lymphoma and Plasma Cell Disorders Track
2014-2017	Co-Chair, National Cancer Institute, Lymphoma Steering Committee (LYSC)
2015-present	Co-Chair, NCCN Hematologic Malignancies Congress
2016-2017	ASCO Scientific Program Committee Track Leader for Lymphoma and Chronic lymphocytic leukemia.
2016-present	Scientific Committee: International Symposium on Hodgkin Lymphoma (ISHL) Cologne, Germany
2017-present	NCCN Framework for Resource Stratification of the NCCN Guidelines for NHL
2019-present	NCCN Harmonized Guidelines Committee for Sub-Saharan Africa: Representative for HL
2021-present	FDA Oncology Drug Advisory Committee (ODAC)

EDITORIAL BOARD

2013-present	<i>Blood</i>
2013-2019	<i>Journal of Clinical Oncology</i>

HOSPITAL AND UNIVERSITY COMMITTEES

1999-2003	Staff of the Myelodysplastic Syndrome (MDS) center at Stanford
2002-2009	Stanford General Clinical Research Center (GCRC) Advisory Committee
2003-2004	Stanford Clinical Fellows and Resident Postdoctoral Committee

2006-2010	Stanford Hospital EPIC Team Coordinator: Lymphoma
2007-2008	Stanford Cancer Center Survivorship Program: Co-chair
2008-2009	Stanford University School of Medicine: Faculty Fellow
2008-2009	Oncology Fellowship Associate Program Director
2009	Department of Medicine Compensation Committee, Stanford University Medical Center (SUMC)
2010	Radiology Chair Search Committee, SUMC
2010-present	Clinical Care Program (CCP), Physician Leader for Lymphoma, SUMC
2013	VA Oncology Chief Search Committee, SUMC
2013	Phase I Trialist Search Committee, Division of Oncology, SUMC
2014	Pathology Chair Search Committee, SUMC
2014-2016	Chair, Lymphoma Search Committee, Division of Oncology, SUMC
2018	Radiation Therapy Search Committee
2020	Neuro Oncology Chair Search Committee

AWARDS

2004	Kathryn McCormick Fund for Women: Travel Award
2006	Oncology Division Teaching Award
2006	Orsak Foundation Grant
2007	Stanford Cancer Center Translational Research Seed Grant
2008	Stanford Cancer Center Translational Research Seed Grant
2009	Indian Women Empowered Annual Award for Contributions in Medicine
2011	Cancer League Award
2013	Endowed Chair, Saul A Rosenberg Professor of Lymphoma
2015	Indo-American Cancer Association (IACA) Outstanding Achievement Award in Hematology-Oncology
2018	Peter S. Bing Humanitarian Award

OTHER RECOGNITION

2009-present	Best Doctors in America
2014-present	America's Top Doctors (Castle Connolly)
2015-present	San Francisco Magazine, Top Doctors
2019	Castle Connolly Exceptional Women in Medicine

INVITED PRESENTATIONS / CME TEACHING ACTIVITIES (since 2015):

INTERNATIONAL:

02/15	<i>Innovations in the management of HL ASH2014 Highlights.</i> Apollo Cancer Conclave. Hyderabad, India
02/15	<i>ASH 2014: Highlights on NHL.</i> Apollo Cancer Conclave. Hyderabad, India
02/15	<i>HL: PET Scans and Other Treatment Strategies.</i> 2015 Highlights of ASH in Asia. Bangkok, Thailand.

- 03/15 *Is there a specific treatment for AITL?* 1st Postgraduate Lymphoma Conference. Rome, Italy.
- 04/15 *Examining Targeted Therapy in HL and NHL: A Case-Based Discussion.* CME conference in conjunction with 2015 ASH. Cartagena, Columbia.
- 04/15 *Standard Front-Line Treatment and the Ongoing Potential New Alternatives: CHOP vs A+CHP.* T-Cell Lymphomas Conference. Bologna, Italy.
- 04/15 *NK/T Cell Lymphoma: NCCN Guidelines.* T-Cell Lymphomas Conference. Bologna, Italy.
- 06/15 *The Standard Therapy for HL.* Session Chair. 2nd European Society of Oncology (ESO) Course: Leukemia and Lymphoma, Certificate of Competance in Lymphoma. Ascona, Switzerland.
- 06/15 *Management of NLPHL.* Chair, Educational Symposium on HL Session. 13th International Conference on Malignant Lymphoma (ICML). Lugano, Switzerland.
- 09/15 *Recent and Future Lymphoma Research at Stanford University.* 15th Lymphoma Summit. Tokyo, Japan.
- 09/15 *Treatment strategy and new drug development in PTCL.* 15th Lymphoma Summit. Tokyo, Japan.
- 09/15 *Optimizing Outcomes in Advanced HL.* 4th Annual Symposium, Hematopoietic Stem cell Therapy. Cologne, Germany.
- 12/15 *Management of Relapsed/Refractory HL: The Basics and What's New?* 17th International Workshop on Lymphoproliferative disorders. Naples, Italy
- 03/16 *How I Treat Peripheral T-Cell Lymphoma (PTCL).* Hematology Symposium, European Institute of Oncology, Milan, Italy.
- 05/16 *Current Standard Treatment of DLBCL.* MabThera National Conference, Fu Zhou, China.
- 05/16 *Optimizing Treatment of DLBCL.* MabThera National Conference, Fu Zhou, China.
- 10/16 *Interactive Case Discussions.* 10th ISHL. Cologne, Germany.
- 11/16 *Immunotherapy in Lymphoma.* 57th Annual Conference of the Indian Society of Hematology & Blood Transfusion. Jaipur, India.
- 11/16 *How Do I Treat the Patient with Advanced Stage HL?* 57th Annual Conference of the Indian Society of Hematology & Blood Transfusion. Jaipur, India.
- 02/17 *Clinical Lymphoma Highlights of 2016 ASH Annual Meeting.* Apollo Cancer Conclave & Cancer CI 2017. Hyderabad, India.
- 02/17 *Lymphoma Case Presentations, Audience Response, and Panel Discussion.* Apollo Cancer Conclave & Cancer CI 2017. Hyderabad, India.
- 03/17 *How I Treat Advanced Stage HL.* 7th Emirates Haematology Conference, Dubai, UAE.
- 03/17 *Interactive Case Presentations in Pregnancy & HL and Early Stage HL.* 7th Emirates Haematology Conference, Dubai, UAE
- 03/17 *News on T-Cell Lymphoma Drugs.* 3rd Postgraduate Lymphoma Conference, Rome, Italy

- 04/17 *New Drugs in Refractory/Relapse HL.* ASH day at AMEH, Guanajuato, Mexico
- 05/17 *Role of PET in HL.* Quebec Annual Oncology and Hematology Meeting, Quebec, Canada
- 05/17 *Follicular Lymphoma: New Agents.* Indolent Lymphomas Workshop, Bologna, Italy
- 06/17 *Clinical Case Discussion: HL.* 14th ICML. Lugano, Switzerland.
- 10/17 *WHO 2016 Classification of Lymphomas – Clinician’s Perspective (B-NHL).* 1st Annual Update On Lymphomas At The Tata Memorial Centre. Mumbai, India
- 10/17 *Management of Classical HL: Discussing the Best Regimen and Response Guided Therapy.* 1st Annual Update On Lymphomas At The Tata Memorial Centre. Mumbai, India
- 02/18 *Key Updates From ASH 2017.* Singapore General Hospital. Singapore.
- 04/18 *AITL. T-Cell Project Investigator Meeting.* Montevideo, Uruguay.
- 05/18 *New Potential Alternatives In PTCL Front-Line.* T-Cell Lymphomas. Bologna, Italy.
- 05/18 *Immunotherapy In Lymphoma.* 22nd Annual Meeting of Japanese Association for Molecular Target Therapy of Cancer. Tokyo, Japan.
- 05/18 *PTCL: What Is New? Anti Cancer Treatment Conference.* Tokyo, Japan.
- 05/18 *Optimizing Outcomes in PTCL Treatment.* T-Cell Lymphoma Seminar in conjunction with the 22nd Annual Meeting of Japanese Association for Molecular Target Therapy of Cancer. Tokyo, Japan.
- 06/18 *Understanding Biology To Help Guide Treatment Options In PTCL.* European Society of Hematology 23rd Congress. Stockholm, Sweden.
- 10/18 *Novel Agents in First Line Salvage.* 11th International Symposium on HL. Cologne, Germany.
- 11/18 *How Do I Treat DLBCL?* Indian Society of Medical & Paediatric Oncology (ISMPOCON) 2018. Jaipur, India.
- 11/18 *Early Stage HL – Controversies in Treatment.* Indian Society of Medical & Paediatric Oncology (ISMPOCON) 2018. Jaipur, India.
- 01/19 *Update of relapsed/refractory Hodgkin’s lymphoma treatment.* Takeda OncoSummit 2019. Seoul, South Korea.
- 01/19 *Optimal treatment for Relapsed Primary Mediastinal Large B-Cell Lymphoma.* Takeda OncoSummit 2019. Seoul, South Korea.
- 02/19 *What’s new in NHL treatment.* Integra Cancer Institute. Guatemala City, Guatemala.
- 02/19 *Recent Advances in the Treatment of HL: Highlights from ASH 2018.* Hematology Update Year In Review. New Delhi, India.
- 02/19 *NHL: Update from ASH 2018.* Hematology Update Year In Review. New Delhi, India.
- 03/19 *Key Lymphoma Insights from ASH 2018.* Lymphoma Teaching Session, Singapore.
- 03/19 *Where do BV + AVD Fit Into The HL Treatment Landscape.* Takeda Lymphoma Teaching Session and HL Advisory Board, Singapore.

- 03/19 *How I Treat Nodular Lymphocyte Predominant HL.* 9th Emirates Haematology Conference (EHC 2019). Dubai, United Arab Emirates.
- 03/19 *Management of Relapsed HL In The Era of Checkpoint Inhibitors.* 9th Emirates Haematology Conference (EHC 2019). Dubai, United Arab Emirates.
- 03/19 *How I Treat Low Grade B-Cell Lymphoma.* 9th Emirates Haematology Conference (EHC 2019). Dubai, United Arab Emirates.
- 05/19 *Peripheral T-cell Lymphoma.* Aggressive Lymphoma Workshop. Bologna, Italy.
- 05/19 *Hu5F9-G4 and Rituximab.* Aggressive Lymphoma Workshop. Bologna, Italy.
- 05/19 *Polatuzumab Vedotin.* Aggressive Lymphoma Workshop. Bologna, Italy.
- 06/19 *Clinical Implications Of The 2016 WHO Classification.* ESO Lymphoma Course: Leukemia and Lymphoma, Certificate of Competance in Lymphoma. Lugano, Switzerland.
- 07/19 *Novel approaches in Aggressive B cell Malignancy.* 2019 Post ICML Meeting & Guangzhou Lymphoma Summit Forum. Guangzhou, China.
- 08/19 *Update of ICML 2019 Lugano Lymphoma Update.* Bombay Hematology Society. Bombay, India.
- 10/19 *Targeting CD 47; A Macrophage Check Point in Lymphoma.* 5th Lymphoma Study Association Meeting. Montpellier, France.
- 10/19 *The First-In-Class Anti-CD47 Antibody Hu5F9-G4 With Rituximab In Relapsed/Refractory Lymphoma.* XVII Italian Network For Tumor Bio-Immunotherapy. Verona, Italy.
- 10/19 *Targeting CD 47 A Macrophage Check Point in Lymphoma.* Annual Meeting of the German Austrian & Swiss Associations For Hematology. Berlin, Germany.
- 11/19 *The Double Hit Story And Is It Really Of Clinical Importance.* Lymphoma Forum of Ireland. Dublin, Ireland.
- 02/20 *Initial Therapy For Advanced Stage Hodgkin Lymphoma.* Rajiv Gandhi Cancer Institute 19th Annual International Conference (RGCON2020). New Delhi, India.
- 02/20 *Double Hit Lymphoma- What Is It & How Should Be Treated.* Rajiv Gandhi Cancer Institute 19th Annual International Conference (RGCON2020). New Delhi, India.
- 02/20 *Practice Changing Innovations In Lymphoma In Last Two Years.* 5th Apollo Cancer Conclave and 8th Biennial Cancer Cl. Hyderabad, India.
- 8/20 *Incorporating Recent Data in HL into Clinical Practice.* Onco Virtual Summit 2020.
- 10/20 *Lymphoma Case Discussions.* 4th Annual International Precision Oncology & IBCJaipur Conference. Virtual.
- 11/20 *What's new in HL in 2020.* 61st Hematacon. Virtual meeting of the Indian Society of Hematology and Blood Transfusion (ISHBT).
- 11/20 *Targeting the microenvironment and beyond in HL.* European Society of Medical Oncology (ESMO) Asia Virtual Congress 2020.

NATIONAL:

- 01/15 *NHL (High Grade/Aggressive)*. LRF Post-ASH 2014 Meeting. San Francisco, CA.
- 04/15 *Oncology Exchange: Emerging Strategies in Newly Diagnosed and Relapsed/Refractory HL*. Potomac Center for Medical Education CME Certified Symposium. New Orleans, LA.
- 05/15 *2014 ASH Clinical Highlights*. Renown Regional Medical Center. Reno, NV.
- 05/15 *“Chimeric Antigen Receptor T-Cell Therapy for B Cell Malignancies”*. Co-Chair, Clinical Science Session. ASCO. Chicago, IL.
- 09/15 *Case Study: Advanced Stage LPHL*. Society of Hematologic Oncology (SOHO) Annual Meeting. Houston, TX.
- 10/15 *Double-hit/T-Cell/Mantle Cell Lymphoma*. Co-Chair, Case Discussions. 10th NCCN Annual Hematologic Malignancies Congress. San Francisco, CA.
- 10/15 *PET-Guided Treatment Approach for Advanced Stage Classical HL*. Co-Chair. 10th NCCN Annual Hematologic Malignancies Congress. San Francisco, CA.
- 03/16 *2015 ASH Clinical Highlights*. Renown Regional Medical Center, Reno, NV.
- 04/16 *HL: A Walk Down Memory Lane*. Visiting Professor Program. University of Chicago, Chicago, IL.
- 05/16 *Novel Bispecific Antibodies and ADCs*. Memorial Sloan Kettering Symposium on Lymphoma. New York, NY.
- 06/16 *Education Session, PET-Directed Strategies in Lymphoma*. ASCO Annual Meeting. Chicago, IL.
- 06/16 *Virtual Consult: Clinical Investigator Perspectives on Current Cases & Emerging Research in the Management of Lymphoma & Multiple Myeloma*. Research to Practice Satellite Symposium. Chicago, IL.
- 07/16 *Case Study — Advanced Stage, High Risk BEACOPP or ABVD, Aggressive vs Less Aggressive Treatment*. Pan Pacific Lymphoma Conference. Koloa, HI.
- 09/16 *How I Treat Follicular Lymphoma*. 2016 ASH Meeting on Hematologic Malignancies. Chicago, IL.
- 09/16 *Patient Case Studies and Panel Discussion: Nasal NK/T-cell*. NCCN Annual Congress. New York, NY.
- 09/16 *Early-stage Classical HL: Can We Eliminate Radiation Therapy for Most Patients?* NCCN Annual Congress. New York, NY.
- 09/16 *Scientific Rationale for Immunotherapy in Lymphoma: What are the current and emerging clinical applications?* 1st Annual Symposium on Integrating Immune Therapies & Targeted Therapies. San Francisco, CA.
- 09/16 *Debate: Novel Immunotherapeutic Approaches vs Allogeneic Transplant in DLBCL and HL*. 1st Annual Symposium on Integrating Immune Therapies & Targeted Therapies. San Francisco, CA.
- 10/16 *How Should We Approach Primary Mediastinal DLBCL?* Lymphoma and Myeloma 2016. New York, NY.

- 12/16 *Capitalizing on Lessons Learned to Date: Moving Toward Personalized Lymphoma Therapy for Relapsed Refractory Disease.* Healthy Days Grand Rounds. Las Vegas, NV.
- 01/17 *HL. 2017 Highlights of 59th Annual ASH in North America.* Atlanta, GA.
- 01/17 *HL. 2017 Highlights of 59th Annual ASH in North America.* Chicago, IL.
- 07/17 *Polatuzumab Vedotin in B-cell NHL. 2017 Annual Lymphoma Non-Hodgkin & Hodgkin Expert Forum.* Dallas, TX.
- 08/17 *Management of Follicular Lymphoma.* 5th International Conference on Advances in Hematology and Oncology. Coeur d'Alene, ID.
- 08/17 *Management of DLBCL.* 5th International Conference on Advances in Hematology and Oncology. Coeur d'Alene, ID.
- 10/17 *New Options for the Management of HL.* 2017 NCCN 12th Hematologic Malignancies Conference. San Francisco, CA.
- 12/17 *Incorporating New Therapeutic Strategies in the Treatment of Hodgkin Lymphoma (HL).* Satellite Symposium Clinical Care Options ASH 2017, Atlanta, GA.
- 03/18 *Follicular Lymphoma: Picking An Induction Regimen and Who Needs Maintenance Therapy?* 22nd International Congress on Hematologic Malignancies. Miami, FL
- 03/18 *"HL" A Walk Down Memory Lane.* Mayo Clinic Visiting Professor. Rochester, MN.
- 04/18 *"HL" A Walk Down Memory Lane.* Northwestern University Grand Rounds. Chicago, IL.
- 05/18 *HL: What's New In Frontline Management.* 15th International Ultmann Chicago Lymphoma Symposium (IUCLS 2018). Chicago, IL.
- 06/18 *New Treatment Algorithms in HL: Too Much or Too Little?* Education Session ASCO Annual Meeting 2018. Chicago, IL.
- 07/18 *HL Upfront Therapy in Germany vs the US.* Pan Pacific Lymphoma Conference. Maui, HI.
- 08/18 *Follicular Lymphoma: New Updates.* 6th International Conference on Advances In Hematology and Oncology. Coeur d'Alene, ID.
- 09/18 *Updates To The Front-Line Therapy In HL.* 2018 NCCN 13th Hematologic Malignancies Conference. New York, NY.
- 12/18 *HL: Beyond ABVD for Everyone?* 60th ASH Annual Meeting. San Diego, CA.
- 02/19 *Hodgkin Lymphoma.* Hematological Malignancies Demystified 2019. Houston, TX.
- 06/19 *Updates in Lymphoma.* 7th International Conference on Advances in Hematology & Oncology (ICAO19). Seattle, WA.
- 09/19 *Indications of Brentuximab Vedotin And Stem Cell Transplantation In The Management of T-Cell Lymphomas.* 17th International Workshop on Non-Hodgkin Lymphoma (iwNHL2019). Cambridge, MA.
- 09/19 *Targeting the Macrophage Checkpoint in NHL.* 17th International Workshop on Non-Hodgkin Lymphoma (iwNHL2019). Cambridge, MA.
- 09/19 *Updates In Treatment Strategies For Hodgkin Lymphoma.* NCCN 2019 Annual Congress: Hematologic Malignancies. San Francisco, CA.

- 12/19 *Emerging Paradigms To Address Unmet Needs in Relapsed/Refractory DLBCL.* Orlando, FL.06/20 Advances in Lymphoma: Data and Clinical Context From 2020 Summer Meetings. Virtual Medscape CME meeting: Virtual
- 10/20 *Controversies in the Management of Early Stage HL.* NCCN 2020 Annual Congress: Hematologic Malignancies. Virtual.
- 12/20 *Bridging unmet needs with emerging data in relapsed/refractory DLBCL to improve patient outcomes.* ASH 2020 Satellite Symposium PERs Medical Crossfire

REGIONAL:

- 01/15 *Words of Wisdom: Advantages and Challenges.* Cutaneous Lymphoma International Consortium (CLIC) Investigator Meeting. Stanford, CA
- 02/15 *2014 ASH Clinical Highlights: Stanford Hematology Review of the 56th annual ASH meeting*
- 04/15 *Highlights from ASH 2014.* Dominican Hospital, Santa Cruz, CA.
- 01/16 *2015 ASH Clinical Lymphoma Highlights: Stanford Hematology Review of the 57th annual ASH meeting.* Half Moon Bay, CA.
- 03/16 *18th Multi-Disciplinary Approach to Cancer Treatment, Lymphoma Panel Chairperson.* Silverado, CA.
- 02/17 *Hodgkin and Non-Hodgkin Lymphomas.* Stanford's Review of the 58th Annual ASH meeting. Half Moon Bay, CA.
- 02/18 *Hodgkin and Non-Hodgkin Lymphomas.* Stanford's Review of the 59th Annual ASH Meeting. Half Moon Bay, CA.
- 03/18 *ASH 2017 – Clinical Highlights for Hodgkins & Non-Hodgkin Lymphoma.* Dominican Hospital. Santa Cruz, CA.
- 02/19 *Hodgkin and Non-Hodgkin Lymphomas.* Stanford's Review of the 60th Annual ASH Meeting. Half Moon Bay, CA.
- 03/19 *19th Multidisciplinary Management of Cancers: A Case-Based Approach (MMC2019).* Lymphoma Panel Chairperson. Silverado, CA.
- 08/19 *ASH 2018 Clinical Highlights for Hodgkin's & Non-Hodgkin Lymphoma.* Dominican Hospital. Santa Cruz, CA.
- 08/19 *Real-World Case Discussions – Lymphoma.* 3rd Annual Federal Oncology Seminar Series. Palo Alto, CA.
- 08/19 *Supportive Care and Survivorship.* 3rd Annual Federal Oncology Seminar Series. Palo Alto, CA.
- 02/20 *Hodgkin and Non-Hodgkin Lymphomas.* Stanford's Review of the 61st Annual ASH Meeting. Half Moon Bay, CA.
- 6/20 *20th Multidisciplinary Management of Cancers: A Case-Based Approach (MMC 2020).* Lymphoma Panel. Virtual.
- 10/20 *Clinical Highlights for Hodgkin's & Non-Hodgkin Lymphoma. Review of the 61st Annual ASH Meeting.* Dominican Hospital. Santa Cruz, CA. Virtual.

11/20 *Non-Hodgkin Lymphoma*. 4th Annual Oncology Federal Workshop Series. Virtual.

STANFORD:

01/15 *ASH 2014 Clinical Lymphoma Highlights*. Cancer Education Series. Stanford Cancer Center.

08/15 *ASCO 2015 Lymphoma Update*. Cancer Education Series, Stanford Cancer Center.

01/16 *ASH 2015 Clinical Lymphoma Highlights*. Cancer Education Series. Stanford Cancer Center.

08/16 *ASCO 2016 Lymphoma Update*. Cancer Education Series, Stanford Cancer Center.

01/17 *ASH 2017 Clinical Lymphoma Highlights*. Cancer Education Series. Stanford Cancer Center.

01/17 Osler Evening for Medical Students. Stanford University School of Medicine.

08/17 *ASCO 2017 Lymphoma Update*. Cancer Education Series, Stanford Cancer Center.

01/18 *ASH 2017: Lymphoma Highlights*. Cancer Education Series. Stanford Cancer Center.

07/18 *Fellow Education/Orientation: Hodgkin Lymphoma*. Stanford Cancer Center.

02/19 *ASH 2018 Lymphoma Highlights*. Cancer Education Series. Stanford Cancer Center.

07/19 *Fellow Education/Orientation: Hodgkin Lymphoma*. Stanford Cancer Center.

01/20 *ASH 2019 Lymphoma Highlights*. Cancer Education Series. Stanford Cancer Center.

07/20 *Fellow Education Boot Camp Series: Hodgkin Lymphoma*. Stanford Cancer Center.

INVITED WORKSHOPS/TASK FORCE (since 2015)

05/15 *"Advances in Treatment in WM"*. International WM Foundation. New York, NY.

05/15 13th International LLBC Workshop. Boston, MA.

06/15 Invited Attendee, Closed Workshop. *"Landscape of Emerging New Therapy in Lymphoma"*. 13th ICML Closed Workshop. Lugano, Switzerland.

06/15 Invited Attendee, Closed Workshop. *"Recent Insights and Future Directions (Moving Towards Biology Driven Treatments)"*. 13th ICML. Lugano, Switzerland.

10/15 13th International Workshop on NHL (IWNHL). Lake Maggiore, Italy.

04/16 14th International LLBC Workshop. Paris, France.

09/16 iwNHL 14th International Workshop on NHL 2016. San Diego, CA.

03/17 Steering Committee, International Workshop on WM. Jersey City, NJ.
 04/17 15th International LLBC Workshop, Paris, France
 05/17 *Follicular Lymphoma: New Agents*. Indolent Lymphomas Workshop.
 Bologna, Italy.
 06/17 Invited Attendee, Closed Workshop: Design of Clinical Trials: Biological and
 Clinical Endpoints in the Design of Future Clinical Trials. 14th ICML. Lugano,
 Switzerland.
 04/18 16th International LLBC Workshop. Stanford, CA.
 10/18 10th Annual International Workshop on WM (IWWM-10). New York, NY.
 04/19 17th International LLBC Workshop. Stantpoort,
 Netherlands.
 06/19 Invited Attendee, Closed Workshop: Bridging Liquid Biopsy Into
 Management Of Lymphoma Patients: Development of Frameworks For
 Clinical Research And Recommendations For Clinical Practice. 15th ICML.
 Lugano, Switzerland.
 09/19 17th International Workshop on NHL (IWNHL). Boston, MA.
 09/20 18th International Workshop on NHL (IWNHL). Virtual

CLINICAL RESEARCH

NATIONAL COOPERATIVE GROUP RESEARCH (ACTIVELY ENROLLING)

Opened 12/03/2014 *E4412: A Phase I Study with an Expansion Cohort of the Combination of
 Nivolumab and Brentuximab Vedotin in Patients with
 Relapsed/Refractory HL/NCT01896999*
 Role: Stanford PI
 Sponsor: ECOG, NIH/NCI

Opened 02/15/2020 *SWOG CANCER RESEARCH NETWORK: A Phase III, Randomized Study of
 Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD
 in Patients (age >= 12 Years) with Newly Diagnosed Advanced Stage
 Classical HL.*
 Role: Stanford PI
 Sponsor: SWOG/NCTN

INVESTIGATOR-INITIATED (ACTIVELY ENROLLING)

Opened 2007 *Identification and Validation of a Paraffin-Based Molecular Prognostic
 Model for DLBCL Patients Treated with R-CHOP: The Stanford Biomarkers
 Consortium Project*
 Role: Study PI / Single institution
 Sponsor: Stanford Cancer Center Seed Grant

Opened 02/02/2008 *International T cell NHL Study Group Project: Prospective Collection of Data in Patients with Peripheral T-Cell Lymphoma. (Massimo, PI) / NCT01142674*

Role: Stanford PI

Sponsor: Universita di Italy, Modena Reggio Emilia

Opened 07/14/2011 *Immune Evasion Mechanisms in HL (PI Schipp)*

Sponsor: Dana Farber Cancer Institute

Role: Stanford PI

Opened 01/01/2005 *Investigation of Oncogenes in Lymphoma*

Role: Stanford Co-Investigator, (Felsher, PI) / Single institution

Sponsor: Burroughs Wellcome Foundation; Department of Defense; NIH; Stanford University

INDUSTRY SPONSORED (ACTIVELY ENROLLING)

Opened 03/06/2015 *R1979-HM-1333: An Open-label, Multi-center Phase I Study to Investigate the Safety and Tolerability of REGN1979, an anti-CD20 x anti-CD3 bispecific monoclonal antibody, in Patients with CD20+ B-cell Malignancies previously treated with CD20 directed antibody therapy*

Role: Stanford PI / Multi-institutional

Sponsor: Regeneron

Opened 03/10/2017 *A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab in Patients with Relapsed/Refractory B-cell NHL*

Role: Stanford PI / Multi-institutional

Sponsor: Forty Seven, Inc.

Opened 07/01/2020 *ADCT-301-201: A Phase 2, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients with Relapsed or Refractory HL*

Role: Stanford PI

Sponsor: ADC Therapeutics

Opened 06/08/2020 *A Multi-Center, Open Label Phase 1/2 Study of CYY-0851, An Oral RAD51 Inhibitor, In Patients With Relapsed/Refractory B-cell Malignancies And Advanced Solid Tumors*

Role: Stanford PI

Sponsor: Cyteir Therapeutics

PEER-REVIEWED PUBLICATIONS

1. Varthakavi PK, **Advani R**, Parthasarathi R, Mehta PJ, Jaykar VV, Nihalani KD. Case report. Tricuspid valvectomy as therapy for spontaneous right sided endocarditis. J. Assoc Phys. India, 34: 873-76, 1986. PMID: 3584045
2. **Advani R**, Varthakavi PK and Parthasarathi RL. "Torsade de Pointes:" occurring in a case of fatal sub arachnoid hemorrhage. J. Assoc Phys. India, 35:155-7 1987. PMID: 1370789
3. **Advani R**, Mentzer W, Andrews D and Schrier SL. Oxidation of hemoglobin F may contribute to the aging process of neonatal RBC. Paediatric Research. 32(2)165-68, 1992. PMID: 1380688
4. **Advani R**, Rubin E, Mohandas N and Schrier SL. Oxidative RBC membrane injury in the pathophysiology of severe β thalassemia. Blood 79(4)1064-7, 1992. PMID: 1737090
5. **Advani R**, Sorenson S, Shinar E, Lande W, Rachmilewitz EA and Schrier SL. Characterization and comparison of the RBC membrane damage in severe human alpha & beta thalassemia. Blood 79(4):1058-63, 1992. PMID: 173089
6. **Advani R**, Chao NJ, Horning S, Blume K, Ahn D, Lamborn K, Fleming N, Bonnem E and Greenberg P. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma. Annals of Internal Medicine. 116(3):183-9, 1992. PMID: 1345803
7. Chao NJ, Berry GJ, **Advani R**, Horning S, Weiss L and Blume K. Epstein Barr virus associated lymphoproliferative disease following autologous bone marrow transplantation for Non-Hodgkin's lymphoma. Transplantation, 55(6)1425-8, 1993. PMID: 8390736
8. Greenberg P, **Advani R**, Keating A, Gulati S, Nimer S, Champlin R, Karanes C, Gorin NC, Powles RL, Smith A, Lamborn K, Cuffie C. GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation. Bone Marrow Transplantation. 18:1057-64, 1996. PMID: 8971373
9. Peng NJ, **Advani R**, Kopiwoda S, Fisher G and Strauss HW. Clinical decision making based on radionuclide determined ejection fraction in oncology patients. J of Nucl Med. 38(5):702-5, 1997. PMID: 9170431
10. **Advani R**, Warnke R, Sikic BI, and Horning S. Treatment of angioimmunoblastic T-cell lymphoma with cyclosporine. Ann. Oncol. 8:601-3, 1997. PMID: 9261530
11. **Advani R** and Horning S. Treatment of early stage Hodgkin's disease. Semin Hematol. 36:270-281, 1999. PMID: 10462327
12. **Advani R**, Saba HI, Tallman M, Rowe JM, Wiernik PH, Ramek J, Dugan K, Lum B, Villena J, Sikic BI, Davis E, Paietta E, Litchman M and Greenberg P. Treatment of refractory and relapsed

- acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). *Blood* 93:787-95, 1999. PMID: 9920827
13. **Advani R**, Warnke R and Rosenberg S. Treatment of Multicentric Castleman's disease complicated by the development of Non-Hodgkin's lymphoma with high dose chemotherapy and autologous peripheral stem cell support. *Ann Oncol.* 10:1207-9, 1999. PMID: 10586338
14. **Advani R**, Lum BL, Fisher GA, Hausdorff J, Halsey J, Litchman M and Sikic BI. A phase I trial of doxorubicin, paclitaxel and PSC 833 (PSC) as a modulator of multidrug resistance (MDR) in refractory solid tumors. *Clin Cancer Res.* 5:1221-9, 2001. PMID: 11350887
15. Nguyen D, Loo B, Dorfman R, Goffinet D, Jacobs C and **Advani R**. Plasmablastic lymphoma in a HIV negative patient. *Ann Hematol.* 82(8):521-5, 2003. PMID: 12783213
16. **Advani R**, Fisher GA, Lum BL, Jambalos C, Cho CD, Cohen M, Gollerkeri A, Sikic BI. Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. *Clin Cancer Res.* 9(14):5187-94, 2003. PMID: 14613998
17. **Advani R**, Peethambaram P, Lum B, Fisher GA, Hartmann L, Long H, Halsey J, Holmlund J, Dorr A and Sikic BI. A phase II trial of Aprinocarsen (ISIS 3521, LY900003), an antisense oligonucleotide inhibitor of protein kinase c alpha administered as a 21-day infusion to patients with advanced ovarian cancer. *Cancer.* 100(2): 321-6, 2004. PMID: 14716767
18. Greenberg PL, Lee SJ, **Advani R**, Tallman MS, Sikic BI, Letendre L, Dugan K, Lum B, Chin DL, Dewald G, Paietta E, Bennett JM and Rowe JM. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995). *J Clin Oncol* 22(6):1078-86, 2004. PMID: 15020609
19. **Advani R**, Rosenberg SA and Horning SJ. Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy. *J Clin Oncol* 22(8):1454-9, 2004. PMID: 15024027
20. **Advani R**, Lum BL, Fisher GA, Halsey J, Geary RS, Holmlund JT, Kwoh TJ, Dorr FA, and Sikic BI. A phase I trial of aprinocarsen (ISIS 3521/ly900003), an antisense inhibitor of protein kinase c- α administered as a 24-hour weekly infusion schedule in patients with advanced cancer. *Investigational New Drugs*, 23(5):467-77, 2005. PMID: 16133798
21. Kuo T, Cho CD, Halsey J, Wakelee HA, **Advani RH**, Ford JM, Fisher GA, Sikic BI. Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. *J Clin Oncol* 23(24):5613-9, 2005. PMID: 16110021
22. **Advani R**, Lum BL, Fisher GA, Halsey J, Chin DL, Jacobs CD, Sikic BI. A phase I trial of liposomal doxorubicin, paclitaxel, and valspodar (PSC-833): An inhibitor of multidrug resistance. *Ann Oncol* 16:1968-73, 2005. PMID: 16126736

23. Brody J, **Advani R**. Treatment of mantle cell lymphoma: Current approach and future directions. *Crit Rev Oncol Hematol*. 58(3):257-65, 2006. PMID: 16751087
24. **Advani R**, Ai WZ, Horning, SJ. Management of advanced stage Hodgkin lymphoma. *J Natl Compr Canc Netw* 4(3):241-7, 2006. PMID: 16507271
25. Tsai EY, Taur A, Espinosa L, Quon A, Johnson D, Dick S, Chow S, **Advani R**, Warnke R, Kohler S, Hoppe RT, Kim YH. Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography. *Arch Dermatol* 142(5):577-84, 2006. PMID: 16702495
26. Brody JD, **Advani R**, Shin LK, Bingham DB, Rosenberg SA. Splenic diffuse large B-cell lymphoma in a patient with type 1 Gaucher disease: Diagnostic and therapeutic challenges. *Ann Hematol* 85(11):817-20, 2006. PMID: 16937096
27. Jayaraman AG, Cassarino D, **Advani R**, Kim YH, Tsai E, Kohler S. Cutaneous involvement by angioimmunoblastic t-cell lymphoma: A unique histologic presentation, mimicking an infectious etiology. *J Cutan Pathol* 33 (S2):6-11, 2006.
28. **Advani R**, Horwitz S, Zelenetz A, Horning S. Angioimmunoblastic T cell lymphoma: Treatment experience with cyclosporine. *Leuk Lymphoma*. 48(3):521-5, 2007. PMID: 17454592
29. Ganjoo K, **Advani R**, Mariappan MR, McMillan A, Horning S. Non-Hodgkin lymphoma of the breast. *Cancer* 110(1):25-30, 2007. PMID: 17541937
30. Treon SP, Hunter ZR, Matous J, Joyce RM, Mannion B, **Advani R**, Cook D, Songer J, Hill J, Kaden BR, Sharon D, Steiss R, Leleu X, Branagan AR, Badros A. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: Results of WMCTG Trial 03-248. *Clin Cancer Res* 13(11):3320-5, 2007. PMID: 17445538
31. **Advani R**, Maeda L, Lavori P, Quon A, Hoppe R, Breslin S, Rosenberg SA, Horning SJ. Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease. *J Clin Oncol* 25 (25):3902-7, 2007. PMID: 17664458
32. Rubenstein J, Abrey L, **Advani RH**, Shuman M, Tsai T, and O'Brien J. In Reply to; Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. *J Clin Oncol* 25(28):4509-4511, 2007. PMID: 23197589
33. Malumbres R, Chen J, Tibshirani R, Johnson NA, Sehn LH, Natkunam Y, Briones J, **Advani RH**, Connors JM, Byrne GE, Levy R, Gascoyne RD, Lossos IS. Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. *Blood* 111(12):5509-14, 2008. PMID: 18445689

34. Morales AV, **Advani R**, Horwitz SM, Riaz N, Reddy S, Hoppe RT and H. Kim YH. Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab. *J Am Acad Dermatol*. 59(6):953-7, 2008. PMID: 18817999
35. Alizadeh AA and **Advani R**. Evaluation and management of Angioimmunoblastic T-cell lymphoma: A review of current approaches and future strategies. *Clin Adv Hematol Oncol*. 6(12):899-909, 2008. PMID: 19209140
36. Chen AI, **Advani RH**. Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development. *J Natl Compr Canc Netw* 6(4):428-35, 2008. PMID: 18433608
37. Woo DK, Jones CR, Vanoli-Storz MN, Kohler S, Reddy S, **Advani R**, Hoppe RT, and Kim YH. Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome. *Arch Dermatol* 145(6):667-74, 2009. PMID: 19528422
38. Kohrt H, **Advani R**. Extranodal natural killer/T-cell lymphoma: Current concepts in biology and treatment. *Leuk Lymphoma* 50(11):1773-84, 2009. PMID: 19883307
39. **Advani R**, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, Harrop K, Whiting N, Drachman JG. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. *J Clin Oncol* 27(26): 4371-7, 2009. PMID: 1963610
40. Kohrt H, Johannsen A, Hoppe R, Horning SJ, Rosenberg S, **Advani R**, and Lee P. Dynamic CD8 T cell responses to tumor-associated Epstein-Barr Virus antigens in patients with Epstein-Barr Virus negative Hodgkin's Disease. *Onc Rsch* 18(5-6), 287-292, 2009. PMID: 20225766
41. Gratzinger D, **Advani R**, Zhao S, Talreja N, Tibshirani RJ, Shyam R, Horning S, Sehn LH, Farinha P, Briones J, Lossos IS, Gascoyne RD, Natkunam Y. Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP). *Br J Haematol* 148(2): 235-44, 2010. PMID: 19821819
42. Horning SJ, Juweid ME, Schoder H, Wiseman G, McMillan A, Swinnen LJ, **Advani R**, Gascoyne RD, and Quon A. Interim positron emission tomography (PET) in diffuse large B cell lymphoma: Independent expert nuclear medicine evaluation of ECOG 3404. *Blood* 115(4): 775-7, 2010. PMID: 19767508
43. **Advani R**, Hurwitz HI, Gordon MS, Ebbinghaus SW, Mendelson DS, Wakelee HA, Hoch U, Silverman JA, Havrilla NA, Berman CJ, Fox JA, Allen RS, Adelman DC. Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules *Clin Cancer Res* 16(7): 2167-75, 2010. PMID:20233886
44. **Advani R**, Chen H, Habermann TM, Morrison VA, Weller EA, Fisher RI, Peterson BA, Gascoyne RD, and Horning SJ. Comparison of conventional prognostic indices in patients older

than 60 years with diffuse large B-cell lymphoma patients treated with R-CHOP in the US intergroup study (ECOG 4494, CALGB 9793): Consideration of age greater than 70 years in an elderly prognostic index (E-IPI). *Br J Haematol.* 151 (2): 143-151, 2010. PMID:20735398

45. Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, **Advani R**, Kim YH, Hoppe RT, Knox SJ, Shin LK, Wapnir I, Tibshirani RJ, Levy R. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression. *J Clin Oncol.* 28(28):4324-32, 2010. PMID:22045986

46. Kohrt H, Lee M and **Advani R**. Risk stratification in NK/T-cell lymphoma. *Expert Rev Anticancer Ther.* 10 (9):1395-1405, 2010. PMID:20836675

47. Galatin PS, **Advani R**, Fisher GA, Francisco B, Julian T, Losa R, Sierra MI, Sikic BI. Phase I trial of oblimersen (Genasense(R)) and gemcitabine in refractory and advanced malignancies. *J Clin Oncol.* 28(28):4295-6, 2010. PMID:20349264

48. **Advani R**, Hoppe RT, Maeda LS, Baer DM, Mason J, Rosenberg SA, and Horning SJ. Stage I-IIA non-bulky Hodgkin lymphoma. Is further distinction based on prognostic factors useful? The Stanford experience. *Int J Radiat Oncol Biol Phys.* (5):1374-9, 2011. PMID:20934280

49. Alencar AJ, Malumbres R, **Advani R**, Talreja N, Shyam R, Briones J, Natkunam Y, Sehn LH, Gascoyne RD, Tibshirani R, Lossos IS. MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. *Clin Cancer* 17(12):4125-35, 2011. PMID:21525173

50. Maeda LS, Lee M, and **Advani RH**. Current concepts and controversies in the management of early stage Hodgkin lymphoma. *Leuk Lymphoma.* 52(6):962-71, 2011. PMID:21463118

51. Burington B, Yue P, Shi X, **Advani RH**, Lau JT, Tan J, Stinson J, Januario T, deVos S, Ansell S, Forero-Torres A, Fedorowicz G, Yang TC, Elkins K, Du C, Mohan S, Yu N, Modrusan Z, Seshagira S, Yu SF, Pandita A, Koeppen H, French D, Polson AG, Offringa R, Whiting N, Ebens A, and Dornan D. CD40 pathway activation status predicts the anti-tumor activity of CD40 therapy in diffuse large B cell lymphoma. *Sci Transl Med.* 3(74):74ra22, 2011. PMID:21411738

52. Nguyen TT, Arbor D. **Advani RH**, Gubens M, Aziz N. Vaginal non-Hodgkin's lymphoma in pregnancy misdiagnosed as Lichen Planus, *Obstet Gynecol.* 118(Vol. 2, Part 2):486-9. 2011. PMID:21768862

53. Alizadeh AA, Gentles AJ, Alencar A, Liu CL, Kohrt HE, Houot R, Goldstein M, Zhao S, Natkunam Y, **Advani R**, Gascoyne RD, Briones J, Tibshirani R, Myklebust JH, Plevritis S, Lossos IS, and Levy R. Prediction of survival in diffuse large B-cell lymphoma based on the expression of two genes reflecting tumor and microenvironment. *Blood.* 118:1350-1358, 2011. PMID: 21670469

54. **Advani RH**, Optimal therapy of advanced Hodgkin lymphoma. *American Soc Hematol Educ Program:* 310-6, 2011. PMID: 22160051

55. **Advani R**, Hong F, Horning SJ, Kahl BS, Manola J, Swinnen LJ, Habermann TM, Ganjoo K. Cardiac toxicity associated with Bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T Cell lymphoma in ECOG 2404 trial. *Leuk Lymphoma*. 53(4) 718-20, 2012. PMID:21916830
56. Fanale M, Forero-Torres A, Rosenblatt J, **Advani R**, Franklin A, Kennedy D, Han T, Sievers E, and Bartlett N. A phase 1 weekly dosing study of Brentuximab Vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. *Clin Cancer Res*. 18(1): 248-255, 2012. PMID:22080439
57. Kim YH, Gratzinger D, Harrison C, Brody JD, Czerwinski DK, Ai WZ, Morales A, Abdulla F, Xing L, Navi D, Tibshirani RJ, **Advani RH**, Lingala B, Shah S, Hoppe RT, Levy R. In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. *Blood*. 119(2):355-63, 2012. PMCID 3257006.
58. Tseng D, Rachakonda L, Su Z, **Advani RH**, Horning S, Hoppe R, Quon, A, Graves E, Loo B, Tran P. Interim-treatment quantitative PET parameters predict progression and death among patients with Hodgkin's disease. *Radiat Oncol*. 7(5), 2012. PMCID 3398283
59. Gopal AK, Ramchandren R, O'Connor OA, Berryman RB, **Advani RH**, Chen R, Smith SE, Cooper M, Rothe A, Matous JV, Grove LE, and Zain J. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplant. *Blood*. 120(3):560-8, 2012. PMID:22510871
60. Pro B, **Advani R**, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A. Brentuximab Vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: results of a phase II study. *J Clin Oncol*. 30(18):2190-6, 2012. PMID:22614995
61. Powell AA, Talasz AH, Zhang H, Coram MA, Reddy A, Deng G, Telli ML, **Advani RH**, Carlson RW, Mollick J, Sheth S, Kurian AW, Ford JM, Stockdale FE, Quake SR, Pease RF, Mindrinos MN, Bhanot G, Dairkee SH, Davis RW, Jeffrey SS. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. *PLoS One* 7(5):e33788, 2012. PMID:22586443
62. Tan KL, Scott DW, Hong F, Kahl BS, Fisher RI, Bartlett NL, **Advani RH**, Buckstein R, Rimsza LM, Connors JM, Steidl C, Gordon LI, Horning SJ, Gascoyne RD. Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. *Blood*. 120(16):3280-7, 2012. PMID:22948049
63. Forero-Torres A, Fanale M, **Advani R**, Bartlett NL, Rosenblatt JD, Kennedy DA, Younes A. Brentuximab vedotin in transplant-naïve patients with relapsed or refractory Hodgkin lymphoma: analysis of two phase I studies. *Oncologist*. 17(8):1073-80, 2012. PMID: 22855426

64. Smith MR, Li H, Gordon L, Gascoyne RD, Paietta R, Forero-Torres A, Kahl BS, **Advani R**, Hong F, Horning SJ. Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by Yttrium-90-Ibritumomab Tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499. *J Clin Oncol.* 30(25): 3119-26, 2012. PMID: 22851557
65. Rezvani K, Brody JD, Kohrt HE, Logan AC, **Advani R**, Czerwinski DK, Weng WK, Negrin RS, Carlton V, Faham M, Levy R, Barrett J. Cancer vaccines and T-cell therapy. *Biol Blood Marrow Transplant.* 19(1 Suppl):S97-S101, 2013. PMID:23041602
66. **Advani R**, Buggy JJ, Sharman JP, Smith S, Boyd TE, Grant B, Kolibaba KS, Furman R, Rodriguez S, Chang BY, Sukbuntherng J, Izumi R, Hamdy A, Hedrick E, Fowler N. The Bruton Tyrosine kinase inhibitor Ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-Cell malignancies. *J Clin Oncol.* 31(1):88-94. 2013. PMID:23045577
67. Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Gospodarowicz M, **Advani R**, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ. Randomized phase III trial of ABVD vs. Stanford V +/- radiation therapy in locally extensive and advanced stage Hodgkin's lymphoma: An intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). *J Clin Oncol.* 120(16):3280-7. 2013. PMID:23182987
68. Foss FM, Sjak-Shie N, Goy A, Jacobsen E, **Advani R**, Smith MR, Komrokji R, Pendergrass K, Bolejack V. A Multicenter Phase II Trial to Determine the Safety and Efficacy of Combination Therapy With Denileukin Diftitox and CHOP in Untreated Peripheral T-Cell Lymphoma: The CONCEPT Study. *Leuk Lymphoma.* 54(7):1373-9, 2013. PMID:23278639
69. **Advani RH**, Hoppe RT, Baer D, Mason J, Warnke R, Rosenberg SA, Allen J, Daadi S, Horning SJ. Efficacy of abbreviated Stanford V chemotherapy and involved field radiotherapy in early stage Hodgkin's disease: Mature results of the G4 trial. *Ann Oncol.* 24(4):1044-8, 2013. PMID: 3603439
70. Rubenstein L, Li J, Chen L, **Advani RH**, Drappatz J, Gerstner E, Batchelor T, Krouwer H, Hwang J, Auerback G, Kadoch C, Lowell C, Munster P, Cha S, Shuman M, Damon LE, Damon E. Multicenter Phase I Trial of Intraventricular Immuno-Chemotherapy in Recurrent CNS Lymphoma. *Blood.* 121(5): 745-751, 2013. PMID: 23197589
71. Koontz MZ, Horning SJ, Balise R, Greenberg P, Rosenberg SA, Hoppe RT, and, **Advani R**. Risk of therapy-related secondary leukemia in Hodgkin's lymphoma: The Stanford University experience of three generations of clinical trials. *J Clin Oncol.* 31(5):592-8, 2013. PMID: 23295809
72. Scott DW, Chan FC, Hong F, Rogic S, Tan K, Meissner B, Ben-Neriah S, Boyle M, Kridel R, Telenius A, Woolcock B, Farinha P, Fisher RI, Bartlett NL, Shepherd LE, **Advani RH**, Connors JM,

- Kahl BS, Gordon LI, Horning SJ, Steidl C and Gascoyne RD. Gene expression and overall survival in advanced stage classic Hodgkin lymphoma. *J Clin Oncol.* 31(6):692-700, 2013.
73. Evens, Hong F, Gordon LI, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Gospodarowicz M, Cheson BD, Stiff PJ, **Advani RH**, Miller TP, Hoppe RT, Kahl BS, Horning SJ. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. *Br J Haematol.* 161(1):76-86, 2013. PMID: 23356491
74. Kanarky JA, Li H, Gellert LL, Lemas MV, Hsieh WS, Hong F, Tan KL, Gascoyne RD, Gordon LI, Fisher RI, Bartlett NL, Stiff P, Cheson BD, **Advani R**, Miller TP, Kahl BS, Horning SJ, Ambinder RF. Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American co-operative group trial. *Blood.* 121(18):3547-53, 2013. PMID: 23386127
75. Han T, Chen R, **Advani R**, Berryman R, Smith S, Forero-Torres A, Rosenblatt J, Smith M, Zain J, Hunder N, Engert A. Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies. *Cancer Chemother Pharmacol.* 72(1):241-249, 2013.
76. Dunleavy K, Pittaluga S, Maeda LS, **Advani R**, Chen CC, Hessler J, Steinberg SM, Grant C, Wright G, Varma G, Staudt LM, Jaffe ES, Wilson WH. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. *N Engl J Med.* 368(15):1408-16, 2013. PMID:23574119
77. Tan D, Horning SJ, Rosenberg SA, Hoppe RT, Warnke R, Natkunam Y, Yuen A, Plevritis SK, Sigal BM, Levy R and **Advani RH**. Improvements in observed and relative survivals in follicular grade 1-2 lymphoma over four decades: The Stanford experience. *Blood.* 122 (6) 981-7, 2013. PMID: 23777769
78. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, **Advani RH**, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivoy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA. Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. *N Eng J Med.* 369(6):507-16, 2013. PMID:23782157
79. **Advani R**, Dinner S. Targeted therapy in relapsed classical Hodgkin lymphoma. *J Natl Compr Canc Netw.* 11(8)968-76, 2013. PMID:23946175
80. Evens A, Galloway T, **Advani R**, Press O, Lossos I, Vose J, Hernandez-Ilizaliturri F, Robinson B, Otis S, Dagan L, Abdallah R, Kroll A, Yarber J, Sandoval J, Parker L, Gordon L, Blum K, Flowers C, Leonard J, Habermann T, Bartlett N. Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. *J Clin. Oncol.* 31(32):4132-9, 2013. PMID: 24043736
81. Scott DW, Chan FC, Hong F, Rogic S, Tan KL, Meissner B, Ben-Neria S, Boyle M, Kridel R, Telenius A, Woolcock BW, Farinha P, Fisher RI, Rimsza LM, Bartlett NL, Cheson BD, Shepherd LE, **Advani RH**, Connors JM, Kahl BS, Gordon LI, Horning SJ, Steidl C, Gascoyne RD. Gene

- expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. *J Clin Oncol.* 31(6):692-700. 2013. PMID: 23182984
82. Tan D, Yong Tan S, Thye Lim S, Jim Kim S, Kim WS, **Advani R**, Kwong YL. Management of B-Cell Non-Hodgkin Lymphoma in Asia: Consensus Statement from the Asia Lymphoma Study Group. *Lancet Oncol.* 14(12) 548-61, 2013. PMID: 24176573
83. Aalipour A, **Advani R**. Bruton's Tyrosine Kinase Inhibitors: A promising novel targeted treatment for B cell lymphomas. *Br J Haematol.* 163(4): 436-43, 2013. PMID: 24111579
84. Ganjoo K, Hong F, Horning S, Gascoyne R, Natkunami Y, Swinnen L, Habermann T, Kahl B, **Advani R**. Bevacizumab and CHOP (A-CHOP) in Combination for Patients with Peripheral T-Cell or Natural Killer Cell Neoplasms: An Eastern Cooperative Group Study (E2404). *Leuk Lymphoma.* 55(4):768-72, 2014. PMID: 23786456
85. **Advani RH**, Hoppe, RT. How I treat nodular lymphocyte predominant Hodgkin lymphoma. *Blood.* 122(26) 4182-8. 2014. PMID:24215035
86. Percival M, Hoppe R, **Advani R**. Bulky mediastinal classical Hodgkin lymphoma in young women. *Oncology (Williston Park.* 28(3):253-6, 258-60, C3, 2014. PMID:24855735
87. Diefenbach C, **Advani R**. Customized Targeted Therapy in Hodgkin Lymphoma: Hype or Hope? *Hematol Oncol Clin North Am.* 28(1):105-22, 2014. PMID: 24287071
88. Horst KC, Hancock SL, Ognibene G, Chen C, **Advani RH**, Rosenberg SA, Donaldson SS, Hoppe RT. Histologic subtypes of breast cancer following radiotherapy for Hodgkin lymphoma. *Ann Oncol.* 25(4):848-51, 2014. PMID:24608191
89. **Advani RH**, Horning SJ, Hoppe RT, Daadi S, Allen J, Natkunam Y, Bartlett NL. Mature results of phase II study of rituximab therapy for nodular lymphocyte predominant Hodgkin lymphoma. *J Clin Oncol* 32(9):912-8, 2014. PMID:24516013
90. Chang JE, Li, Smith MR, Gascoyne RD, Palletta EM, Yang DT, **Advani RH**, Horning SJ, Kahl BS. Phase II Study of with rituximab maintenance for untreated mantle cell lymphoma: An Eastern Cooperative Oncology Group Study (E1405). *Blood.* 123(11):1665-73, 2014. PMID: 24458437
91. Hosein PJ, Maragulia JC, Salzberg MP, Press OW, Haberman TM, Vose JM, Base M, **Advani RH**, Tibshirani R, Evens AM, Islam N, Leonard JP, Martin P, Zelenetz AD, Lossos IS. A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. *Br J Haematol.* 165(3):358-63, 2014. PMID: 24467658
92. Horwitz S, **Advani R**, Bartlett N, Jacobsen ED, Sharman J, O'Connor OA, Siddiqi T, Kennedy DA, Oki Y. Objective responses in T-Cell lymphomas with single-agent brentuximab vedotin in a phase 2 study. *Blood.* 123(20):3095-100, 2014. PMID: 24652992

93. Bartlett N, Chen R, Fanale M, Brice P, Gopal A, Smith S, **Advani R**, Matous J, Ramchandren R, Rosenblatt J, Huebner D, Levine P, Grove L, Forero-Torres A. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. *J Hematol Oncol.* 7:24, 2014. PMID: 24642247
94. de Vos S, Forero-Torres A, Ansell SM, Kahl B, Cheson BD, Bartlett NL, Furman RR, Winter JN, Kaplan H, Whiting NC, Drachman JG, Ren H, **Advani RH**. A phase II study of dacetuzmab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma. *J Hematol Oncol.* *J Hematol Oncol* 7(1):44, 2014. PMID: 24919462
95. Dimopoulos M, Kastiris E, Owen R, Kyle R, Landgren O, Morra E, Leleu X, Garcia-Sanz R, Munshi Nikhil, Anderson K, Terpos E, Ghobrial I, Morel P, Maloney D, Rummel M, Leblond V, **Advani R**, Gertz M, Kyriakou C, Thomas S, Barlogie B, Gregory S, Kimby E, Merlini G, Treon S. Treatment recommendations for patients with Waldenström's Macroglobulinemia (WM) and related disorders: consensus from the Seventh International Workshop on WM. *Blood* 124(9):1404-1411, 2014.
96. Fanale M, Horwitz S, Forero-Torres A, Bartlett, **Advani R**, Pro B, Chen R, Davies A, Illidge T, Huebner D, Kennedy D, Shustov A. Brentuximab Vedotin in the frontline of patients with CD30+ peripheral T-Cell Lymphomas; Results of a Phase 1 Study. *J Clin Oncol* 32(28):3137-43, 2014. PMID: 25135998
97. Foss F, **Advani R**, Duvic M, Hymes K, Intragumtornchai T, Lekhakula A, Shpilberg O, Lerner A, Belt R, Jacobsen E, Laurent G, Ben-Yehuda D, Beylot-Barry M, Hillen U, Knoblauch P, Bhat G, Chawla S, Allen L, Pohlman B. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-Cell lymphoma. *Br J Haematol.* 168(6):811-9, 2015. PMID: 25404094
98. Garfin PM, Link MP, Donaldson SS, **Advani RH**, Luna-Fineman S, Kharbanda S, Porteus M, Weinberg KI, Agarwal-Hashmi R. Improved outcomes autologous bone marrow transplantation of children with relapsed or refractory Hodgkin lymphoma: twenty years experience at a single institution. *Biol Blood Marrow Transplant.* 21(2):326-34, 2015. PMID: 25445024
99. Marostica E, Sukbuntherng J, Loury D, Jong J, de Trixhe X, Vermeulen A, De Nicolao G, O'Brien S, Byrd J, **Advani R**, McGreivy J, Poggesi I. Population Pharmacokinetic model of Ibrutinib, a Bruton's Tyrosine Kinase Inhibitor, in patients with B-cell malignancies. *Cancer Chemother Pharmacol.* 75(1):111-21, 2015. PMID: 25381051
100. Illidge T, Bouabdallah R, Chen R, Gopal A, Moskowitz C, Ramchandren R, Rosenblatt J, Shustov A, Tilly H, Triplett T, Gibb A, Grove L, **Advani R**. Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic cell lymphoma. *Leuk Lymphoma.* 56(3):703-10, 2015. PMID: 24913507
101. Jacobsen E, Sharman J, Oki Y, **Advani R**, Winter J, Bello C, Spitzer G, Palanca-Wessels M, Kennedy D, Levine P, Yang J, Bartlett N. Brentuximab vedotin demonstrates objective

responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. *Blood*. 125(9): 1394-402, 2015. PMID: 25573987

102. Wagner LI, Zhao F, Hong F, Williams ME, Gascoyne RD, Krauss JC, **Advani RH**, Go RS, Habermann TM, Leach JW, O'Connor B, Schuster SJ, Cella D, Horning SJ, Kahl BS. Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: Results from ECOG trial E4402 (RESORT). *J Clin Oncol*. 33(7):740-8, 2015. PMID: 25605841

103. Gordon L, Hong F, Fisher R, Bartlett N, Connors J, Gascoyne R, Wagner H, Stiff P, Cheson B, Gospodarowicz, **Advani R**, Kahl B, Friedberg J, Blum K, Hamberman T, Tuscano J, Hoppe R, Horning S. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). *J Clin Oncol*. 31(6):384-91, 2015. PMID: 23182987

104. Pfeifer M, Zheng B, Erdmann T, Koeppen H, McCord R, Grau M, Staiger A, Chai A, Sandmann T, Madle H, Dörken B, Chu Y, Chen A, Lebovic D, Salles G, Czuczman M, Palanca-Wessels M, Press O, **Advani R**, Morschhauser F, Cheson B, Lenz P, Ott G, Polson A, Mundt K, and Lenz G. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. *Leukemia*. 29(7):1578-86, 2015. PMID:25708134

105. Swinnen LJ, Li H, Quon A, Gascoyne R, Hong F, Ranheim EA, Habermann TM, Kahl BS, Horning SJ, **Advani RH**. Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404). *Br J Haematol*. 170(1):56-65, 2015.

106. King M, Donaldson S, Link M, Natkunam Y, **Advani R**, Hoppe R. Management of nodular lymphocyte predominant Hodgkin lymphoma in the modern era. *Int J Radiat Oncol Biol Phys*. 92(1):67-75, 2015. PMID:25863755

107. Treon S, Tripsas C, Meid K, Warren D, Varma G, Green R, Argyropoulos K, Yang G, Cao Y, Xu L, Patterson C, Rodig S, Zehnder J, Aster J, Harris N, Kanan S, Ghobrial I, Castillo J, Laubach J, Hunter Z, Salman Z, Li J, Cheng M, Clow F, Graef T, Palomba M, **Advani R**. Ibrutinib in previously treated patients with Waldenstrom's Macroglobulinemia. *N Engl J Med*. 372(15):1430-40, 2015. PMID:25853747

108. Witzig T, Hong F, Micallef I, Gascoyne R, Dogan A, Wagner Jr., H, Kahl B, **Advani R**, Horning S. A Phase II Trial of R-CHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402. *Br J Haematol*. 170(5):679-86, 2015. PMID:25974212

109. Palanca-Wessels C, Salles G, Czuczman M, Assouline S, Flinn I, Sehn L, Patel M, Sangha R, Tilly H, **Advani R**, Casasnovas O, Press O, Yalamanchili S, Kahn R, Dere R, Lu D, Jones S, Jones

C, Chu Y, Morschhauser F. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. *Lancet Oncol.* 16(6):704-15, 2015. PMID:25925619

110. **Advani R**, Hong F, Fisher R, Bartlett N, Robinson S, Gascoyne R, Wagner H, Stiff P, Cheson B, Stewart D, Gordon L, Kahl B, Friedberg J, Blum K, Habermann T, Tuscano J, Hoppe R, Horning S. Randomized Phase III trial comparing ABVD + Radiotherapy and the Stanford V Regimen in Patients with Stage I/II Locally Extensive (Bulky Mediastinal) Hodgkin Lymphoma: A Subset Analysis of the US Intergroup Trial E2496. *J Clin Oncol.* 33(17):1936-42, 2015. PMID: 25897153

111. Kim Y, Tavallae M, Sundram U, Salva K, Wood G, Li S, Rozati S, Nagpal S, Krathen M, Reddy S, Hoppe R, Nguyen-Lin A, Weng W, Armstrong R, Pulitzer M, Kong C, **Advani R**, Horwitz S. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sézary syndrome with variable CD30 expression level: A multi-institution collaborative project. *J Clin Oncol.* 33(32):3750-8, 2015. PMID:26195720

112. Kurtz DM, Green MR, Bratman SV, Scherer F, Liu CL, Kunder CA, Takahashi K, Glover C, Keane C, Kihira S, Visser B, Callahan J, Kong KA, Faham M, Corbelli K, Miklos, **Advani R**, Levy R, Hicks R, Hertzberg M, Ohgami RS, Gandhi MK, Diehn M, Alizadeh AA. Non-invasive disease monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. *Blood.* 125(24):3679-87, 2015.

113. **Advani RH**, Hoppe RT. Management of nodular lymphocyte predominant Hodgkin lymphoma. *Hematol Oncol.* 33 Suppl. 1:90-5, 2015. PMID:26062064

114. Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, **Advani RH**, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Zhang L, Baher L, Cheng M, Lee D, Beaupre DM, Rule S. Long-term follow-up of MCL patients treated with single-agent ibrutinib: Updated safety and efficacy results. *Blood.* 126(6):739-45, 2015. PMID: 26059948

115. Evens AM, Kanakry JA, Sehn LH, Kritharis A, Feldman T, Kroll A, Gascoyne RD, Abramson JS, Petrich AM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Adeimy C, Hemminger J, Bartlett NL, Mato A, Caimi PF, **Advani RH**, Klein AK, Nabhan C, Smith SM, Fabregas JC, Lossos IS, Press OW, Fenske TS, Friedberg JW, Vose JM, Blum KA. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort. *Am J Hematol.* 90(9):778-83, 2015. PMID:26044261

116. Roberts AW, **Advani RH**, Kahl BS, Persky D, Sweetenham JW, Carney DA, Yang J, Busman TB, Enschede SH, Humerickhouse RA, Seymour JF. Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20(+) lymphoid malignancies. *Br J Haematol.* 170(5):669-78, 2015. PMID: 25942994

117. Hiniker SM, Pollom EL, Khodadoust MS, Kozak MM, Xu G, Quon A, **Advani RH**, Hoppe RT. Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era. *Int J Radiat Oncol Biol Phys*. 92(1):99-106, 2015. PMID: 25863757
118. Fayad L, Ansell SM, **Advani R**, Coiffier B, Stuart R, Bartlett NL, Forero-Torres A, Kuliczowski K, Belada D, Ng E, Drachman JG. Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. *Leuk Lymphoma*. 56(9):2569-78, 2015. PMID: 25651427
119. Jacobsen ED, Sharman JP, Oki Y, **Advani RH**, Winter JN, Bello CM, Spitzer G, Palanca-Wessels MC, Kennedy DA, Levine P, Yang J, Bartlett NL. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. *Blood*. 125(9):1394-402, 2015. PMID:25573987
120. Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, **Advani R**, Fowler NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC, McGreivy J, Fardis M, Chang BY, Clow F, Munneke B, Moussa D, Beaupre DM, Staudt LM. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. *Nat Med*. 21(8):922-6, 2015. PMID: 26193343
121. Iberri DJ, Hoppe RT, **Advani RH**. Hodgkin lymphoma: the changing role of radiation therapy in early-stage disease-the role of functional imaging. *Curr Treat Options Oncol*. 16(9):45, 2015. PMID: 26187795
122. Binkley MS, Hiniker SM, Wu S, Natkunam Y, Mittra ES, **Advani RH**, Hoppe RT. A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy. *Leuk Lymphoma*. 57(3):604-8, 2015. PMID: 26159046
123. Pfeifer M, Zheng B, Erdmann T, Koeppen H, McCord R, Grau M, Staiger A, Chai A, Sandmann T, Madle H, Dörken B, Chu YW, Chen AI, Lebovic D, Salles GA, Czuczman MS, Palanca-Wessels MC, Press OW, **Advani R**, Morschhauser F, Cheson BD, Lenz P, Ott G, Polson AG, Mundt KE, Lenz G. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. *Leukemia*. 29(7):1578-86, 2015. PMID: 25708834
124. Illidge T, Bouabdallah R, Chen R, Gopal AK, Moskowitz CH, Ramchandren R, Shustov AR, Tilly H, Trippett TM, Gibb A, Grove LE, **Advani R**. Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. *Leuk Lymphoma*. 56(3):703-10, 2015. PMID: 24913507

125. Diefenbach CS, Li H, Hong F, Gordon LI, Fisher RI, Bartlett NL, Crump M, Gascoyne RD, Wagner H Jr, Stiff PJ, Cheson BD, Stewart DA, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ, **Advani RH**. Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era. *Br J Haematol*. 171(4):530-8, 2015. PMID: 26343802
126. Horst KC, Fero KE, Hancock SL, **Advani RH**, Ikeda DM, Daniel B, Rosenberg SA, Donaldson SS, Hoppe RT. Breast imaging in women previously irradiated for Hodgkin lymphoma. *Am J Clin Oncol*. 39(2):114-9, 2016. PMID: 24390271
127. **Advani RH**, Ansell SM, Lechowicz MJ, Beaven AW, Loberiza F, Carson KR, Evens AM, Foss F, Horwitz S, Pro B, Pinter-Brown LC, Smith SM, Shustov AR, Savage KJ, M Vose J. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial. *Br J Haematol*. 172(4):535-44, 2016. PMID: 26627450
128. Xu L, Hunter ZR, Tsakmaklis N, Cao Y, Yang G, Chen J, Liu X, Kanan S, Castillo JJ, Tai YT, Zehnder JL, Brown JR, Carrasco RD, **Advani R**, Sabile JM, Argyropoulos K, Lia Palomba M, Morra E, Trojani A, Greco A, Tedeschi A, Varettoni M, Arcaini L, Munshi NM, Anderson KC, Treon SP. Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia. *Br J Haematol*. 172(5):735-44, 2016. PMID: 26659815
129. White EC, **Advani R**, Hoppe RT. 2 Gy × 2 for palliative treatment of mantle cell lymphoma. *Leuk Lymphoma*. 57(9):2219-21, 2016. PMID: 26763352
130. Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, Rule S, **Advani R**, Iberri D, Phillips T, Spurgeon S, Kozin E, Noto K, Chen Z, Jurczak W, Auer R, Chmielowska E, Stilgenbauer S, Bloehdorn J, Portell C, Williams ME, Dreyling M, Barr PM, Chen-Kiang S, DiLiberto M, Furman RR, Blum KA. Post-ibrutinib outcomes in patients with mantle cell lymphoma. *Blood*. 127(12):1559-63, 2016. PMID: 26764355
131. Minamimoto R, Fayad L, **Advani R**, Vose J, Macapinlac H, Meza J, Hankins J, Mottaghy F, Juweid M, Quon A. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring. *Radiology*. 280(1):220-9, 2016. PMID: 26854705
132. Kim SJ, Yoon DH, Jaccard A, Chng WJ, Lim ST, Hong H, Park Y, Chang KM, Maeda Y, Ishida F, Shin DY, Kim JS, Jeong SH, Yang DH, Jo JC, Lee GW, Choi CW, Lee WS, Chen TY, Kim K, Jung SH, Murayama T, Oki Y, **Advani R**, d'Amore F, Schmitz N, Suh C, Suzuki R, Kwong YL, Lin TY, Kim WS. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. *Lancet Oncol*. 17(3): 389-400, 2016. PMID: 26873565
133. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, **Advani R**, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES. The 2016 revision of the World Health Organization (WHO) classification of lymphoid neoplasms. *Blood*. 127(20):2375-90, 2016. PMID 26980727

134. Aghighi M, Pisani LJ, Sun Z, Klenk C, Madnawat H, Fineman SL, **Advani R**, Von Eyben R, Owen D, Quon A, Moseley M, Daldrup-Link HE. Speeding up PET/MR for cancer staging of children and young adults. *Eur Radiol.* 26(12): 4239-4248, 2016. PMID: 27048532
135. Roemer MG, **Advani RH**, Ligon AH, Natkunam Y, Redd RA, Homer H, Connelly CF, Sun HH, Daadi SE, Freeman GJ, Armand P, Chapuy B, de Jong D, Hoppe RT, Neuberg DS, Rodig SJ, and Shipp MA. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. *J Clin Oncol.* 34(23):2690-7, 2016. PMID: 27069084
136. Duncavage E, **Advani RH**, Agosti S, Foulis P, Gibson C, Kang L, Khoury JD, Medeiros LJ, Ohgami RS, O'Malley DP, Patel KP, Rosenbaum JN, Wilson C; Members of the Cancer Biomarker Reporting Committee, College of American Pathologists. Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified. *Arch Pathol Lab Med.* 140(11):1225-1227. PMID: 27081879
137. Matthews JM, Bhatt S, Patricelli MP, Nomanbhoy TK, Jiang X, Natkunam Y, Gentles AJ, Martinez E, Zhu D, Chapman JR, Cortizas E, Shyam R, Chinichian S, **Advani R**, Tan L, Zhang J, Choi HG, Tibshirani R, Buhrlage SJ, Gratzinger D, Verdun R, Gray NS, Lossos IS. Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma. *Blood.* 128(2):239-48, 2016. PMID: 27151888
138. Lynch RC, **Advani RH**. Risk-Adapted Treatment of Advanced Hodgkin Lymphoma With PET-CT. *Am Soc Clin Oncol Educ Book.* 35:e376-85, 2016. PMID: 27249744
139. Varma G, Johnson TP, **Advani RH**. Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia and Lymphoma. *Clin Adv Hematol Oncol.* 14(7):543-54, 2016. PMID: 27379948
140. Leblond V, Kastritis E, **Advani R**, Ansell SM, Buske C, Castillo JJ, García-Sanz R, Gertz M, Kimby E, Kyriakou C, Merlini G, Minnema MC, Morel P, Morra E, Rummel M, Wechalekar A, Patterson CJ, Treon SP, Dimopoulos MA. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. *Blood.* 128(10):1321-8, 2016. PMID: 26854705
141. Castillo JJ, Palomba ML, **Advani R**, Treon SP. Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience. *Ther Adv Hematol.* 7(4):179-86, 2016. PMID: 27493708
142. Iberri DJ, Kwong BY, Stevens LA, Coutre SE, Kim J, Sabile JM, **Advani RH**. Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management. *Br J Haematol.* 180(1): 164-166. 2016. PMID: 27539794
143. Roemer MG, **Advani RH**, Redd RA, Pinkus GS, Natkunam Y, Ligon AH, Connelly CF, Pak CJ, Carey CD, Daadi SE, Chapuy B, de Jong D, Hoppe RT, Neuberg DS, Shipp MA, Rodig SJ. Classical

Hodgkin Lymphoma with Reduced β 2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. *Cancer Immunol Res.* 4(11):910-916, 2016. PMID: 27737878

144. Chesson BD, Ansell S, Schwartz L, Gordon LI, **Advani R**, Jacene HA, Hoos A, Barrington SF, Armand P. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. *Blood.* 128(21):2489-2496, 2016. PMID: 27574190

145. **Advani RH**, Lebovic D, Chen A, Brunvand M, Goy A, Chang JE, Hochberg E, Yalamanchili S, Kahn R, Lu D, Agarwal P, Dere R, Hsieh HJ, Jones S, Chu YW, Cheson BD. Phase I study of the anti-CD22 antibody-drug conjugate pinatuzumab vedotin with or without rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. *Clin Cancer Res.* 23(5): 1167-1176, 2017. PMID: 27601593

146. Scherer F, Kurtz DM, Newman AM, Stehr H, Craig AFM, Esfahani MS, Lovejoy AF, Chabon JJ, Klass DM, Liu CL, Zhou L, Glover C, Visser BC, Poultides GA, **Advani RH**, Maeda LS, Gupta NK, Levy R, Ohgami RS, Kunder CA, Diehn M, Alizadeh AA. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. *Sci Transl Med.* 8(364):364ra155, 2017. PMID: 27831904

147. Smith MR, Hong F, Li H, Gordon LI, Gascoyne RD, Paietta EM, **Advani RH**, Forero-Torres A, Horning SJ, Kahl BS. Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by (90)Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499. *Leukemia.* 31(2):517-519, 2017. PMID: 27780968

148. Bartlett NL, Smith MR, Siddiqi T, **Advani RH**, O'Connor OA, Sharman JP, Feldman T, Savage KJ, Shustov A, Diefenbach CM, Oki Y, Palanca-Wessels MC, Uttarwar M, Li M, Yang J, Jacobsen ED. Brentuximab Activity in Diffuse Large B-Cell Lymphoma with CD30 Undetectable by Visual Assessment of Conventional Immunohistochemistry. *Leuk Lymphoma.* 58(7): 1607-1616, 2017. PMID: 27868471

149. Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta MA, Shustov AR, **Advani RH**, Feldman TA, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM. A Prospective Cohort Study of Patients with Peripheral T-Cell Lymphoma in the United States. *Cancer.* 123(7):1174-1183, 2017. PMID: 27911989

150. Furman RR, Eradat HA, DiRienzo CG, Hofmeister CC, Hayman SR, Leonard JP, Coleman M, **Advani R**, Chanan-Khan A, Switzky J, Liao QM, Shah D, Jewell RC, Lisby S, Lin TS. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. *Lancet Haematol.* 4(1):e24-e34, 2017. PMID: 27914971

151. Younes A, Ansell S, Fowler N, Wilson W, de Vos S, Seymour J, **Advani R**, Forero A, Morschhauser F, Kersten MJ, Tobinai K, Zinzani PL, Zucca E, Abramson J, Vose J. The landscape of new drugs in lymphoma. *Nat Rev Clin Oncol.* 14(6):335-346, 2017. PMID: 28031560

152. Casulo C, O'Connor O, Shustov A, Fanale M, Friedberg JW, Leonard JP, Kahl BS, Little RF, Pinter-Brown L, **Advani R**, Horwitz S. T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment. *J Natl Cancer Inst.* 109(2), 2017. PMID: 28040682
153. Hsi ED, Horwitz SM, Carson KR, Pinter-Brown LC, Rosen ST, Pro B, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Collie AM, Gruver AM, Grzywacz BJ, Turakhia S, Shustov AR, **Advani RH**, Feldman T, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM. Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States. *Clin Lymphoma Myeloma Leuk.* 17(4): 193-200, 2017. PMID: 28209473
154. Xu L, Tsakmaklis N, Yang G, Chen JG, Liu X, Demos M, Kofides A, Patterson CJ, Meid K, Gustine J, Dubeau T, Palomba ML, **Advani R**, Castillo JJ, Furman RR, Hunter ZR, Treon SP. Acquired mutations associated with ibrutinib resistance in Waldenstrom macroglobulinemia. *Blood.* 129(18):2519-2525, 2017. PMID: 28235842
155. Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, **Advani R**, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MH, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). *Ann Oncol.* 28(7): 1436-1447, 2017. PMID: 28379322
156. Stevens WBC, Mendeville M, Redd R, Clear AJ, Bladergroen R, Calaminici M, Rosenwald A, Hoster E, Hiddemann W, Gaulard P, Xerri L, Salles G, Klapper W, Phreunds Schuh M, Jack A, Gascoyne RD, Natkunam Y, **Advani R**, Kimby E, Sander B, Sehn L, Hagenbeek A, Raemaekers J, Gribben J, Kersten MJ, Ylstra B, Weller E, de Jong D. Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: A study by the Lunenburg Lymphoma Biomarker Consortium. *Haematologica.* 102(8): 1413-1423, 2017. PMID: 28411252
157. Tao L, Clarke CA, Rosenberg AS, **Advani RH**, Jonas BA, Flowers CR, Keegan THM. Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era. *Br J Haematol.* 178(1):72-80, 2017. PMID: 28542862
158. Bartlett NL, Smith MR, Siddiqi T, **Advani RH**, O'Connor OA, Sharman JP, Feldman T, Savage KJ, Shustov AR, Diefenbach CS, Oki Y, Palanca-Wessels MC, Uttarwar M, Li M, Yang J, Jacobsen ED. Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. *Leuk Lymphoma.* 58(7):1607-1616, 2017. PMID 27868471.

159. Lynch RC, Gratzinger D, **Advani RH**. Clinical Impact of the 2016 Update to the WHO Lymphoma Classification. *Curr Treat Options Oncol.* 18(7):45, 2017. PMID: 286706664. Erratum in *Curr Treat Options Oncol.* 18(10):60, 2017. PMID: 28861885.
160. Dabaja BS, Zelenetz AD, Tsang RW, Qi S, Allen PK, Hodgson D, Ricardi U, Hoppe RT, **Advani R**, Mauch PM, Constine LS, Specht L, Li Y, Terezakis SA, Wirth A, Reinartz G, Eich HT, Aleman BMP, Barr P, Yahalom J. Early-Stage Mantle Cell Lymphoma: A Retrospective Analysis From The International Lymphoma Radiation Oncology Group (ILROG). *Ann Oncol.* 28(9): 2185-2190, 2017. PMID: 28911068
161. Muehe AM, Theruvath AJ, Lai L, Aghighi M, Quon A, Holdsworth SJ, Wang J, Luna-Fineman S, Marina N, **Advani R**, Rosenberg J, Daldrup-Link HE. How to Provide Gadolinium-Free PET/MR Cancer Staging of Children and Young Adults in Less than 1 h: the Stanford Approach. *Mol Imagin Biol* 20(2):324-335, 2017. PMID: 28721605
162. Porter JB, Rosenthal EL, Winget M, Smith AS, Seshadri SB, Wetteth Y, Kiamanesh EF, Badwe A, **Advani RH**, Buyyounouski MK, Coutre S, Dirbas F, Divi V, Dorigo O, Ganjoo KN, Johnston LJ, Recht LD, Shrager JB, Skinner EC, Swetter SM, Visser BC, Blayney DW. Improving Care With A Portfolio of Physician-Led Cancer Quality Measures at an Academic Center. *J Oncolo Pract* 13(8):e673-e682, 2017. PMID: 28727487
163. Kharfan-Dabaja M, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, d'Amore F, Jantunen E, Ishida T, Bazarbachi A, Foss F, **Advani R**, Fenske T, Lazarus H, Friedberg J, Alijurf M, Sokol L, Tobinai K, Tse E, Burns L, Horwitz S, Chavez JC, Reddy NM, Suzuki R, Ahmed S, Nademanee A, Mohty M, Gopal AK, Fanale MA, Pro B, Moskowitz A, Sureda A, Perales MA, Carpenter PA, Savani BN. Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T-cell and NK/T-cell Lymphomas: an International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant.* 23(11): 1826-1838, 2017. PMID: 28797780
164. Swinnen L, O'Neill A, Imus P, Gujar S, Schiff D, Kleinberg L, **Advani R**, Dunbar E, Moore Jr. D, Grossman S. Phase II Study of Rituximab Given in Conjunction with Standard Chemotherapy in Primary Central Nervous System (PCNSL) Lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E1F05). *Oncotarget.* 9(1): 766-773, 2017 PMID: 29416652
165. Pro B, **Advani R**, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Fenton K, Huebner D, Pinelli JM, Kennedy DA, Shustov A. Five-Year Results of Brentuximab Vedotin in Patients with Relapsed or refractory Systemic Anaplastic Large Cell Lymphoma. *Blood.* 130(25):2709-2717, 2017. PMID: 28974506
166. Byrd J, Smith S, Wagner-Johnston N, Sharman J, Chen A, **Advani R**, Augustson B, Marlton P, Commerford R, Okrah K, Liu L, Murray E, Penuel E, Ward A, Flinn I. First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. *Oncotarget* 10: 3827-3830, 2017. PMID: 29560128

167. Kunder CA, Roncador G, **Advani RH**, Gualco G, Bacchi CE, Sabile JM, Lossos IS, Nie K, Tibshirani RJ, Green MR, Alizadeh AA, Natkunam Y. KLHL6 Is Preferentially Expressed in Germinal Center-Derived B-Cell Lymphomas. *Am J Clin Pathol.* 148(6):465-476, 2017. PMID: 29140403
168. Henderson TO, Parsons SW, Wroblewski KE, Chen L, Hong F, Smith SM, McNeer JL, **Advani RH**, Gascoyne RD, Constine LS, Horning S, Bartlet NL, Shah B, Connors JM, Leonard JI, Kahl BS, Kelly KM, Schwartz CL, Li H, Friedberg JW, Friedman DL, Gordon LI, Evens AM. Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group (COG AHOD 0031) Comparative Analysis. *Cancer.* 124:136-44, 2017. PMID: 28902390
169. Herrera AF, Moskowitz AJ, Bartlett HL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Ansell SM, Moskowitz CH, Fenton K, Ogden CA, Taft D, Zhang Q, Kato K, Campbell M, **Advani RH**. Interim Results of Brentuximab Vedotin In Combination With Nivolumab In Patients with Relapsed or Refractory Hodgkin Lymphoma. *Blood.* 131(11): 1183-1194, 2017. PMID: 29229594
170. Lynch RC, **Advani RH**. Dramatic Response with Single-Agent Ibrutinib in Multiply Relapsed Marginal Zone Lymphoma with MYD88L265P Mutation. *Case Rep Oncol* 10(3): 813-818, 2017. PMID: 29070995
171. Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, **Advani RH**, Pro B, Chen RW, Davies A, Illidge T, Uttarwar M, Lee SY, Ren H, Kennedy DA, Shustov AR. Five-Year Outcomes for Frontline Brentuximab Vedotin with CHP for CD30-Expressing Peripheral T-Cell Lymphomas. *Blood.* 131(19):2120-2124, 2018. PMID: 29507077
172. Massimo F, Bellei M, Marcheselli L, Schwartz M, Manni M, Taranitino V, Pileri S, Hko Y, Ecabrera M, Horwitz S, Kim W, Shustov A, Foss F, Nagler A, Carson K, Pinter-Brown L, Montoto S, Pina S, Feldman T, Lechow M, Smith S, Lansigan F, Goodrich C, Gabus H, Vose J, **Advani R**. Peripheral T-Cell Lymphoma, Not Otherwise Specified (PTCL_NOS). A new prognostic model developed by the International T-cell Project Network. *Br J Hem.* 181(6):760-769, 2018. PMID: 29672827.
173. Constine L, Yahalom J, Ng A, Hodgson D, Wirth A, Milgrom S, Mikhaeel N, Eich H, Illidge T, Ricardi U, Dieckmann K, Moskowitz C, **Advani R**, Mauch P, Specht L, Hoppe R. The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group. *Int J Radiat Oncol Biol Phys.* 100(5):1100-1118, 2018. PMID: 29722655
174. Carson KR, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta MA, Shustov AR, **Advani RH**, Feldman TA, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM. A prospective cohort study of patients with

peripheral T-cell lymphoma in the United States. *Cancer* 123(7) 1174-1183, 2017. PMID: 27911989.

175. Lacasce A, Bociek RG, Sawas A, Caimi PF, Agura E, Matous J, Ansell S, Crosswell HE, Islas-Ohlmayer M, Behler C, Cheung E, Forero A, Vose J, O'Connor O, Josephson N, Wang Y, **Advani A**. Brentuximab Vedotin Plus Bendamustine: A Highly Active First Salvage Regimen for Relapsed or Refractory Hodgkin Lymphoma. *Blood*. 132(1):40-48, 2018. PMID: 29703778.

176. Melani C, **Advani R**, Roschewski M, Walters KM, Chen CC, Baratto L, Ahlman MA, Miljkovic MD, Steinberg SM, Lam J, Shovlin M, Dunleavy K, Pittaluga S, Jaffe ES, Wilson WH. End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted-EPOCH-R: A paradigm shift in clinical decision making. *Haematologica*. 103(8):1337-1344, 2018. PMID: 29748435.

177. **Advani RH**. Advances In The Management Of Primary Mediastinal Large B-Cell Lymphoma. *Clin Adv Hematol Oncol* 16(1):33-34, 2018. PMID: 29741502.

178. Aghighi M, Theruvath A, Pareek A, Pisani L, Alford R, Muehe A, Sethi T, Holdsworth S, Hazard F, Gratzinger D, Luna-Fineman S, **Advani R**, Spunt S, Daldrup-Link H. Magnetic Resonance Imaging of Tumor Associated Macrophages: Clinical Translation. *Clinical Cancer Research* 24(17):4110-4118, 2018. PMID: 29764855.

179. Bellei M, Foss FM, Shustov AR, Horwitz SM, Marcheselli L, Kim WS, Cabrera ME, Dlouhny I, Nagler A, **Advani RH**, Pesce EA, Ko YH, Martinez V, Montoto S, Chiattoni C, Moskowitz A, Spina M, Biasoli I, Manni M, Federico M. The Outcome of Peripheral T-cell Lymphoma Patients Failing First Line Therapy: A Report From The Prospective International T-Cell Project. *Haematologica* 103(7): 1191-1197, 2018. PMID: 29599200.

180. Castillo JJ, Gustine JN, Meid K, Dubeau TE, Xu L, Yang G, Hunger ZR, **Advani R**, Palomba L, Treon SP. Impact Of Ibrutinib Dose Intensity On Patient Outcomes In Previously Treated Waldenstrom Macroglobulinemia. *Haematologica* 103(10): e466-e468, 2018. PMID: 29773590.

181. Kurtz D, Scherer F, Jin M, Soo J, Craig A, Esfahani M, Chabon J, Stehr H, Liu C, Tibshirani R, Maeda L, Gupta N, Khodadoust M, **Advani R**, Levy R, Newman A, Dührsen U, Hüttmann A, Meignan M, Casasnovas R, Westin J, Roschewski M, Wilson W, Gaidano G, Rossi D, Diehn M, Alizadeh A. Circulating Tumor DNA Measurements as Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. *J Clin Oncol*. 36(28):2845-2853, 2018. PMID: 30125215.

182. Spinner MA, **Advani RH**, Hoppe RT, Lowsky R, Muffly LS. Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplant. *Blood Adv*. 2(13): 1547-1550, 2018. PMID: 29970391.

183. Moding E, **Advani R**, Rosenberg S, Hoppe R. Prognostic Factors and Patterns of Failure in Advanced Stage Hodgkin Lymphoma Treated with Combined Modality Therapy. *Radiother Oncol*. 129(3):507-512, 2018. PMID: 30539763.

184. Spinner MA, Varma G, **Advani RH**. Novel Approaches in Waldenstrom Macroglobulinemia. *Hematol Oncol Clin North Am.* 32(5): 875-890, 2018. PMID: 30190025.
185. Evens AM, **Advani RH**, Helenowski IB, Fanale M, Smith SM, Jovanovic BD, Bociek GR, Klein AK, Winter JN, Gordon LI, Hamlin PA. Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. *J Clin Oncol*, 36(30):3015-3022, 2018. PMID: 30179569
186. Park S, Horwitz S, Foss F, Pinter-Brown L, Carson K, Rosen S, Pro B, His E, Federico M, Gisselbrecht C, Schwartz M, Bellm L, Acosta M, **Advani R**, Feldman T, Lechowicz M, Smith S, Lansigan F, Tulpule A, Craig M, Greer J, Kahl B, Leach J, Morganstein N, Casulo C, Shustov A. The Role of Autologous Stem Cell Transplantation in Patients with Nodal Peripheral T-cell Lymphomas in First Complete Remission: Report from the COMPLETE (Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment), a Prospective Multicenter Cohort Study. *Cancer* 125(9):1507-1517, 2018. PMID: 30694529
187. Spinner MA, **Advani RH**, Connors JM, Azzi J, Deifenbach C. New Treatment Algorithms In Hodgkin Lymphoma: Too Much or Too Little? *Am Soc Clin Oncol Educ Book* (38): 626-636. 2018. PMID: 30231319.
188. **Advani R**, Flinn I, Popplewell L, Forero A, Bartlett N, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins G, Tran T, Lynn J, Chen J, Volkmer J, Agoram B, Huang J, Majeti R, Weissman I, Takimoto C, Chao M, Smith S. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. *N Engl J Med.* 379(18): 1711-1721, 2018. PMID: 30380386.
189. Horwitz S, O'Connor O, Pro B, Illidge T, Fanale M, **Advani R**, Bartlett N, Christensen J, Morschhauser F, Domingo-Domenech E, Rossi G, Kim W, Feldman T, Lennard A, Belada D, Illes A, Tobinai K, Tsukasaki K, Yeh S, Shustov A, Huttman A, Savage K, Yuen S, Ilyer S, Zinzani P, Hua Z, Little M, Rao S, Woolery J, Manley T, Trumper L. Brentuximab Vedotin with Chemotherapy for CD30-positive peripheral T-cell Lymphoma (ECHELON-2): A Global, Double-Blind, Randomised Phase 3 Trial. *Lancet* 393(101-168): 229-240, 2018. PMID: 30522922.
190. Ramchandren R, **Advani R**, Ansell S, Bartlett N, Chen R, Connors J, Feldman T, Forerro A, Friedberg J, Gopal A, Gordon L, Kuruvilla J, Savage K, Younes A, Engley G, Manley T, Fenton K, Straus D. Brentuximab Vedotin Plus Chemotherapy in North American Patients with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. *Clin Cancer Res* 25(6):1718-1726, 2019. PMID: 30617130.
191. Spinner M, Varma G, **Advani R**. Modern Principles in the Management of Nodular Lymphocyte-Predominant Hodgkin Lymphoma. *Br J Haematol* 184(1):17-29, 2019. PMID: 30485408.

192. Spinner M, **Advani R**. Risk-Adapted Therapy for Advanced-Stage Hodgkin Lymphoma. *Hematology Am Soc Hematol Educ Program* 2018(7):200-206, 2018. PMID: 30504311
193. Park S, Horwitz S, Foss F, Pinter-Brown L, Carson K, Rosen S, Pro B, His e, Federico M, Gisselbrecht C, Shwartz M, Bellm L, Acosta M, **Advani R**, Feldman T, Lechowicz M, Smith S, Lansigan F, Tulpule A, Craig M, Greer J, Kahl B, Leach J, Morganstein N, Casulo C, Shustov A. The Role Of Autologous Stem Cell Transplantation In Patients With Nodal Peripheral T-Cell Lymphomas In First Complete Remission: Report From COMPLETE, A Prospective, Multicenter Cohort Study. *Cancer* 125(9):1507-1517, 2019. PMID: 30694529
194. Morschhauser F, Flinn IW, **Advani R**, Sehn LH, Diefenbach C, Kolibaba K, Press OW, Salles G, Tilly H, Chen AI, Assouline S, Cheson BD, Dreyling M, Hagenbeek A, Zinzani PL, Jones S, Cheng J, Lu D, Penuel E, Hirata J, Wenger M, Chu YW, Sharman J. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed/refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). *Lancet Haematol.* 6(5):e254-e265, 2019. PMID: 30935953.
195. **Advani R**, Volkmer J, Chao M. CD47 Blockade and Rituximab in Non-Hodgkin's Lymphoma. *N Engl J Med* 380(5):497-498, 2019. PMID: 30699313.
196. Lansigan F, Horwitz SM, Pinter-Brown L, Rosen ST, Pro B, His Ed, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Shustov AR, **Advani RH**, Feldman T, Lechowicz MJ, Smith SM, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM. Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients After Front-Line Therapy from the COMPLETE Registry. *Acta Haematol* 143(1):40-50, 2020. PMID: 31315113.
197. Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, Chabon JJ, Stehr H, Liu CL, Tibshirani R, Maeda LS, Gupta NK, Khodadoust MS, **Advani RH**, Newmam AM, Duhursen U, Huutmann A, Meignan M, Casasnovas O, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA. Reply to J. Wang et al. *J Clin Oncol.* 37(9): 755-757, 2019. PMID: 30753108.
198. **Advani RH**. Updates in Treatment Strategies for Hodgkin Lymphoma. *J Natl Compr Canc Netw.* 17(11.5):1411-1413, 2019. PMID: 31766016
199. Foss FM, Horwitz SM, Civallero M, Bellei M, Marcheselli L, Kim WS, Cabrera ME, Dlouhy I, Nagler A, **Advani RH**, Pesce EA, Ko YH, Montoto S, Chiattoni C, Moskowitz A, Spina M, Cesaretti M, Biasoli I, Federico M. Incidence and Outcomes of Rare T-Cell Lymphomas from the T-Cell Project: Hepatosplenic, Enteropathy, Associate and Peripheral Gamma Delta T-Cell Lymphomas. *Am J Hematol.* 95(2): 151-155, 2019. PMID: 31709579
200. Rosenwald A, Bens S, **Advani R**, Barrans S, Copie-Bergman C, Elsensohn MH, Natkunam Y, Calaminici M, Sander B, Baia M, Smith A, Painter D, Pham L, Zhao S, Ziepert M, Jordanova ES, Molina TJ, Kersten MJ, Kimby E, Klapper W, Raemaekers J, Schmitz N, Jardin F, Stevens WBC,

Hoster E, Hagenbeek A, Gribben JG, Siebert R, Gascoyne RD, Scott DW, Gaulard P, Salles G, Burton C, de Jong D, Sehn LH, Maucort-Boulch D. Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium. *J Clin Oncol* 37(35): 3559-3368, 2019. PMID: 31498031

201. LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, Ansell SM, Crosswell HE, Islas-Ohlmayer M, Behler C, Cheung E, Forero-Torres A, Vose J, O'Connor OA, Josephson N, Wang Y, **Advani R**. Three-year Outcomes With Brentuximab Vedotin Plus Bendamustine As First Salvage Therapy In Relapsed Or Refractory Hodgkin Lymphoma. *Br J Haematol.*; 189 (3):e86-e90, 2020 PMID: 32048731

202. Torka P, Kothari SK, Sundaram S, Li S, Medeiros LJ, Ayers EC, Landsburg DJ, Bond DA, Maddocks KJ, Giri A, Hess B, Pham LQ, **Advani R**, Liu Y, Barta SK, Vose JM, Churnetski MC, Cohen JB, Burkart M, Karmali R, Zurko J, Mehta A, Olszewski AJ, Lee S, Hill BT, Burns TF, Lansigan F, Rabinovich E, Peace D, Groman A, Attwood K, Hernandez-Ilizaliturri FJ. Outcomes of patients with limited-stage aggressive large B-Cell Lymphoma with high-risk cytogenetics. *Blood Adv*4(2):253-262.2020. PMID: 31945157

203. Straus DJ, Dlugosz-Danecka M, Alekseev S, Illes A, Picardi M, Lech-Maranda E, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Ranchandren R, Zinzani PL, Hutchings M, Conors JM, Radford J, Munoz J, Kim WS, **Advani R**, Ansell SM, Younes A, Miao H, Liu R, Fenton K, Forero A, Gallamini A. Brentuximab Vedotin with Chemotherapy for Stage III/IV Classical Hodgkin Lymphoma: 3-Year Update of the ECHELON-1 Study. *Blood.*;135(10):735-742, 2020PMID: 31945149

204. Merryman R, Carreau N, **Advani R**, Spinner M, Herrera A, Chen R, Tomassetti S, Ramchandren R, Hamid M, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair S, Barta S, Liu Y, Nathan S, Karmali R, Burkart M, Torka P, David K, Wei C, Lansigan F, Emery L, Persky D, Smith S, Godfrey J, Chavez J, Cohen J, Troxel A, Diefenbach C, Armand P. Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma. *Oncologist.*;25(6):e993-e997, 2020PMID: 32275786

205. Fowler NH, Nastoupil L, De Vos S, Knapp M, Flinn IW, Chen R, Advani RH, Bhatia S, Martin P, Mena R, Davis RE, Neelapu SS, Eckert K, Ping J, Co M, Beaupre DM, Neuenburg JK, Palomba ML. The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma. *Br J Haematol.* 189(4):650-660. 2020;PMID: 32180219

206. Binkley MS, Rauf MS, Milgrom SA, Pinnix CC, Tsang RW, Dickinson M, Ng A, Roberts KB, Gao S, Balogh AG, Ricardi U, Levis M, Casulo C, Stolten M, Specht L, Plastaras JP, Wright C, Kelsey CR, Brady JL, Mikhaeel NG, Hoppe BS, Terezakis S, Picardi M, Della Pepa R, Kirova Y, Akhtar S, Maghfoor I, Koenig JL, Jackson C, Song E, Sehgal S, Advani R, Natkunam Y, Constine LS, Eich HT, Wirth A, Hoppe RT. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. *Blood.*;135(26):2365-2374, 2020 PMID: 32211877

207. Lynch R, Sundaram V, Desai M, Henry S, Wood D, Daadi S, Hoppe R, **Advani R**. Utility of Routine Surveillance Laboratory Testing in Detecting Relapse in Patients with Classic Hodgkin Lymphoma in First Remission: Results From a Large Single-Institution Study [e-pub ahead of print]. *JCO Oncol Pract*, 2020. PMID: 32369413.
208. Carreau N, Armand P, Merryman R, **Advani R**, Spinner M, Herrera A, Ramchandren R, Hamid M, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair S, Barta S, Nathan S, Karmali R, Torka P, David K, Lansigan F, Persky D, Godfrey J, Chavez J, Xia Y, Diefenbach C. Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy [e-pub ahead of print]. *Br J Haematol*. 2020. PMID: 32430944.
209. Carreau N, Pail O, Armand P, Merryman R, **Advani R**, Spinner M, Herrera A, Chen R, Tomassetti S, Ramchandren R, Hamid S, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair S, Barta S, Liu Y, Nathan S, Karmali R, Burkart M, Torka P, David K, Wei C, Lansigan F, Emery L, Persky D, Smith S, Godfrey J, Chavez J, Xia Y, Troxel T, Diefenbach C. Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy *Oncologist*..25 (10).878-885. 2020 PMID: 32720734.
210. Frank M, Khodadoust M, Czerwinski D, Haabeth O, Chu M, Miklos D, **Advani R**, Alizadeh A, Gupta N, Maeda L, Reddy S, Laport G, Meyer E, Negrin R, Rezvani A, Weng W, Sheehan K, Faham M, Okada A, Moore A, Phillips D, Wapnir I, Brody J, Levy R. Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. *J Exp Med*.. 217(9):e20191712. 2020 PMID: 32558897.
211. Weil C, Qian Y, Von Eyben R, Daadi S, Corbelli K, Rosenberg S, **Advani R**, Hoppe R. Long-term outcomes of patients with unfavorable stage I-II classic Hodgkin lymphoma treated with Stanford V chemotherapy and limited field irradiation. *Leuk Lymphoma*. 61 (10), 2428-2434, 2020. PMID: 32476541.
212. Evens A, Hong F, Habermann T, **Advani R**, Gascoyne R, Witzig T, Quon A, Ranheim E, Ansell S, Singh P, Cheema P, Dy P, O'Brien T, Winter J, Cescon T, Chang J, Kahl B. A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408. *Clin Cancer Res*..26 (17), 4468-4477. 2020 PMID: 32832532790.
213. Talaulikar D, **Advani R**, Branagan A, Buske C, Dimopoulos M, D'Sa S, Kersten M, Leblond V, Minnema M, Owen R, Palomba M, Tedeschi A, Trotman J, Varettoni M, Vos J, Treon S, Kastritis E, Castillo J. Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic. *Hemasphere*. . 4(4):e433. 2020 PMID: 32803133.
214. Diefenbach C, Hong F, Ambinder R, Cohen J, Robertson M, David K, **Advani R**, Fenske T, Barta S, Palmisiano N, Svoboda J, Morgan D, Karmali R, Sharon E, Streicher H, Kahl B, Ansell S. Ipilimumab, Nivolumab, and Brentuximab Vedotin Combination Therapies in Patients with

Relapsed or Refractory Hodgkin Lymphoma: Phase 1 Results of an Open-label, Multicentre, Phase 1/2 Trial. *Lancet Haematol.* 7(9):e660-e670. 2020 PMID: 32853585.

215. Castillo JJ, **Advani RH**, Branagan AR, Buske C, Dimopoulos MA, D'Sa S, Kersten MJ, Leblond V, Minnema MC, Owen RG, Palomba ML, Talaulikar D, Tedeschi A, Trotman J, Varettoni M, Vos JM, Treon SP, Kastiris E. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. *Lancet Haematol.* 7(11): e827-e837 . 2020 PMID: 33091356.

216. Castillo JJ, Abeykoon JP, Gustine JN, Zanwar S, Mein K, Flynn CA, Demos MG, Guerrera ML, Kofides A, Liu X, Munshi M, Tsakmaklis N, King R, Yang G, Hunter ZR, **Advani RH**, Palomba ML, Ansell SM, Gertz MA, Kapoor P, Treon SP. Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib. *Br J Haematol.* 2020. PMID: 33207010. [Epub ahead of print]

217. Ballas LK, Metzger ML, Milgrom SA, **Advani R**, Bakst RL, Dabaja BS, Flowers CR, Ha CS, Hoppe BS, Mansur DB, Pinnix CC, Plastaras JP, Roberts KB, Smith SM, Terezakis SA, Constine LS. Nodular lymphocyte predominant Hodgkin lymphoma: executive summary of the American radiology society appropriate use criteria. *Leuk Lymphoma.* 2020. PMID: 33274673. [Epub ahead of print]

218. Allen PB, Savas H, Evens AM, **Advani R**, Palmer B, Pro B, Karmali R, Mou E, Bearden J, Dillehay G, Bayer R, Eisner RM, Chmiel JS, O'Shea KL, Gordon LI, Winter JN. Pembrolizumab followed by AVD in untreated early unfavorable and advanced stage classical Hodgkin lymphoma. *Blood.* 2020. PMID: 32992341. [Epub ahead of print]

219. Cheson BD, Bartlett NL, LaPlant B, Lee HJ, **Advani RJ**, Christian B, Diefenbach CS, Feldman TA, Ansell SM. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial. *Lancet Haematol.* 2020. PMID: 33010817. [Epub ahead of print]

220. Ghione P, Faruque P, Mehta-Shah N, Seshan V, Ozkaya N, Bhaskar S, Yeung J, Spinner MA, Lunning M, Inghirami G, Moskowitz A, Galasso N, Ganesan N, van der Weyden C, Ruan J, Prince HM, Trotman J, **Advani R**, Dogan A, Horwitz S. T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma. *Blood Adv.* 2020; 13;4(19):4640-4647. PMID: 33002132.

221. Menke JR, Spinner MA, Natkunam Y, Warnke RA, **Advani RH**, Gratzinger DA. CD20-Negative Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A 20-Year Consecutive Case Series From a Tertiary Cancer Center. *Arch Pathol Lab Med.* 2020. PMID: 32991677. [Epub ahead of print]

222. Treon SP, Meid K, Gustine J, Yang G, Xu L, Liu X, Patterson CJ, Hunter ZR, Branagan AR, Laubach JP, Ghobrial IM, Palomba ML, **Advani R**, Castillo JJ. Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia. *J Clin Oncol.* 2020. PMID: 32931398. [Epub ahead of print]

223. Mou E, **Advani R**, von Eyben R, Rosenberg SA, Hoppe RT. Long-Term Outcomes of Patients with Early-Stage Non-Bulky Hodgkin Lymphoma Treated with Combined Modality Therapy on the Stanford V Trials (The G4 and G5 Studies). *Int J Radiat Oncol Biol Phys*. 2020. [Epub ahead of print]. PMID: 33385495.

REVIEWS

1. **Advani R**, Saba HI, Tallman MS, Rowe JM, Wiernik PH, Ramel J, Dugan K, Lum B, Villena J, Davis E, Paietta E, Litchman M, Covelli A, Sikic BI and Greenberg PL. Treatment of poor prognosis AML patients with PSC 833 and mitoxantrone, etoposide, and cytarabine (PSC-MEC). *Leukemia* 12(2):257, 1998.
2. **Advani R**, Visani G, Milligan D, Saba H, Tallman M, Rowe JM, Wiernik PH, Ramek J, Dugan K, Lum B, Villena J, Davis E, Paietta E, Litchman M, Covelli A, Sikic BI, Greenberg P. Treatment of poor prognoses AML patients using PSC 833 (Valspodar) plus mitoxantrone, etoposide and cytarabine (PSC-MEC). *Adv Exp Med Biol*. 457:47-56, 1999.
3. **Advani R** and Horning S. Treatment of early stage Hodgkin's disease. *Semin Hematol*. 36:270-281, 1999.
4. Brody J, **Advani R**. Treatment of mantle cell lymphoma: Current approach and future directions. *Crit Rev Oncol Hematol*. 58(3):257-65, 2006.
5. Hoppe RT, **Advani RH**, Bierman PJ, Bloomfield CD, Buadi F, Djulgegovic B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Kaminski MS, Love G, Maloney DG, Mauch PM, Moore JO, Schilder RJ, Weiss L, Winter JN, Yahalom J, Zelenetz AD. Hodgkin disease/lymphoma: Clinical practice guidelines in oncology. *J Natl Compr Canc Netw* 4(3):210-30, 2006.
6. **Advani RH**, Buadi F, Cabanillas F, Caligiuri MA, Czuczman MS, Damon LE, Fayad L, Flinn IW, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Kaminski MS, Lacasce AS, Nademanee A, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J. Non-Hodgkin's Lymphoma. *J Natl Compr Canc Netw* 4(3):258-310, 2006.
7. Podoloff DA, **Advani RH**, Allred, C, Benson AB 3rd, Brown E, Burstein HJ, Carlson RW, Coleman RE, Czuczman MS, Delbeke D, Edge SB, Ettinger DS, Grannis FW Jr, Hillner BE, Hoffman JM, Kiel K, Komaki R, Larson SM, Mankoff DA, Rosenzweig KE, Skibber JM, Yahalom J, Yu JM, Zelenetz AD. NCCN Task Force Report: Positron emission tomography (PET)/computed tomography (CT) scanning in cancer. *J Natl Compr Canc Netw* (S1):S1-S22 2007.
8. Hoppe RT, **Advani RH**, Ambinder RF, Bierman PJ, Bloomfield CD, Blum K, Dabaja B, Djulbegovic B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hudson MM, Kaminski MS, Love G, Maloney DG, Mansur D, Mauch PM, Moore JO, Schilder RJ, Weiss LM, Winter JN, Yahalom J, Zelenetz AD. Hodgkin disease/lymphoma. *J Natl Compr Canc Netw*. 6(4):594-622, 2008.

9. Zelenetz AD, **Advani RH**, Byrd JC, Czuczman MS, Damon LE, Duvic M, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Nademanee A, Olsen EA, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J, Yunus F. Non Hodgkin's lymphoma. *J Natl Compr Canc Netw* 6(4):356-421, 2008.
10. Alizadeh AA and **Advani RH**. Evaluation and management of Angioimmunoblastic T-cell lymphoma: A review of current approaches and future strategies. *Clin Adv Hematol Oncol*. 6(12):899-909, 2008.
11. Maeda LS, **Advani RH**. The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma. *Curr Opin Oncol* 21(5): 397-400, 2009.
12. Kohrt H, **Advani R**. Extranodal natural killer/T-cell lymphoma: Current concepts in biology and treatment. *Leuk Lymphoma* 50(11):1773-84, 2009.
13. Mark Lee and **Ranjana Advani**. Targeting CD40 in Waldenstrom's Macroglobulinemia. *Clin Lymphoma Myeloma* 9(1):87-9, 2009.
14. Kwong YL, Anderson BO, **Advani R**, Kim WS, Levine AM, Lim ST. Management of T-cell and natural-killer-cell neoplasms in Asia: Consensus statement from the Asian Oncology Summit 2009. *Lancet Oncol* 11:1093-101, 2009.
15. Kohrt H, Lee M and **Advani R**. Risk Stratification in NK/T-cell lymphoma. *Expert Rev Anticancer Ther*. 10 (9) 1395-1405, 2010.
16. Ng A, Constone LS, **Advani R**, Das P, Flowers C, Friedberg J, Hodgson DC, Schwartz CL, Wilder RB, Wilson LD, Yunes MJ. ACR Appropriateness Criteria: Follow-up of Hodgkin's lymphoma. *Curr Probl Cancer* 34, 211-27, 2010. PMID: 20541059
17. Zelenetz AD, Abramson JS, **Advani RH**, Andreadis CB, Byrd JC, Czuczman MS, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Mughal TI, Nademanee A, Porcu P, Press O, Prosnitz L, Reddy N, Smith MR, Sokol L, Swinnen L, Vose JM, Wierda WG, Yahalom J, and Yunus F. NCCN clinical practice guidelines in oncology: Non-Hodgkin's lymphomas. *J Natl Compr Canc Netw* 8(3): 288-334, 2010. PMID: 20202462
18. Olsen EA, Rook AH, Zic J, Kim Y, Porcu P, Querfeld C, Wood G, Demierre MF, Pittelkow M, Wilson LD, Pinter-Brown L, **Advani R**, Parker S, Kim EJ, Junkins-Hopkins JM, Foss F, Cacchio P, Duvic M. Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). *J Am Acad Dermatol* 64(2):352-404, 2011. PMID: 21145619.

19. Das P, Ng A, Constine LS, **Advani R**, Das P, Flowers C, Friedberg J, Hodgson DC, Schwartz CL, Wilder RB, Wilson LD, Yunes MJ. ACR appropriateness criteria topic, Hodgkin's lymphoma-unfavorable clinical stage I and II. *J Am Coll Radiol* 8: 302-308, 2011. PMID: 20541059.
20. Zelenetz AD, Abramson JS, **Advani RH**, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Lacasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen LJ, Tsien C, Vose JM, Wierda WG, Yahalom J, Zafar N. Non-Hodgkin's Lymphomas. *J Natl Compr Canc Netw*. 2011 9(5): 484-560, 2011. PMID: 21550968
21. Hoppe RT, **Advani R**, Ai WZ, Ambinder RF, Aoun P, Bello CM, Bierman PJ, Blum KA, Chen R, Dabaja B, Duron Y, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Maloney DG, Mansur D, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Poppe M, Pro B, Winter JN, Yahalom J, Sundar H. Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. *J Natl Compr Canc Netw*. 10(5):589-97, 2012. PMID: 22570290
22. Zelenetz AD, Wierda WG, Abramson JS, **Advani RH**, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer MA, Naganuma M. Non-Hodgkin's Lymphoma, version 3.2012. *J Natl Compr Canc Netw*. 11(3):257-72, 2013. PMID: 23221787
23. Hoppe BS, Hodgson DC, **Advani R**, Dabaja BS, Flowers CR, Ha CS, Metzger ML, Plastaras JP, Roberts KB, Shapiro R, Terezakis SA, Winkfield KM, Younes A, Constine LS. ACR Appropriateness Criteria: Localized nodal indolent lymphoma. *Oncology (Williston Park)*. (8):786-94, 2013. PMID: 24133827
24. Ha C, Hodgson D, **Advani R**, Dabaja B, Dhakal S, Flowers C, Hoppe B, Mendenhall N, Metzger M, Plastaras J, Roberts K, Shapiro R, Smith S, Terezakis S, Winkfield K, Younes A, Constine L. ACR Appropriateness Criteria Follow-up of Hodgkin Lymphoma. *J Am Coll Radiol*. 11(11): 1026-1033, 2014. PMID:25278496
25. Terezakis S, Metzger M, Hodgson D, Schwartz C, **Advani R**, Flowers C, Hoppe B, Ng A, Roberts K, Shapiro R, Wilder R, Yunes M, Constine L. ACR Appropriateness Criteria® Pediatric Hodgkin Lymphoma. *Pediatr Blood Cancer*. 61(7);1305-12, 2014. PMID: 24616347
26. Zelenetz A, Gordon LI, Wierda WG, Abramson JS, **Advani R**, Adreadis C, Bartlett N, Byrd J, Czuczman M, Fayad L, Fisher R, Glenn M, Harris N, Hoppe R, Horwitz S, Kelsey R, Kim Y, Krivacic S, LaCasce A, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Saad A, Sokol L, Swinnen L, Tsien C, Vose J, Yahalom J, Zafar N, Dwyer M, Sundar H. Non-Hodgkin's Lymphomas, version 2.2014. *J Natl Compr Canc Netw*. 12(6); 916-46, 2014. PMID: 24925202
27. Zelenetz A, Gordon LI, Wierda WG, Abramson JS, **Advani R**, Adreadis C, Bartlett N, Byrd J, Czuczman M, Fayad L, Fisher R, Glenn M, Harris N, Hoppe R, Horwitz S, Kelsey R, Kim Y, Krivacic

S, LaCasce A, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Saad A, Sokol L, Swinnen L, Tsien C, Vose J, Yahalom J, Zafar N, Dwyer M, Sundar H. Non-Hodgkin's Lymphomas, version 4.2014. J Natl Compr Canc Netw. 12(9); 1282-303. 2014. PMID: 25190696

28. Hoppe RT, **Advani RH**, Ai WZ, Ambinder RF, Aoun P, Bello CM, Benitez CM, Bierman PJ, Blum KA, Chen R, Dabaja B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Khan N, Maloney DG, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Poppe M, Rabinovitch R, Seropian S, Tsien C, Winter JN, Yahalom J, Burns JL, Sundar H. Hodgkin lymphoma, version 2.2015. Natl Compr Canc Netw. 13(5):554-86, 2015. PMID:25964641

29. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, **Advani RH**, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Saad AA, Sokol L, Swinnen LJ, Tsien C, Vose JM, Wilson L, Yahalom J, Zafar N, Dwyer M, Sundar H. Chronic lymphocytic leukemia/small lymphocytic lymphoma. J Natl Compr Canc Netw. 13(3):326-62, 2015. PMID:25736010

30. Dabaja BS, **Advani R**, Hodgson DC, Dhakal S, Flowers CR, Ha CS, Hoppe BS, Mendenhall NP, Metzger ML, Plastaras JP, Roberts KB, Shapiro R, Smith SM, Terezakis SA, Winkfield KM, Younes A, Constine LS. ACR Appropriateness Criteria® diffuse large B-cell lymphoma. Am J Clin Oncol. 38(6):610-20, 2015. PMID: 26583344

31. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, **Advani RH**, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H. Diffuse Large B-Cell Lymphoma Version 1.2016. J Natl Compr Canc Netw. 14(2):196-231, 2016. PMID: 26850490

32. Roberts KB, Younes A, Hodgson DC, **Advani R**, Dabaja BS, Dhakal S, Flowers CR, Ha CS, Hoppe BS, Mendenhall NP, Metzger ML, Plastaras JP, Shapiro R, Smith SM, Terezakis SA, Winkfield KM, Constine LS; Expert Panel on Radiation Oncology Lymphoma. ACR Appropriateness Criteria Hodgkin Lymphoma-Unfavorable Clinical Stage I and II. Am J Clin Oncol. 39(4):384-95, 2016. PMID: 27299425.

33. Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, **Advani RH**, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H, Porcu P. NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. J Natl Compr Canc Netw. 14(9):1067-79, 2016. PMID: 27587620.

34. Dhakal S, **Advani R**, Ballas LK, Dabaja BS, Flowers CR, Ha CS, Hoppe BS, Mendenhall NP, Metzger ML, Plastaras JP, Roberts KB, Shapiro R, Smith SM, Terezakis SA, Winkfield KM, Younes A, Constine LS; Expert Panel on Radiation Oncology–Lymphoma. ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II. *Am J Clin Oncol*. 39(6):535-544, 2016. PMID: 27643717
35. Winkfield KM, **Advani RH**, Ballas LK, Dabaja BS, Dhakal S, Flowers CR, Ha CS, Hoppe BS, Mansur DB, Mendenhall NP, Metzger ML, Plastaras JP, Roberts KB, Shapiro R, Smith SM, Terezakis SA, Younes A, Constine LS. ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma. *Oncology (Williston Park)*. 30(12):1099-103, 1106-8, 2016. PMID: 27987203
36. Wierda WG, Zelenetz AD, Gordon LI, Abramson JS, **Advani RH**, Andreadis CB, Bartlett N, Byrd JC, Caimi P, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Martin MG, Nademanee A, Porcu P, Press O, Rabinovitch R,
37. Reddy N, Reid E, Roberts K, Saad AA, Snyder ED, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Dwyer MA, Sundar H. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017. *J Natl Compr Canc Netw*. 15(3):293-311, 2017. PMID: 28275031.
38. Hoppe RT, **Advani RH**, Ai WZ, Ambinder RF, Aoun P, Bello CM, Benitez CM, Bernat K, Bierman PJ, Blum KA, Chen R, Dabaja B, Forero A, Gordon LI, Harnandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Kaminski MS, Kenkre VP, Khan N, Maloney DG, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Poppe M, Rabinovitch R, Seropian S, Smith M, Winter JN, Yahalom J, Burns J, Ogba N, Sundar H. Hodgkin Lymphoma Version 1.2018. *NCCN Clinical Practice Guidelines in Oncology*. *J Natl Compr Canc Netw*. 15(5):608-638, 2017. PMID: 28476741.
39. Hoppe R, **Advani R**, Ai W, Ambinder R, Aoun P, Armand P, Bello C, Benitez C, Bierman P, Chen R, Dabaja B, Dean R, Forero A, Gordon L, Hernandez-Ilizaliturri F, Hochberg E, Huang J, Johnston P, Kaminski M, Kenkre V, Khan N, Maddocks K, Maloney D, Metzger M, Moore J, Morgan D, Moskowitz C, Mulroney C, Rabinovitch R, Seropian S, Tao R, Winter J, Yahalom J, Burns J, Ogba N. NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018. *J Natl Compr Canc Netw*. 16(3):245-254, 2018. PMID: 29523663.
40. Zelenetz AD, Gordon LI, Abramson JS, **Advani RH**, Bartlett NL, Caimi PF, Chang JE, Chavez JC, Christian B, Fayad LE, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Mehta A, Nademanee A, Rabinovitch R, Reddy N, Reid E, Roberts KB, Smith SD, Snyder ED, Swinnen LJ, Vose JM, Dwyer MA, Sundar H. *J Natl Compr Canc Netw*. 17(6):650-661, 2019. PMID: 31200358.
41. Hoppe RT, **Advani RH**, Ai WZ, Ambinder R, Armand P, Bello C, Benitez C, Bierman P, Boughman K, Dabaja B, Gordon L, Hernandez-Ilizaliturri F, Herrera A, Hochberg E, Huang J, Johnston P, Kaminski M, Kenkre V, Khan N, Lynch R, Maddocks K, McConathy J, McKinney M,

Metzgar M, Morgan D, Mulrone C, Rabinovich R, Rosenspire K, Seropian S, Tao R, Winter J, Yahalom J, Burns J, Ogba N. Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18(6):755-781. PMID: 32502987.

42. Ballas, LK; Metzger, ML; Milgrom, SA; **Advani**, R; Bakst, RL; Dabaja, BS; Flowers, CR; Ha, CS; Hoppe, BS; Mansur, DB; Pinnix, CC; Plastaras, JP; Roberts, KB; Smith, SM; Terezakis, SA; Constine, LS. Nodular lymphocyte predominant Hodgkin lymphoma: executive summary of the American radiology society appropriate use criteria Leuk Lymphoma, pp. 1-14, 2020 PMID: 33274673

CHAPTERS

1. **Advani R**, Saba H, Tallman M, Rowe JM, Wiernik P, Ramek J, Dugan K, Litchman M, Sikic BI, Davis E, Paietta E, and Greenberg P. Treatment of poor prognosis acute myelogenous leukemia with PSC-833 and mitoxantrone, etoposide, cytarabine. In: Acute Leukemias VII - Experimental Approaches and Management of Refractory Disease. Hiddeman W et al. (Eds.) Springer-Verlag, Berlin, 456-60, 1998.

2. **Advani RH**, Horwitz SM, Horning SJ. "Lymphoma". In: Wachter RM, Goldman L Hollander H, eds. Hospital Medicine, 2nd Edition. Philadelphia, PA. Lippincott Williams & Wilkins, Chapter 94, 937-946, 2005.

3. Hoppe, RT, Kim Y, **Advani R**, "Mycoses fungoides and the Sezary Syndrome". In: Kufe DW et al, eds, Cancer Medicine 7, BC Decker, Inc., Chapter 119, 1839-1847, 2006.

4. Hoppe R, Kim YK, **Advani R**. The Primary Cutaneous Lymphomas. In: The Lymphomas, Canellos GP, Lister TA, and Young B, eds., Second Edition, Saunders, Chapter 25, 424-436, 2006.

5. **Advani R** and Jacobs CD. "Lymphomas of the Head and Neck". In: Bailey BJ, and Johnson, JT, eds. Head and Neck Surgery-Otolaryngology, Fourth Edition, Lippincott Williams & Wilkins, V2, Section VIII, Chapter 115, 1621-1628, 2006.

6. Guardino AE, Ganjoo K, **Advani R**. Treatment Approach to Mantle Cell Lymphomas. In: Sekeres M, Bolwell B, and Kalaycio, M, eds. Clinical Malignant Hematology. McGraw Hill, New York, Chapter 55. 555-565, 2007.

7. Diehl V, Behringer K, Raemaker J, **Advani R** and Horning SJ. Treatment of Stage III-IV Hodgkin Lymphoma. In: Hodgkin Lymphoma, Second edition, Hoppe RT et al eds, Lippincott Williams & Wilkins, Chapter 18, 253-271, 2007.

8. Kim YH, **Advani RH**, Harevell JD, Hoppe RT. Mycosis Fungoides and Sezary Syndrome. In: Non-Hodgkin Lymphomas, Armitage JO, Mauch P, Harris NL, Coiffier B, Dalla-Favera R. eds. Lippincott Williams & Wilkins, Philadelphia, Chapter 25, 381-292, 2010.

9. Hoppe RT, Kim YH, **Advani R**: Mycosis Fungoides and the Sezary Syndrome. In: Cancer Medicine 8. Holland and Frei, eds, B.C. Decker, Inc. Chapter 114, 2010.
10. Kim YH, **Advani R**, Hoppe RT: Mycosis Fungoides and Sezary Syndrome. In: The Lymphoid Neoplasms, 3rd Edition. Magrath I, eds, Oxford University Press, Chapter 41, 2010.
11. Hoppe RT, Kim Y, **Advani R**: Mycoses Fungoides. In: Textbook of Radiation Oncology. Leibel S, Hoppe RT, Roach M, Phillips TL eds, Saunders, Philadelphia, Chapter 62, 1380-93, 2010.
12. Eichenauer D, **Advani RH**, Engert A, Delabie J, Rodig, S: Lymphocyte predominant Hodgkin lymphoma, In Rare lymphomas, 2014 Edition. Dreying M and Williams ME, eds. Springer, Chapter 18, 2014.

ACCEPTED ABSTRACTS FOR PUBLICATION (since 2015):

2015 (36 Total)

1. **Advani R**, Blum K, Truong V, Cheng M, Lee D, Beaupre D, Rule S, Wang S. Safety and tolerability of Bruton's tyrosine kinase inhibitor ibrutinib in previously treated Mantle cell lymphoma (MCL). Hematology Oncology Pharmacy Association Conference. Austin, TX. 2015 Poster Presentation.
2. Fanale M, Horowitz M, Forero-Torres A, Bartlett N, **Advani R**, Pro B, Chen R, Davies A, Illidge T, Huebner D, Kennedy D, Shustov A. Brentuximab vedotin in combination with CHP in patients with newly diagnosed CD30-positive peripheral T-cell lymphomas: 2-year follow up. T-Cell Lymphoma Conference. San Francisco, CA. 2015 Poster Presentation.
3. Rule S, Goy A, Martin P, Ramchandren R, Alexeeva J, Popat R, Avivi I, **Advani R**, Le Gouill S, Horowitz N, Yuan Z, Kranenburg B, Zhuang S, Deraedt W, Rizo A, Wildgust M, Wang M. Single-agent ibrutinib for the treatment of mantle cell lymphoma (MCL): Evaluating the link between durable response and quality of life (QoL) in the SPARK study. British Society of Haematology Annual Scientific Meeting. 2015 Poster Presentation.
4. **Advani RH**, Flinn I, Sharman JP, Diefenbach C, Kolibaba KS, Press OW, Sehn LH, Chen AI, Salles GA, Tilly H, Cheson BD, Assouline SE, Dreyling MH, Hagenbeek A, Zinzani PL, Jones C, Chu Y, Hirata J, Wenger M, Morschhauser F. Two doses of polatuzumab vedotin (PoV, anti-CD79b antibody-drug conjugate) in patients (pts) with relapsed/refractory (RR) follicular lymphoma (FL): Durable responses at lower dose level. J Clin Oncol 33 (15s): 8503a, 2015. Oral Presentation.
5. Bartlett NL, Farber CM, Yasenachak CA, Ansell SM, **Advani RH**, Knapp MH, Fayad L, Kolibaba KS, Patel-Donnelly D, Seetharam M, Yimer HA, Manley TJ, Burke JM, Holkova B, Budde LE, Halwani AS. Updated results of a phase II trial of brentuximab vedotin combined with R-CHOP

in frontline treatment of patients (pts) with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL). J Clin Oncol 33 (15s): 8506a, 2015. Oral Presentation.

6. Brownstein, CM, Adriaens L, Bannerji R, Chavez JC, Levy R, Ansell SM, **Advani RH**, Patel S, Kostic A, Trail P, Lowy I, Kohrt HE. First-in-human study assessing safety and tolerability of REGN1979, a novel CD20xCD3 bispecific antibody, in patients with CD20+ B-cell malignancies previously treated with anti-CD20 therapy. J Clin Oncol 33 (15s): TPS3089, 2015. Poster Presentation.

7. Federico M, Bellei M, Luminari S, Horwitz SM, Montoto S, Zucca E, Pileri SA, Ko YH, Zinzani PL, Connors JM, Foss FM, Polliack A, Cabrera ME, Kim WS, Spina M, De Souza CA, Varela SB, Dlouhy I, **Advani RH**, Vose J. CD30+ expression in peripheral T-cell lymphomas (PTCLs): A subset analysis from the international, prospective T-Cell Project. J Clin Oncol 33 (15s): 8552a, 2015. Poster Presentation.

8. Khodadoust MS, Chu MP, Czerwinski D, McDonald K, Long S, Kohrt HE, Hoppe RT, **Advani RH**, Lowsky R, Levy R. Phase I/II study of intratumoral injection of SD-101, an immunostimulatory CpG, and intratumoral injection of ipilimumab, an anti-CTLA-4 monoclonal antibody, in combination with local radiation in low-grade B-Cell lymphomas. J Clin Oncol 33 (15s): TPS8604, 2015. Poster Presentation.

9. Diefenbach C, Li H, Kahl BS, Robertson MJ, Cohen J, **Advani RH**, Ambinder R, Fenske TS, Ansell SM. A phase I study with an expansion cohort of the combination of ipilimumab and brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412). J Clin Oncol 33 (15s): TPS8602, 2015. Poster Presentation.

10. Scherer F, Kurtz DM, Green MR, Newman AM, Klass DM, Zhou L, Krishnan R, Liu CL, Glover C, Ohgami RS, Hicks RJ, Keane C, Kong KA, Faham M, Hertzberg MS, Gandhi MK, **Advani RH**, Levy R, Diehn M, Alizadeh, A. Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL). J Clin Oncol 33 (15s): 8539a, 2015. Poster Presentation.

11. Treon SP, Tripsas C, Meid K, Warren D, Varma G, Green R, Argyropoulos KV, Yang G, Rodig S, Zehnder J, Aster J, Harris NL, Kanan S, Ghobrial I, Castillo JJ, Laubach J, Hunter ZR, Salman Z, Graef T, Li J, Cheng M, Clow F, Palomba L, **Advani R**. Ibrutinib is highly active and produces durable responses in previously treated Waldenstrom's Macroglobulinemia. Hematol Oncol. 33(1) 77a, 2015. Oral Presentation.

12. Ansell SM, Farber CM, Bartlett NL, Halwani AS, Yassenchak CA, Knapp M, Fayad L, Kolibaba KS, Patel-Donnelly D, Seetharam M, Yimer HA, Manley T, Burke JM, Holkova B, Budde L, **Advani R**. Updated results of a phase 2 trial of brentuximab vedotin combined with RCHOP in frontline treatment of PTS with high-intermediate/high risk DLBCL. Hematol Oncol. 33(1) 92a, 2015. Oral Presentation.

13. Evens AM, Kanakry JA, Sehn L, Kritharis A, Feldman T, Kroll A, Gascoyne RD, Petrich AM, Abramson JS, Hernandez-Ilizaliturri F, Al-Mansour Z, Hemminger J, Bartlett NL, Mato AR, Caimi P, **Advani R**, Klein A, Lossos IS, Press OW, Smith SM, Nabhan C, Fenske TS, Friedberg JW, Vose JM, Blum KK. Gray Zone Lymphoma (GZL): Characteristics, outcomes and prognostication among a large multicentre cohort. *Hematol Oncol.* 33(1) 126a, 2015. Oral Presentation.
14. Sharman J, Flinn I, **Advani R**, Diefenbach C, Kolibaba K, Press O, Sehn L, Chen A, Salles G, Tilly H, Cheson B, Assouline S, Dreyling M, Hagenbeek A, Zinzani P, Jones C, Jones S, Chu Y, Hirata J, Wenger M, Morschhauser F. Two doses of polatuzumab vedotin in patients with relapsed/refractory (R/R) follicular lymphoma (FL): Durable responses at lower doses. *Hematol Oncol.* 33(1) 142a, 2015. Oral Presentation.
15. Martin P, Maddocks K, Leonard J, Ruan J, Goy A, Wagner-Johnston N, Rule S, **Advani R**, Iberri D, Spurgeon S, Kozin E, Noto K, Chen Z, Jurczak W, Auer R, Chmielowska E, Stilgenbauer S, Dreyling M, Barr P, Furman R, Blum K. Poor overall survival of patients with ibrutinib-resistant mantle cell lymphoma. *Hematol Oncol.* 33(1) 207a, 2015. Poster Presentation.
16. Federico M, Bellei M, Pesce EA, Horwitz SM, Montoto S, Zucca E, Pileri SA, **Advani RH**, Caballero D, Cabrera ME, Carson K, Chiattoni CS, Davies A, Dlouhy L, Fernandez-Alvarez R, Gabus R, González de Villambrosia Pellón S, Hitz F, Kim WS, Nagler A, Pavlovsky A, Shustov A, Spina AM, Vitolo U, Vose JM. T-Cell project: An international, prospective, observational study of patients with aggressive peripheral NK/T-Cell lymphoma. Lesson from the first 1308 patients. *Hematol Oncol.* 33(1) 70a, 2015. Oral Presentation.
17. Evens AM, Hamlin P, Nabhan C, **Advani RH**, Fanale M, Petrich AM, Smith SM, Bociek GR, Winter JN, Gordon LI. Sequential brentuximab vedotin and AVD for older Hodgkin Lymphoma patients: Initial results from a phase 2 multicentre study. *Hematol Oncol.* 33(1) 89a, 2015. Oral Presentation.
18. Smith MR, Jacobsen ED, Siddiqi T, O'Connor OA, **Advani RH**, Sharman JP, Feldman T, Shustov A, Savage KJ, Palanca-Wessels M, Uttarwar M, Li M, Bartlett NL. Brentuximab vedotin demonstrates antitumour activity in CD30+ DLBCL. *Hematol Oncol.* 33(1) 91a, 2015. Oral Presentation.
19. Bellei M, Marcheselli L, Pesce EA, Horwitz SM, Vose JM, Montoto S, Pileri SA, Ko YH, Zucca E, Foss FM, Connors JM, Polliack A, Zinzani PL, **Advani RH**, Cabrera ME, De Souza CA, Kim WS, Martinez V, Merli F, Moskowitz A, Nagler A, Radford J, Shustov A, Spina M, Federico M. Clinical characteristics and patterns of care of patients (PTS) with peripheral T-Cell lymphoma (PTCLS) according to age at time of diagnosis: A T-Cell project snapshot. *Hematol Oncol.* 33(1) 231a, 2015. Poster Presentation.
20. Roemer M, **Advani RH**, Ligon AH, Natkunam Y, Redd RA, Homer H, Connelly C, Sun HH, Daadi SE, Chapuy B, de Jong D, Hoppe RT, Neuberg DS, Rodig SJ, and Shipp MA. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. *Blood* 126 (23) 176a, 2015. Oral Presentation.

21. Moskowitz CH, Fanale MA, Shah BD, **Advani RH**, Chen R, Kim S, Kostic A, Liu T, Peng J and Forero-Torres A. A phase 1 study of denintuzumab mafodotin (SGN-CD19A) in relapsed/refractory B-lineage non-Hodgkin lymphoma. Blood 126(23) 182a, 2015. Oral Presentation.
22. Fowler N, Nastoupil L, de Vos S, Knapp M, Flinn IW, Chen R, **Advani RH**, Bhatia S, Martin P, Mena R, Suzuki S, Beaupre DM, Neuenburg JK, and Palomba ML. Ibrutinib plus rituximab in treatment-naive patients with follicular lymphoma: Results from a multicenter, phase 2 study. Blood 126(23), 470a, 2015. Oral Presentation.
23. Diefenbach CS, Hong F, Cohen JB, Robertson MJ, Ambinder RF, Fenske TS, **Advani RH**, Kahl BS and Ansell S. Preliminary safety and efficacy of the combination of brentuximab vedotin and ipilimumab in relapsed / refractory Hodgkin lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412). Blood 126 (23) 585a, 2015. Oral Presentation.
24. Yasenchak CA, Halwani A, **Advani R**, Ansell S, Budde LE, MD, Burke JM, Farber CM, Holkova B, Fayad LE, Kolibaba KS, Knapp M, Li M, Manley TJ, Patel-Donnelly D, Seetharam M, Yimer HA, and Bartlett NL. Brentuximab Vedotin with RCHOP as frontline therapy in patients with high-intermediate/high-risk diffuse large B cell lymphoma (DLBCL): Results from an ongoing phase 2 study. Blood 126(23) 814a, 2015. Oral Presentation.
25. Xu L, Hunter Z, Tsakmaklis N, Cao Y, Yang G, Chen J, Liu X, Kanan S, Castillo JJ, Tai YT, Zehnder JL, Brown JR, Carrasco RD, **Advani RH**, Argyropoulos KV, Palomba ML, Morra E, Trojani A, Greco A, Tedeschi A, Varettoni M, Arcaini L, Munshi NC, Anderson KC, and Treon SP. The clonal architecture of CXCR4 mutations in Waldenstrom's Macroglobulinemia shows highly variable subclonal distribution, and multiple mutations within individual patients indicative of targeted genomic instability. Blood 126(23) 1486a, 2015. Poster Presentation.
26. Swinnen LJ, O'Neill A, Imus PH, Gujar S, Schiff D, Kleinberg L, **Advani R**, Dunbar E, Moore DF and Grossman S. Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL)[E1F05]. Blood 126(23) 1530a. 2015. Poster Presentation.
27. Chu MP, Brody J, Kohrt HE, Frank MJ, Khodadoust M, Reddy S, **Advani RH**, Gupta NK, Laport G, Maeda LS, MD, Meyer E, Miklos DB, Negrin RS, Rezvani AR, Weng WK, Sheehan K, Faham M, Czerwinski DK, Okada A, and Levy R. Phase I/II clinical trial of CpG-activated whole cell vaccine in mantle cell lymphoma (MCL): Results in safety and efficacy from planned interim analysis. Blood 126(23) 1536a, 2015. Poster Presentation.
28. Horwitz SM, Shustov AR, Forero-Torres A, Bartlett NL, **Advani R**, Pro B, Chen R, Davies AJ, Illidge T, Huebner D, Kennedy DA and Fanale MA. Frontline treatment of CD30+ peripheral T-cell lymphomas with brentuximab vedotin in combination with CHP: 3-Year durability and survival follow-up. Blood 126(23) 1537a, 2015. Poster Presentation.
29. Thomas SK, Harb WA, Beck JT, Nashat G, Palomba ML, Ansell SM, Eradat H, Libby EN, **Advani RH**, Hajdenberg J, Heffner JT, Hoffman J, Vesole DH, Simov L, Wyant N, Brevard J, O'Leary J, and Agrawal S. Preliminary results from a phase 1/2, open-label, dose-escalation

clinical trial of IMO-8400 in patients with relapsed or refractory Waldenstrom's Macroglobulinemia. Blood 126(23) 1540a, 2015. Poster Presentation.

30. Henderson TO, Parsons SK, Wroblewski K, Chen L, Hong F, Smith SM, McNeer J, **Advani R**, Gascoyne RD, Constine L, Horning SJ, Bartlett NL, Shah BD, Connors JM, Leonard JP, Kahl BS, Kelly KM, Schwartz C, Friedman DL, Gordon LI, and Evens AM. Outcomes in adolescents and young adults (AYA) with Hodgkin lymphoma (HL) treated on US Cooperative Group Protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. Blood 126(23) 2636a, 2015. Poster Presentation.

31. Smith MR, Li H, Hong F, Gordon LI, Gascoyne RD, Paietta E, **Advani RH**, Forrero-Torres A, Horning, SJ and Kahl BS. Initial therapy for mantle cell lymphoma with abbreviated R-CHOP followed by Y90-Ibritumomab Tiuxetan: Ten year follow-up of the phase 2 ECOG-ACRIN study E1499. Blood 126(23) 2702a, 2015. Poster Presentation.

32. Fowler N, Boyd TE, Sharman JP, Smith SM, Clow F, Chu AD and **Advani RH**. Long-term follow-up and analysis of dose groups with ibrutinib in relapsed follicular lymphoma. Blood 126(23) 2706a, 2015. Poster Presentation.

33. Sawas A, Savage KJ, Perez R, **Advani RH**, Butturini A, Lackey J, Trave F, Anand B, Huang Y, Reyno L, and O'Connor OA. A phase 1 study of the anti-CD37 antibody-drug conjugate AGS67E in advanced lymphoid malignancies. Interim results. Blood 126(23) 3976a, 2015. Poster Presentation.

34. LaCasce AS, Bociek G, Sawas A, Caimi PF, Agura E, Matous J, Ansell, S, Crosswell H, Islas-Ohlmayer M, Behler C, Cheung E, Forero-Torres A, Vose J, O'Connor OA, Josephson N and **Advani R**. Brentuximab vedotin plus bendamustine: A highly active salvage treatment regimen for patients with relapsed or refractory Hodgkin lymphoma. Blood 126(23) 3982a, 2015. Poster Presentation.

35. Minamimoto R, Fayad L, **Advani R**, Vose J, Macapinlac H, Meza, J, Hankins J, Mottahgy F, Juweid M, Quon A. Prospective multicenter comparison of early interim F-FLT PET/CT versus F-FDG PET/CT. J Nucl Med 56 (S3) 1354a. Oral Presentation

36. Rule S, Goy A, Martin P, Ramchandren R, Alexeeva J, Popat R, Arivi A, **Advani R**, Le Gouill S, Horowitz N, Yuan Z, Kranenberg B, Zhuang S, Deraedt W, Rizo A, Wildgust M and Wang M: Ibrutinib for the treatment of mantle cell lymphoma: Evaluating the correlation between patient reported outcomes and durability of response in a phase 2 study. ISPOR 20th Annual meeting 2015. Poster presentation

2016 (31 Total)

1. Horwitz SM, Shustov AR, Forero-Torres A, Bartlett NL, **Advani R**, Pro B, Chen R, Davies AJ, Illidge T, Huebner D, Kennedy DA and Fanale MA Frontline treatment of CD30+ peripheral T-cell lymphomas with brentuximab vedotin in combination with CHP: 3-year durability and survival follow-up. T-Cell Lymphoma Conference. San Francisco, CA. January 2016 Poster Presentation

2. Lai L, Muehe A, Larson D, Neyssa M, **Advani R**, Rangaswami A, Taviani V, Holdsworth S, Holley D, Daldrup-Link H. Streamlining PET/MRI workflow in pediatric oncologic imaging. 7th International Pediatric Radiology Conjoint Meeting & Exhibition, Chicago, IL. May 2016. Poster Presentation
3. Lai LM, Muehe A, Quon A, Holdsworth S, Taviani V, Rangaswami A, **Advani R**, Marina N, Daldrup-Link H. PET/MRI detection of pulmonary nodules for pediatric cancer staging. 7th International Pediatric Radiology Conjoint Meeting & Exhibition, Chicago, IL. May 2016. Oral Presentation
4. Lai LM, Muehe A, Larson D, Marina N, **Advani R**, Rangaswami A, Taviani V, Holdsworth S, Holley D, Daldrup-Link H. Streamlining PET/MRI Workflow in Pediatric Oncologic Imaging. 7th International Pediatric Radiology Conjoint Meeting & Exhibition, Chicago, IL. May 2016. Oral Presentation
5. Penuel E, Mundt K, Bourgon R, Sumiyoshi T, Flinn I, Press O, Patel M, **Advani R**, Venstrom JM, Chu Y, Hirata J. Biomarkers in relapsed/refractory DLBCL and FL patients treated with polatuzumab vedotin: results from the phase ii clinical trial (Romulus). Haematologica 2016 101(s1) abstr E1397. Poster Presentation
6. Kurtz DM, Scherer F, Newman AM, Craig AFM, Khodadoust MS, Lovejoy AF, Klass DM, Chabon JJ, Glover C, Zhou L, Liu CL, Gupta NK, Maeda LS, **Advani RH**, Levy R, Diehn M, Alizadeh AA. Prediction of therapeutic outcomes in DLBCL from circulating tumor DNA dynamics. J Clin Oncol 34, 2016 (suppl; abstr 7511). Oral Presentation
7. Sawas A, Savage KL, Perez RP, **Advani RH**, Melhem-Bertrandt A, Lackey, Trave JF, Anand B, Huang Y, Vincent M, Reyno LM, O'Connor OA. A first in human experience of the anti-CD37 antibody-drug conjugate AGS67E in lymphoid malignancies. J Clin Oncol 34, 2016 (suppl; abstr 7549). Poster Presentation
8. Evens AM, Hong F, Habermann TM, **Advani RH**, Gascoyne RD, Witzig TE, Quon A, Wagner LI, Ansell SM, Petrich AM, Chang JE, O'Brien TE, Cheema, PS Cescon T, Sturtz K, Kahl BS. Effect of bortezomib on complete remission (CR) rate when added to bendamustine-rituximab (BR) in previously untreated high-risk (HR) follicular lymphoma (FL): A randomized phase II trial of the ECOG-ACRIN Cancer Research Group (E2408). J Clin Oncol 34, 2016 (suppl; abstr 7507). Oral Presentation
9. Keegan THM, Clarke CA, Rosenberg AS, **Advani RH**, Jonas BA, Flowers C, Tao L. Subsequent primary malignancies (SPMs) after diffuse large B-cell lymphoma (DLBCL) in the modern treatment era. J Clin Oncol 34, 2016 (suppl; abstr 7543). Poster Presentation
10. Scherer F, Kurtz DM, Newman AM, Stehr H, Craig AFM, Esfahani MS, Lovejoy AF, Chabon JJ, Klass DM, Liu CL, Zhou L, Glover C, **Advani RH**, Maeda LS, Gupta NK, Levy R, Ohgami RS, Kunder C, Diehn M, Alizadeh AA. Noninvasive Molecular Subtyping and Risk Stratification of DLBCL. J Clin Oncol 34, 2016 (suppl; abstr 7554). Poster Presentation
11. Evens AM, Hamlin PA, Nabhan C, **Advani RH**, Fanale M, Petrich A, Smith SM, Bociek G, Winter J, Gordon LI. Sequential Brentuximab Vedotin (BV) and Adriamycin, Vinblastine, and

Dacarbazine (AVD) for Older Patients with Untreated Hodgkin Lymphoma (HL): Findings from a Phase II Window Study. *Haematologica* 101(s5) 20, 2016. Abstract #P001. Poster Presentation

12. Henderson TO, Parsons SK, Wroblewski K, Chen L, Hong F, Smith S, McNeer J, **Advani R**, Gascoyne RD, Constine LS, Horning S, Bartlett NL, Shah B, Connor JM, Leonard J, Kahl BS, Kelly K, Schwartz CL, Friedman D, Gordon LI, Evens AM. Outcomes in adolescents and young adults (AYA) with Hodgkin Lymphoma (HL) treated on US cooperative group protocols: an adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. *Haematologica* 101(s5) 34, 2016. Abstract #P086. Oral Presentation

13. Diefenbach CSM, Hong F, Ambinder RF, Cohen JB, Robertson MJ, Fenske TS, **Advani RH**, Kahl BS, Ansell SM. A Phase I Study with an Expansion Cohort of the Combination of Ipilimumab and Brentuximab Vedotin in Patients with Relapsed / Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412). *Haematologica* 101(s5) 44, 2016. Abstract #P080. Poster Presentation

14. LaCasce A, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, Ansell S, Crosswell H, Islas-Ohlmayer M, Behler C, Cheung E, Forero-Torres A, Vose J, O'ConnoR OA, Josephson N, **Advani R**. Brentuximab Vedotin Plus Bendamustine as a Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma. *Haematologica* 101(s5) 45, 2016. Abstract #P093. Poster Presentation

15. Scherer F, Kurtz DM, Newman AM, Esfahani MS, Craig A, Stehr H, Lovejoy AF, Chabon JJ, Liu CL, Zhou L, Glover C, Visser BC, Poultides G, **Advani RH**, Maeda LS, Gupta NK, Levy R, Ohgami RS, Davis ER, Gaidano G, Kunder CA, Rossi D, Westin JR, Diehn M, Alizadeh AA. Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma. *Blood* 128 1089a, 2016. Oral Presentation.

16. Budde LE, Halwani A, Yassenchak CA, Farber CM, Burke JM, Fayad LE, Holkova B, Knapp M, Kolibaba KS, **Advani RH**, Ansell SM, Patel-Donnelly D, Yimer HA, Smith SE, Levy MY, Seetharam M, Belada D, Brooks D, Kingsley EC, Klein LM, Wagner-Johnston N, Ruffner K, Bartlett NL. Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL). *Blood* 128 104a 2016. Oral Presentation.

17. Bannerji R, Brown JR, **Advani RH**, Arnason J, O'Brien SM, Allan JN, Chavez JC, Barnes JA, Joyce R, Ansell S, Topp MS, Adriaens L, Ufkin M, Kostic A, Paccaly A, Gao B, Trail PA, Lowy I, MD, Brownstein C. Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy. *Blood* 128 621a 2016. Oral Presentation.

18. Bellei M, Foss FM, Horwitz SM, Marcheselli L, Kim WS, Cabrera ME, Dlouhy I, Nagler A, **Advani RH**, Pesce E, Ko YH, Martinez V, Montoto S, Chiattonne C, Moskowitz AJ, Spina M, Cesaretti M, Biasoli I, Federico M. The Outcome of Patients with Primary Refractory or Relapsed Peripheral T-Cell Lymphoma: Analysis of 1020 Cases Registered in the Prospective T-Cell Project. *Blood* 128 921a 2016. Oral Presentation.

19. Xu L, Tsakmaklis N, Yang G, Chen JG, Liu X, Chen J, Demos M, Patterson CJ, Dubeau T, Meid K, Gustine J, Castillo JJ, **Advani RH**, Palomba ML, Furman RR, Hunter Z, Treon SP. Molecular Basis of Ibrutinib Resistance in Waldenstrom's Macroglobulinemia. *Blood* 128 756a 2016. Oral Presentation.
20. Melani CJ, **Advani R**, Chen CC, Walters KM, Venzon D, Steinberg SM, Shovlin M, Jaffe ES, Pittaluga S, Roschewski M, Wilson WH, Dunleavy K. DA-EPOCH-R in Primary Mediastinal B-Cell Lymphoma; Analysis of End of Therapy FDG-PET and Outcome. *Blood* 128 1116a 2016. Oral Presentation.
21. Herrera AF, Bartlett NL, Ramchandren R, Vose JM, Moskowitz AJ, Feldman TA, LaCasce AS, Ansell SM, Moskowitz CH, Fenton K, Kato K, Fong A, **Advani RH**. Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma. *Blood* 128 1105a 2016. Oral Presentation.
22. Diefenbach CS, Hong F, David KA, Cohen J, Robertson M, **Advani R**, Palmisiano ND, Ambinder RF, Kahl BS, Ansell S. A Phase I Study with an Expansion Cohort of the Combination of Ipilimumab and Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412 Arms D and E). *Blood* 128 1106a 2016. Oral Presentation.
23. Kurtz DM, Scherer F, Newman AM, Craig A, Jin M, Stehr S, Chabon JJ, Esfahani M, Liu CL, Zhou L, Glover C, Visser BC, Poultides G, **Advani RH**, Maeda LS, Gupta NK, Levy R, Ohgami RS, Davis RE, Kunder CA, Westin JR, Diehn M, Alizadeh AA. Noninvasive Detection of *BCL2*, *BCL6*, and *MYC* Translocations in Diffuse Large B-Cell Lymphoma. *Blood* 128 2930a 2016. Poster Presentation.
24. Ribrag V, Chavez JC, Kaplan JB, Vitolo U, Chandler JC, Santoro A, Corradini P, Cassier P, Flinn IW, **Advani R**, Sangha R, Isufi I, Kenkre VP, Hagner PR, Trowe T, Gandhi AK, Wu X, Hege K, Pourdehnad M, Kuruvilla J. A Phase 1b, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma: CC-122-DLBCL-001. *Blood* 128 1849a 2016. Poster Presentation.
25. Kanakry JA, Hong F, Martinez-Maza O, Horning SJ, Gordon LI, Gascoyne RD, Gellert LL, Lemas MV, Cheson B, **Advani RH**, Pohlman B, Kenkre VP, Winter JN, Stiff PJ, Tuscano J, Friedberg J, Dreosti L, Fisher RI, Laneville P, Kahl BS, Ambinder RF. Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial. *Blood* 128 2992a 2016. Poster Presentation.
26. Fowler N, Nastoupil L, de Vos S, Knapp M, Flinn IW, Chen RW, **Advani RH**, Bhatia S, Martin P, Mena R, Suzuki S, Beaupre DM, Neuenburg JK, Palomba ML. Ibrutinib Combined with Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Arm 1 + Arm 2 Results from a Multicenter, Open-Label Phase 2 Study. *Blood* 128 1804a 2016. Poster Presentation.
27. Jan M, Scherer F, Kurtz DM, Newman AM, Stehr H, Liu CL, Zhou L, Glover C, **Advani RH**, Maeda LS, Gupta NK, Levy R, Kunder CA, Sánchez-García I, Diehn M, Alizadeh AA. Absence of

Evidence Implicating Hematopoietic Stem Cells As Common Progenitors for DLBCL Mutations. Blood 128 4107a 2016. Poster Presentation.

28. Casulo C, Sancho JM, Eygen KV, de Vos S, Mercadal S, Johnson RJ, Bouabdallah K, Holmes H, Lemmens J, Gyan E, Merli M, **Advani RH**, Steelman L, Pearlberg J, Goy A. Contempo: Preliminary Results in First-Line Treatment of Follicular Lymphoma with the Oral Dual PI3K- δ,γ Inhibitor, Duvelisib, in Combination with Rituximab or Obinutuzumab. Blood 128 2979a 2016. Poster Presentation.

29. Treon SP, Tsakmaklis N, Meid K, Yang G, Chen JG, Liu X, Chen J, Demos M, Patterson CJ, Dubeau T, Gustine J, Castillo JJ, **Advani RH**, Palomba ML, Xu L, Hunter Z. Mutated MYD88 Zygosity and CXCR4 Mutation Status Are Important Determinants of Ibrutinib Response and Progression Free Survival in Waldenstrom's Macroglobulinemia. Blood 128 2984a 2016. Poster Presentation.

30. Pro B, **Advani RH**, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale MA, Connors JM, Fenton K, Huebner D, Pinelli J, Shustov AR. Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. Blood 128 4144a 2016. Poster Presentation.

31. Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, **Advani RH**, Pro B, Chen RW, Davies AJ, Illidge T, Uttarwar M, Huebner D, Ren H, Shustov AR. Four-Year Survival and Durability Results of Brentuximab Vedotin in Combination with CHP in the Frontline Treatment of Patients with CD30-Expressing Peripheral T-Cell Lymphomas. Blood 128 2993a 2016. Poster Presentation.

2017 (27 Total)

1. Porter, Segura Smith, Rosenthal, Seshadri, Vetteth, Kiamanesh, **Advani**, Coutre, Dirbas, Dorigo, Ganjoo, Holsinger, Johnston, Koong, Recht, Shrager, Skinner, Swetter, Visser, Blayney. Improving care with portfolio of physician-led cancer quality measures at an academic center. 2017 ASCO Quality Care Symposium; Orlando, FL, March 3-4, 2017. Oral Presentation.

2. Karki S, Aviña H, Lackey J, Sawas A, Savage KJ, Perez R, **Advani R**, Zain J, O'Connor OA, Gulesserian S, Zhao H, Yang P, Morrison K, Reyno L, Doñate F. Evaluation of CD37 expression and binding of AGS67E, an antibody-drug conjugate (ADC) against CD37, on white blood cells (WBCs) collected from phase I non-Hodgkin lymphoma (NHL) patients. AACR Annual Meeting 2017; Washington, DC, April 1-5, 2017. Poster Presentation.

3. Winkler SA, Muehe A, Theruvath A, Aghighi M, Luna-Fineman S, Marina N, **Advani R**, Taviani V, Holdsworth SJ, Gulaka P, Daldrup-Link H. Optimized Fast High-Resolution Whole-Body Imaging Protocols for Clinical Oncologic PET/MRI. ISMRM 25th Annual Meeting & Exhibition, April 22-24, 2017. Oral Presentation.

4. Soo J, Kurtz DM, Scherer F, Craig AFM, Jin MC, Westin JR, Rossi D, Gaidano G, **Advani RH**, Diehn M, Alizadeh AA. Elucidation of distinct mutational patterns between diffuse large B cell lymphoma subtypes utilizing circulating tumor DNA. J Clin Oncol 35 (suppl, abstr 7538). Poster Presentation.

5. Jin MC, Kurtz DM, Esfahani MS, Scherer F, Craig AFM, Soo J, Khodadoust MS, Saganty RS, Chabon JJ, Schroers-Martin J, Stehr H, **Advani RH**, Rossi D, Gaidano G, Westin JR, Diehn M, Alizadeh AA. Noninvasive detection of clinically relevant copy number alterations in diffuse large B-cell lymphoma. J Clin Oncol 35 (suppl, abstr 7507). Oral Presentation
6. Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, Lacasce AS, Ansell SM, Moskowitz CH, Fenton K, Ogden C, Taft D, Zhang Q, Kato K, Campbell M, **Advani RH**. Interim Results From A Phase I/II Study of Brentuximab Vedotin In Combination With Nivolumab In Patients With Relapsed Or Refractory Hodgkin Lymphomas. ICML; Lugano, Switzerland, June 14-17, 2017. Hematological Oncology, Volume 35, Issue S2, June 2017, Pages: 85-86. Oral Presentation
7. Diefenbach CS, Hong F, David K, Cohen J, Roberston M, **Advani R**, Palmisano N, Ambinder R, Kahl B, Ansell S. Safety And Efficacy Of Combination Of Brentuximab Vedotin and Nivolumab In Relapsed/Refractory Hodgkin Lymphoma: A Trial Of The ECOG-ACRIN Cancer Research Group (E4412). Hematological Oncology. ICML; Lugano, Switzerland, June 14-17, 2017. Volume 35, Issue S2, June 2017. Pages: 84-85. Oral Presentation
8. Kumar A, Casulo C, **Advani R**, Budde E, Barr PM, Batlevi CL, Chen R, Constine LS, Courtien AI, Dandapani SV, Drullinsky P, Friedberg JW, Hamlin PA, Hoppe RT, Matasar MJ, McArthur GN, Miller ST, Moskowitz AJ, Noy A, Schoder H, Straus DJ, Yang J, Younes A, Zelenetz AD, Yahalom J, Moskowitz CH. A Pilot Study Of Brentuximab Vedotin And AVD Chemotherapy Followed By 20 GY Involved-Site Radiotherapy In Early Stage Unfavorable Risk Hodgkin Lymphoma. Hematological Oncology. ICML; Lugano, Switzerland, June 14-17, 2017. Volume 35, Issue S2, June 2017. Pages: 171-172. Poster Presentation
9. Witzig T, Sokol L, Jacobsen E, **Advani R**, Mondejar R, Piris M, Burrows F, Melvin C, Mishra V, Scholz C, Gualberto A. Preliminary Results From An Open-Label, Phase II Study of Tipifarnib in Relapsed or Refractory Peripheral T-Cell Lymphoma. Hematological Oncology. ICML; Lugano, Switzerland, June 14-17, 2017. Volume 35, Issue S2, June 2017. Pages: 251-252. Poster Presentation
10. Fox CP, Bellei M, Manni M, Kim SJ, Ko YH, Shustov AR, Cabrera ME, Chiattonne CS, Horwitz SM, Spina M, **Advani RH**, Angrilli F, DeSouza CA, Dlouhy I, Fernandez-Alvarez R, Gabus R, Hitz F, Laszlo D, Montono S, Nagler A, Pavlovsky A, Vitolo U, Zoppegno L, Federico M, Kim WS. Improved Survival Outcomes For Patients With Extra-Nodal NK/T Lymphoma: Data From 140 Patients Prospectively Registered In The International T-Cell Project. ICML; Lugano, Switzerland, June 14-17, 2017. Hematological Oncology. Volume 35, Issue S2, June 2017. Pages: 78-79. Oral Presentation
11. Sawas A, Savage KJ, Perez RP, **Advani RH**, Zaine JM, Lackey JM, Trave F, Anand B, Chu R, Reyno LM, O'Connor OA. A Phase 1 Study Of The Anti-CD37 Antibody-Drug Conjugate AGS67E In Advanced Lymphoid Malignancies. Interim Results. ICML; Lugano, Switzerland, June 14-17, 2017. Hematological Oncology. Volume 35, Issue S2, June 2017. Page 49. Oral Presentation

12. Frank M, Khodadoust M, Chu M, Kohrt H, **Advani R**, Alizadeh A, Reddy S, Maeda L, Gupta N, Laport G, Meyer E, Miklos D, Negrin R, Rezvani A, Weng W, Sheehan K, Czerwinski D, Faham M, Okada A, Moore H, Phillips D, Wapnir I, Brody J, Levy R. Phase I/II Clinical Trial Of An Activated Whole Tumor Cell Vaccine Followed By Transfer Of Immune T Cells In Patients With Mantle Cell Lymphoma. ICML; Lugano, Switzerland, June 14-17, 2017. Hematological Oncology. Volume 35, Issue S2, June 2017. Pages: 207-208. Poster Presentation
13. Park S, Horwitz S, Foss F, Pinter-Brown L, Carson K, Rosen S, Pro B, His E, Federico M, Gisselbrecht C, Schwartz M, Bellm L, Acosta M, **Advani R**, Feldman T, Lechowicz M, Smith S, Lansigan F, Tulpule A, Craig M, Greer J, Kahl B, Leach J, Morganstein N, Casulo C, Shustov A. The Role of Upfront Hematopoietic Stem Cell Transplantation in Peripheral T-Cell Lymphoma Patients in Complete Remission with a Special Focus on Nodal PTCL: Report from the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE), a Prospective Multicenter Cohort Study. Blood 130 (1) 342a, 2017. Oral Presentation.
14. Kumar A, Casulo C, **Advani R**, Budde L, Barr P, Batlevi C, Caron P, Chen R, Constine L, Courtien A, Dandapani S, Drullinsky P, Friedberg J, Gerecitano J, Hamilton A, Hamlin P, Hoppe R, Horwitz S, Matasar M, Miller S, Moskowitz A, Noy A, Palomba M, Portlock C, Schoder H, Straus D, Yang J, Younes A, Zelentz A, Zhang Z, Yahalom J, Moskowitz C. A Pilot Study of Brentuximab Vedotin and AVD Chemotherapy Followed by 20 Gy Involved-Site Radiotherapy in Early Stage Unfavorable Risk Hodgkin Lymphoma. Blood 130 (1) 734a, 2017. Oral Presentation.
15. Kurtz D, Scherer F, Jin M, Soo J, Craig A, Esfahani M, Chabon J, Stehr H, Liu C, Tibshirani R, Maeda L, Gupta N, Khodadoust M, **Advani R**, Levy R, Newma A, Westin J, Gaidano G, Rossi D, Diehn M, Alizadeh A. Development of a Dynamic Model for Personalized Risk Assessment in Large B-Cell Lymphoma. Blood 130 (1) 826a, 2017. Oral Presentation
16. Evens A, Hong F, Habermann T, **Advani R**, Gascoyne R, Witzig T, Quon A, Ranheim E, Cheema P, Dy P, O'Brien T, Winter J, Cescon T, Chang, Kahl B. A 3-Arm Randomized Phase II Trial with Bendamustine/Rituximab Therapy in Untreated High Risk Follicular Lymphoma (FL): Bortezomib Induction or Novel IMiD Continuation (BIONIC) Study from the ECOG-ACRIN Cancer Research Group. Blood 130 (1) 482a, 2017. Oral Presentation
17. Herrera A, Moskowitz A, Bartlett N, Vose J, Ramchandren R, Feldman T, LaCasce A, Ansell S, Moskowitz C, Fenton K, Ogden C, Taft D, Zhang Q, Kato K, Campbell M, **Advani R**. Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma. Blood 130 (1) 649a, 2017. Oral Presentation
18. Evens A, **Advani R**, Fanale M, Smith S, Helenowski I, Jovanovic B, Bociek RG, Klein A, Winter J, Gordon L, Hamlin P. Sequential Brentuximab Vedotin (Bv) before and after Adriamycin, Vinblastine, and Dacarbazine(Bv-AVD) for Older Patients with Untreated Classical Hodgkin Lymphoma (cHL): Final Results from a Multicenter Phase II Study. Blood 130 (1) 733a, 2017. Oral Presentation

19. Ribrag V, Chaves J, Vitolo U, Kaplan J, Chandler J, Santoro A, Corradini P, Flinn I, Nastoupil L, Cassier P, Sangha R, Kenkre V, **Advani R**, Isufi I, Witzig T, Petrarca M, Hagner P, Gandhi A, Wu X, Hege K, Pourdehnad M, Kuruvilla J. CC-122 DLBCL-001: Phase Ib Study of CC-122 Plus Rituximab in Patients with Chemo-Refractory Diffuse Large B-Cell Lymphoma (DLBCL). *Blood* 130 (1) 1551a, 2017. Poster Presentation
20. Schroers-Martin J, Kurtz D, Soo J, Jin M, Scherer F, Craig A, Chabon J, Liu C, Stehr H, Duehrsen U, Huttmann A, Cottreau A, Meignan M, Casasnovas O, Westin J, Gaidano G, Rossi D, **Advani R**, Roscheski M, Wilson W, Diehn M, Alizadeh A. Determinants of Circulating Tumor DNA Levels across Lymphoma Histologic Subtypes. *Blood* 130 (1) 4018a, 2017. Poster Presentation
21. Jin M, Kurtz D, Esfahani M, Soo J, Craig A, Scherer F, Stehr H, Schroers-Martin J, Bangs C, cherry A, Natkunam Y, Roschewski M, Wilson W, Duehrsen U, Huttmann A, rossi D, Gaidano G, Westin J, **Advani R**, Diehn M, Alizadeh A. Clinical Impact of Somatic Copy Number Alterations in Circulating Tumor DNA from Diverse Lymphoma Subtypes. *Blood* 130 (1) 2747a, 2017. Poster Presentation
22. Bannerji R, **Advani R**, Brown J, Arnason J, Barnes J, Allan J, Ansell S, O'Brien S, Chavez J, Adriaens L, Ufkin M, Kostic A, Paccaly A, Gao B, Lowy I, Sternberg D, Topp M. Safety and Preliminary Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 bispecific Antibody, in Patients with B-NHL Previously Treated with CD20-Directed Antibody Therapy. *Blood* 130 (1) 1550a, 2017. Poster Presentation
23. Kyriakou C, **Advani R**, Ansell S, Buske C, Castillo J, Dreger P, Gertz M, Giral S, Leblond V, Maloney D, Tournilhac O, Montonto S. Indications for Hematopoietic Stem Cell Transplantation in Patients with Waldenstrom's Macroglobulinemia: A Consensus Project of the EBMT Lymphoma Working Party (LWP)/European Consortium for Waldenstrom's Macroglobulinemia (ECWM)/International Walderstrom's Macroglobulinemia Foundation (IWMF). *Blood* 130 (1). 2026a, 2017. Poster Presentation
24. Treon S, Meid K, Gustine J, Bantilan K, Dubeau T, Severns P, Yang G, Xu L, Patterson C, Ghobrial I, Laubach J, Hunter Z, Castillo J, Palomba M, **Advani R**. Long-Term Floow-up of Previously Treated Patients Who Received Ibrutinib for Symptomatic Waldenstrom's Macroglobulinemia: Update of Pivotal Clinical Trial. *Blood* 130 (1) 2766a, 2017. Poster Presentation
25. Witzig T, Sokol L, Jacobsen E, **Advani R**, Foss F, Mondejar R, Piris M, Bolognese J, Burrows F, Kessler L, Bracken K, Mishra V, Scholz C, Gualberto A. The CXCL12/CXCR4 Pathway As A Potential Target of Tipifarnib: Preliminary Results from an Open-Label, Phase II Study in Relapsed or Refractory Peripheral T-Cell Lymphoma. *Blood* 130 (1) 2788, 2017. Poster Presentation
26. Melani C, **Advani R**, Roschewski M, Walters K, Chen C, Barrato L, Ahlman M, Milijovic M, Steinberg S, Shovlin M, Dunleavy K, Pittaluga S, Jaffe E, Wilson W. End-of-Treatment and Serial

FDG-PET Imaging to Assess Residual Disease in Primary Mediastinal B-Cell Lymphoma. Blood 130 (1) 2859a, 2017. Poster Presentation

27. Herrera A, Patel M, Burke J, **Advani R**, Chese B, Sharman J, Penuel E, Polson A, Leng N, Li C, Schuth E, Vaze A, Samineni D, Elstrom R, Diefenbach C. A Phase I Study of the Anti-CD79b THIOMAB-Drug Conjugate DCDS0780A in Patients (pts) with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). Blood 130 (1) 4129a, 2017. Poster Presentation

2018 (37 Total)

1. Lunning M, Horwitz S, Mehta-Shah N, Moskowitz A, **Advani R**, Haverkos B, Oki Y, Vose J, Zain J, Ansell S. Phase I/II Study of CHOEP Plus Lenalidomide As Initial Therapy For Patients With Stage II-IV Peripheral T-Cell Non-Hodgkin Lymphoma: Phase I Results. LaJolla, CA. 10th Annual T-Cell Lymphoma Forum. Poster Presentation.

2. **Advani R**, Flinn I, Popplewell L, Forero-Torres A, Bartlett N, Ghosh N, Kline J, Tran T, Lynn J, Chen J, Agoram B, Huang J, Takimoto C, Chao M, Smith S. Activity and tolerability of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results. 2018 ASCO Annual Meeting. J Clin Oncol 36, 2018 (suppl; abstr 7504). Oral Presentation.

3. Evens A, **Advani R**, Fanale M, Smith S, Helenowski I, Bociek G, Klein A, Winter J, Gordon L, Hamlin P. Prognostication of older Hodgkin lymphoma (HL) patients (pts): Findings from a multicenter phase II study. 2018 ASCO Annual Meeting. J Clin Oncol 36, 2018 (suppl; abstr 7540). Poster Presentation.

4. Diefenbach C, Hong F, Ambinder R, Cohen J, David K, **Advani R**, Robertson M, Fenske T, Barta S, Palmisano N, Svoboda J, Morgan D, Karmali R, Kahl B, Ansell S. Immune toxicity in post autologous transplant patients treated with brentuximab vedotin in combination with immune checkpoint blockade. 2018 ASCO Annual Meeting. J Clin Oncol 36, 2018 (suppl; abstr 7538). Poster Presentation.

5. Ramchandren R, **Advani R**, Ansell S, Bartlett N, Chen R, Feldman T, Forero-Torres A, Friedberg J, Gopal A, Gordon L, Kuruvilla J, Savage K, Straus D, Younes A, Fenton K, Manley T, Engley G, Connors J. Brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma (HL): North American results. 2018 ASCO Annual Meeting. J Clin Oncol 36, 2018 (suppl; abstr 7541). Poster Presentation.

6. Charalampia K, **Advani R**, Ansell S, Buske C, Castillo J, Dreger P, Gertz M, Giralto S, Leblond V, Maloney D, Tournilhac O, Montoto S. A Consensus Project of The EBMT Lymphoma Working Party (LWP)/ECWM/IWMF To Define Indications For Hematopoietic Stem Cell Transplantation In Patients With Waldenstrom's Macroglobulinemia. Abstract # OS1-144th Annual Meeting of the EBMT 2018. Oral Presentation.

7. Treon SP, Meid K, Gustine J, Bantilan K, Dubeau T, Yang G, Xu L, Patterson CJ, Ghobrial I, Laubach JP, Hunter ZR, Palomba ML, **Advani R**, Castillo JJ. Ibrutinib Shows Prolonged Progression-Free Survival In Symptomatic, Previously Treated Patients With MYD88 Mutated Waldenstrom's Macroglobulinemia: Long-term Follow-up Of Pivotal Trial (NCT01614821). 23rd Annual European Hematology Association (EHA) Congress. Poster Presentation. Abstract # P1185
8. Ribrag V, Vitolo U, Kaplan J, Chandler J, Santoro A, Corradini P, Flinn I, Nastoupil L, Cassier P, Sangha R, Kenkre V, **Advani R**, Isufi I, Witzig T, Uttamsingh S, Petrarca M, Hagner P, Gandhi A, Wu X, Risueño A, Hege K, Pourdehnad M, Kuruvilla J, Chavez J. CC-122-DLBCL-001: Phase IB Study Of CC-122 Plus Rituximab In Patients With Chemo-Refractory Diffuse Large B-Cell Lymphoma. 23rd Annual EHA Congress. Poster Presentation. Abstract # P1013
9. Castillo J, Treon S, Davids M, Allan J, **Advani R**, Furman R, Siddiqi T. Prospective Phase II Study on Venetoclax in Patients With Previously Treated Waldenstrom Macroglobulinemia. 23rd Annual EHA. Oral Presentation. Abstract # 854
10. Moding E, **Advani R**, Rosenberg S, Hoppe R. Prognostic Factors and Patterns of Failure in Advanced Stage Hodgkin Lymphoma Treated with Stanford V and Radiotherapy. American Society for Therapeutic Radiology and Oncology (ASTRO) 60th Annual Meeting 2018. Oral Presentation.
11. Kyriakou C, **Advani R**, Ansell S, Buske C, Castillo J, Dreger P, Gertz M, Giralat S, Leblond V, Maloney D, Tournilhac O, Montoto S. The EBMT/ECWM/IEMF Consensus Project on the Role of Autologous and Allogeneic Stem Cell Transplantation in Waldenstrom's Macroglobulinemia. International Workshop for Waldenstrom's Macroglobulinemia, New York, 2018. Oral Presentation.
12. Oki Y, Kim W, Ardeshtna K, Lin Y, Ruan J, Porcu P, Brammer J, Jacobsen E, Yoon D, Suh C, Suarez F, Radford J, Budde L, Kim J, Salles G, Lee H, Bollard C, Jaccard A, Kang H, Inman S, Murray M, Combs K, Gunter K, Lee D, **Advani R**, Rooney C, Heslop H. Autologous Epstein-Barr virus (EBV)-specific T cells (baltaleucel T): preliminary results from a multicenter, multinational phase 2 study for treatment of EBV-associated NK/T cell lymphoma. SITC 2018. Abstract # P240. Poster presentation.
13. Jin MC, Kurtz DM, Esfahani MS, Sworder BJ, Schroer-Martin J, Soo J, Glover C, Roschewski M, Wilson W, Duehrsen U, Huttmann A, Rossi D, Gaidano G, Westin J, Diehn M, **Advani R**, Alizadeh AA. Circulating Tumor DNA As A Biomarker For The Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma. 11th ISHL. Abstract # T009. Oral presentation.
14. Yang JC, Kumar A, Casulo C, **Advani R**, Budde E, Barr PM, Batlevi CL, Caron P, Chen R, Constine LS, Courtien A, Dandapani SV, Drullinsky P, Friedberg JW, Hamilton A, Hamlin PA, Hoppe RT, Horwitz AJ, Noy A, Palomba ML, Portlock CS, Schoder H, Straus DJ, Vardhana S, Vemuri S, Younes A, Zelenetz AD, Zhang Z, Yahalom J, Moskowitz CH. Brentuximab Vedotin and

AVD Chemotherapy Followed by Reduced Dose/Volume Radiotherapy in Patients With Early Stage, Unfavorable Hodgkin Lymphoma. 11th ISHL. Abstract # T015. Oral presentation.

15. Lynch RC, Sundaram V, Desai M, Henry S, Wood D, Daadi SE, Corbelli K, Rosenberg SA, Hoppe RT, **Advani R**. Is Routine Laboratory Testing Useful in Detecting Relapse in Patients with Classic Hodgkin Lymphoma in First Remission? 11th ISHL. Abstract # T017. Oral presentation.

16. Evens AM, **Advani R**, Helenowski I, Fanale M, Smith SM, Jovanovic B, Bociek GR, Klein AK, Winter JN, Gordon LI, Hamlin PA. A Multicenter Phase 2 Study of Sequential Brentuximab Vedotin and AVD Chemotherapy for Older Patients with Untreated Classical Hodgkin Lymphoma. 11th ISHL. Abstract # P024. Poster presentation.

17. Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ranchandren R, Feldman TA, LaCasse AS, Ansell SM, Moskowitz CH, Fenton K, Sacchi M, Galderisi F, **Advani RH**. Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma: Follow-up Results From the Phase 1/2 Study. 11th ISHL. Abstract # T025. Oral presentation. Abstract # T025

18. Allen PB, Evens AM, Pro B, Karmali R, Savas H, Dillehay G, Rademaker A, Palmer B, **Advani R**, Gordon LI, Winter JN. A Phase II Study of Pembrolizumab (pem) Followed by AVD for Frontline Treatment of Classical Hodgkin Lymphoma (cHL): Interim Results. ISHL. Abstract # P105. Poster presentation.

19. Diefenbach CH, Hong F, Ambinder RF, Cohen JB, Robertson MJ, David KA, **Advani RH**, fenske TS, Barta SK, Palmisano ND, Svoboda J, Morgan DS, Karmali R, Kahl BS, Ansell SM. Long Term Safety and Efficacy of Combination of Brentuximab Vedotin and Ipilimumab or Nivolumab in Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412). 11th ISHL. Abstract # P118. Poster presentation.

20. Carreau N, Pail O, Armand P, Merryman R, **Advani R**, Spinner M, Herrera A, Chen R, Tomassetti S, Ramchandren R, Hamid M, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair S, Barta S, Liu Y, Nathan S, Burkart M, Karmali R, Torka P, David K, Wei C, Lansigan F, Emery L, Persky D, Smith S, Chavez J, Xia Y, Troxel S, Diefenbach C. Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy. Blood 132 (1) 1626a, 2018. Oral Presentation. .

21. Kothari S, Li S, Medeiros L, Ayers E, Landsburg D, Bond D, Maddocks K, Giri A, Hess B, Pham L, **Advani R**, Liu Y, Barta S, Vose J, Churnetski M, Cohen J, Burkart M, Karmali R, Zurko J, Mehta A, Olszewski A, Lee S, Hill B, Burns T, Lansigan F, Rabinovich E, Peace D, Groma A, Attwood K, Hernandez-Ilizaliturri F, Torka P. Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 US Academic Centers. Blood 132 (1) 451a, 2018. Oral Presentation.

22. Lynch R, Sundaram V, Desai M, Henry S, Wood D, Daad S, Corbelli K, Rosenberg S, Hoppe R, **Advani R**. No Utility of Routine Laboratory Testing during Surveillance in Detecting Relapse Patients with Classic Hodgkin Lymphoma in First Remission. *Blood* 132 (1) 615a, 2018. Oral Presentation.
23. Hong F, Thanarajasingam G, Ansell S, Ambinder R, Cohen J, Robertson M, David K, **Advani R**, Fenske T, Barta S, Palmisiano N, Svoboda J, Morgan D, Karmali R, Witzig T, Dueck A, Novotny P, Kahl B, Diefenbach C. Longitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F). *Blood* 132 (1) 623a, 2018. Oral Presentation.
24. Diefenbach C, Hong F, Ambinder R, Cohen J, Robertson M, David K, **Advani R**, Fenske T, Barta S, Palmisiano N, Svoboda J, Morgan D, Karmali R, Kahl B, Ansell S. A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms G-I). *Blood* 132 (1) 679a, 2018. Oral Presentation.
25. Horwitz S, O'Connor O, Pro B, Illidge T, Fanale M, **Advani R**, Bartlett N, Christensen J, Morchhauser F, Domingo-Domenech E, Rossi G, Kim W, Feldman T, Lennard A, Belada D, Illes A, Tobinai K, Tsukasaki K, Yeh S, Shustov A, Huttman A, Savage K, Yuen S, Zinzani P, Hua Z, Little M, Rao S, Woolery J, Manley T, Truemper. The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas. *Blood* 132 (1) 997a, 2018. Oral Presentation.
26. Baratto L, Jegede O, Hong F, Habermann T, **Advani R**, Gascoyne R, Kostakoglu L, Witzig T, Ranheim E, Kahl B, Quon A, Evens A. The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E2408, the Bortezomib Induction or Novel Imidazole® Continuation (BIONIC) Study. *Blood* 132 (1) 1615a, 2018. Poster Presentation.
27. Carreau N, Pail O, Armand P, Merryman R, **Advani R**, Spinner M, Herrera A, Chen R, Tomassetti S, Ramchandren R, Hamid M, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair S, Barta S, Liu Y, Nathan S, Burkart M, Karmali R, Torka P, David K, Wei C, Lansigan F, Emery L, Persky D, Smith S, Chavez J, Xia Y, Troxel A, Diefenbach C. Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy. *Blood* 132 (1) 1626a, 2018. Poster Presentation.
28. **Advani R**, Moskowitz A, Bartlett N, Vose J, Ramchandren R, Feldman T, LaCasce A, Christian B, Ansell S, Moskowitz C, Fenton K, Ogdon C, Taft D, Zak D, Sacchi M, Galderisi F, Herrera A. Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing). *Blood* 132 (1) 1635a, 2018. Poster Presentation.

29. Savas H, Allen P, Evens A, Pro B, Dillahay, Rademaker A, Palmer B, **Advani R**, Gordon L, Winter J. A Phase II Study of Sequential Pembrolizumab (PEM) Followed By AVD for Frontline Treatment of Classical Hodgkin Lymphoma (CHL): Quantifying Response Following PEM Monotherapy with FDG-PET-Derived Metabolic Tumor Volume and Total Lesion Glycolysis. Blood 132 (1) 1651a, 2018. Poster Presentation.
30. Bannerji R, Arnason J, **Advani R**, Brown J, Allan J, Answell S, Barnes J, O'Brien S, Chavez J, Duell J, Lowy I, Charnas R, Sternberg D, Ambati S, Adriaens L, Ufkin M, Yan X, Li J, Navarro M, Gasparini P, Jankovic V, Fiaschi N, Zhang W, Hamon S, Thurston G, Topp M. Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), and Other B-Cell Non-Hodgkin Lymphoma (B-NHL) Subtypes. Blood 132 (1) 1690a, 2018. Poster Presentation.
31. Jin M, Schroers-Martin J, Kurtz D, Buedts L, Esfahani M, Macaulay C, Sworder B, Soo J, Glover C, Roschewski M, Wilson W, Duhrsen U, Huttmann A, Rossi D, Gaidano G, Westin J, Maeda L, **Advani R**, Vandenberghe P, Diehn M, Alizadeh A. Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma. Blood 132 (1) 2838a, 2018. Poster Presentation.
32. Schroers-Martin J, Garofalo A, Soo J, Jin M, Kurtz D, Buedts L, Duhrsen U, Huttmann A, Cottreau A, Meignan M, Casasnovas O, Westin J, Gaidano G, Rossi D, Roschewski M, Wilson W, **Advani R**, vandenberghe P, Diehn M, Khush K, Alizadeh A. Lymphoma Virome Dynamics Revealed By Cell-Free DNA Sequencing. Blood 132 (1) 2861a, 2018. Poster Presentation.
33. Castillo J, Gustin J, Meid K, Dubeau T, Keezer A, Allan J, Furman R, Siddiqi T, **Advani R**, Lam J, Hunter Z, Yang G, Xu L, Davids M, Treon S. Multicenter Prospective Phase II Study of Venetoclax in Patients with Previously Treated Waldenstrom Macroglobulinemia. Blood 132 (1) 2888a, 2018. Poster Presentation.
34. Lunning M, Horwitz S, **Advani R**, Vose J, Lee H, Mehta-Shah N, Zain J, Haverkos B, Lechwicz M, Moskowitz A, Pham L, Lyden E, Heires P, Ansell S. Phase I/II Study of CHOEP Plus Lenalidomide As Initial Therapy for Patients with Stage II-IV Peripheral T-Cell Lymphoma: Phase II Results. Blood 132 (1) 2899a, 2018. Poster Presentation.
35. Connor J, Gallamini A, Ansell S, Won-Seog K, **Advani R**, Bartlett N, Straus D, Sureda A, Hutchings M, Dlugosz-Danecka M, Engley G, Fenton K, Liu R, Miao H, Jolin H, Gautam A, Radford J. Brentuximab Vedotin Plus Chemotherapy in Patients with Advanced-Stage Classical Hodgkin Lymphoma (cHL): Evaluation of Modified Progression-Free Survival (mPFS) and Traditional PFS in the Phase 3 ECHELON-1 Study. Blood 132 (1) 2904a, 2018. Poster Presentation.
36. Witzig T, Sokol L, Jacobsen E, Kim W, Foss F, **Advani R**, Vidal J, Niebla A, Izquierdo A, Navarrete Raquel, Vicente F, Caballero D, Mondejar R, Piris M, Curry R, Scholz C, Gualberto A. Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+

Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study. Blood 132 (1) 2937a, 2018. Poster Presentation.

37. Hong F, Evens A, Novotny P, Habermann T, **Advani R**, Gascoyne R, Witzig T, Quon A, Ranheim E, Dueck A, Kahl B, Thanarajasingam. A Longitudinal Toxicity over Time (ToxT) Analysis of Bortezomib When Added to Bendamustine-Rituximab (BR) in Previously Untreated High Risk (HR) Follicular Lymphoma (FL) from in E2408 - Risk-Adapted Upfront Therapy for Hodgkin Lymphoma in 2018. Blood 132 (1) 4157a, 2018. Poster Presentation.

2019 (31 Total)

1. **Advani R**, Horwitz S, Iyer S, Bartlett N, Kim W, tilly H, Belada D, Feldman T, Illes A, Jacobsen E, Huettmann A, Zinzani P, O'Connor O, Trepicchio W, Miao H, Rao S, Onsum M, Manley T, Illidge T. Response to A+CHP By CD30 In The ECHELON-1 Trial. J Clin Oncol 37, 2019 (suppl; abstr 7538). Poster Presentation.

2. Jagadeesh D, Horwitz S, Bartlett N, **Advani R**, Jacobsen E, Duvic M, Gautam A, Rao S, Onsum M, Fanale M, Kim Y. Response To Brentuximab Vedotin By CD30 Expression: Results From Five Trials in PTCL, CTCL, and B-Cell Lymphomas. J Clin Oncol 37, 2019 (suppl; abstr 7543). Poster Presentation.

3. Thanarajasingam G, Dueck A, Novotny P, Habermann T, **Advani R**, Gascoyne R, Witzig T, Quon A, Ranheim E, Kahl B, Evens A, Hong F. Longitudinal Toxicity Analysis With Novel Summary Metrics Of Lenalidomide Maintenance In Follicular Lymphoma in ECOG-ACRIN 2408. J Clin Oncol 37, 2019 (suppl; abstr 6511). Oral Presentation.

4. **Advani R**, Bartlett N, Smith S, Roschewski M, Popplewell L, Flinn I, Collins G, Ghosh N, LaCasce A, Asch A, Kline j, Kesavan M, Tran T, Lynn J, Huang J, Agoram B, Volkmer J, Takimoto C, Chao M, Mehta A. The First-In-Class Anti-CD47 Antibody HU5F9-G4 With Rituximab Induces Durable Response In Relapsed/Refractory DLBCL And Indolent Lymphoma: Interim Phase 1B/2 Results. 24th EHA Congress. HemaSphere 3:388. Abstract S867. Oral Presentation.

5. Castillo J, Abeykoon J, Gustine J, Zanwar S, Keezer A, Meid K, Dubeau T, Xu L, Yang Guang, Hunter Z, **Advani R**, Ansell S, Gertz M, Kapoor P, Palomba L, Treon S. Partial Response Or Better At 6 Months Is Prognostic Of Progression-Free Survivan In Patients With Waldenstrom Macroglobulinemia Treated With Ibrutinib. 24th EHA Congress. HemaSphere 3:194-195. Abstract PF485. Poster Presentation.

6. Witzig T, Sokol L, Kim W, Foss F, Jacobsen E, de la Cruz Vicente F, Caballero D, **Advani R**, Vidal M, Niebla A, Izquierdo A, de Ona Navarrete R, Terol M, Domingo-Domenech E, Rodriguez, Piris M, Bolognese J, Janes M, Burrows F, Kessler L, Mishra V, Curry R, Kurman M, Scholz C, Gualberto A. Tipifarnib In Relapsed Or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) And CXCL12+ Peripharaal T-Cell Lymphoma (PTCL): Preliminary Results From An Open-Label, Phase 2 Study. 24th EHA Congress. HemaSphere 3:389. Abstract S869. Oral Presentation.

7. Illidge T, Pro B, Trumper L, O'Connor O, **Advani R**, Iyer S, Bartlet N, Christensen J,

Morchhauser F, Domingo-Domenech E, Rossi G, Kim W, Feldman T, Lennard A, Belada D, Illes A, Tobinai K, Tsukasaki K, Huttmann A, Savage K, Shustov A, Yuen S, Zinzani P, Little M, Manley T, Rao S, Fanale M, Horwitz S. The ECHELON-1 Trial: Results Of A Randomized, Double-Blind Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus Chop In Frontline Treatment Of Patients With CD30+ Peripheral T-Cell Lymphomas. 24th EHA Congress. HemaSphere 3:484-485. Abstract PS1070. Poster Presentation.

8. Bannerji R, Arnason J, **Advani R**, Brown J, Allan J, Ansell S, O'Brien S, Chavez J, Duell J, Rosenwald A, Charnas R, Ambati S, Adriaens L, Ufkin M, Zhu M, Li J, Gasparini P, Jankovic V, Fiaschi N, Zhang W, Hamon S, Thurston G, Murphy A, Yancopoulos G, Lowy I, Sternberg D, Topp M. Emerging Clinical Activity of REGN1979, An Anti-CD20 X Anti-CD3 Bispecific Antibody (AB), In Patients (PTS) With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL). 24th EHA Congress. HemaSphere 3:388-389. Abstract #S868. Poster Presentation.

9. Witzig T, Sokol L, Kim W, Foss F, Jacobsen E, de la Cruz Vincente F, Caballero D, **Advani R**, Roncero Vidal JM, Marin-Niebla A, Rodriguez Izquierdo A, de Ona Navarete R, Terol MJ, Domingo-Domenech E, Rodriguez M, Piris MA, Bolognese J, James MR, Burrows F, Kessler L, Mishra V, Curry R, Kurman M, Scholz C, Gualberto A. Tipifarnib In Relapsed Or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) And CXCL12+Peripheral T-Cell Lymphoma (PTCL): Preliminary Results From A Phase 2 Study. Hematological Oncology Vol. 37 Suppl. 2, 64-65. Abstract #032. Oral Presentation.

10. **Advani R**, Bartlett NL, Smith SM, Roschewski M, Popplewell L, Flinn I, Collins G, Ghosh N, LaCasce A, Asch A, Kline J, Kesevan M, Tran T, Lynn J, Huang J, Agoram B, Volkmer J, Takimoto CH, Chao MP, Mehta A. The First-In-Class Anti-CD47 Antibody HU5F9-G4 + Rituximab Induces Durable Responses In Relapsed/Refractory DLBCL And Indolent Lymphoma: Interim Phase 1B/2 Results. Hematological Oncology Vol. 37 Suppl. 2, 89-90. Abstract #051. Oral Presentation.

11. Topp MS, Arnason J, **Advani R**, Brown JR, Allan J, Ansell S, O'Brien S, Chavez J, Duell J, Rosenwald A, Charnas R, Ambati SR, Adriaens L, Ufkin M, Zhu M, Li J, Gasparini P, Jankovic V, Fiaschi N, Zhang W, Hamon S, Thurston G, Murphy AJ, Yancopoulos GD, Lowy I, Sternberg D, Bannerji R. Clinical Activity of REGN1979, An Anti-CD20 X Anti-CD3 Bispecific Antibody (AB) In Patients (PTS) With (W/) Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL). Hematological Oncology Vol. 37 Suppl. 2, 90-91. Abstract #052. Oral Presentation.

12. Diefenbach CS, Hong F, Ambinder R, Cohen J, Robertson M, David K, **Advani R**, Fenske T, Barta S, Palmisano N, Svoboda J, Morgan D, Karmali R, Kahl B, Ansell S. Extended Follow-Up Of A Phase I Trial Of Ipilimumab, Nivolumab, and Brentuximab Vedotin In Relapsed Hodgkin Lymphoma: A Trial Of The ECOG-ACRIN Research Group (E4412). Hematological Oncology Vol. 37 Suppl. 2, 123-4. Abstract #077. Oral Presentation.

13. Binkley MS, Rauf M, Milgrom SA, Pinniz CC, Tsang R, Ng A, Roberts KB, Gao S, Ricardi U, Levis M, Casulo C, Stolten M, Kelsey CR, Brady JL, Mikhaeel N, Hoppe BS, Terezakis SA, Kirova Y, Akhtar S, Maghfoor I, Koenig JL, Jackson C, Song E, Segai S, **Advani R**, Natkunam Y, Constine LS, Eich H, Wirth A, Hoppe RT. Stage I-II Nodular Lymphocyte-Predominant Hodgkin Lymphoma In The Modern Era: A Multi-Institutional Experience of Adult Patients By ILROG. Hematological

Oncology Vol. 37 Suppl. 2, 145-6. Abstract #097. Oral Presentation.

14. Dickinson M, Briones Mejide J, Herrera AF, Gonzalez Barca E, Ghosh N, Cordoba R, Rutherford SC, **Advani R**, Bournazou E, Labriola-Tompkins E, Friess T, Chesne E, Brower-Visser J, Lechner K, Brennan B, Nueesch E, Da Mario M, Hutchings M. BET Inhibitor RG6146, Venetoclax, And Rituximab Is A Highly Active Regimen In Relapsed/Refractory (R/R) DLBCL: Initial Report of Phase 1B Safety, Biomarker, and Response Data. Hematological Oncology Vol. 37 Suppl. 2, 174-5. Abstract #125. Oral Presentation.

15. Treon SP, Meid K, Custine J, Yang G, Xu L, Patterson CJ, Ghobrial I, Laubach JP, Hunter ZR, Dubeau T, Palomba L, **Advani R**, Castillo JJ. Ibrutinib Monotherapy Produces Long-term Disease Control In Previously Treated Waldenstrom's Macroglobulinemia. Final Report Of The Pivotal Trial (NCT0164821). Hematological Oncology Vol. 37 Suppl. 2, 184-5. Abstract #135. Poster Presentation.

16. Lunning M, Horwitz S, **Advani R**, Vose J, Lee H, Mehta-Shah N, Zain J, Haverkos B, Lechowicz M, Moskowitz A, Heires P, Lyden L, Answell S. Phase I/II Study of CHOEP Plus Lenalidomide As Initial Therapy For Patients With Stage II-IV Peripheral T-Cell Lymphoma: Phase II Results. Hematological Oncology Vol. 37 Suppl. 2, 281. Abstract #227. Poster Presentation.

17. Illidge T, Horwitz S, Iyer S, Bartlett N, Kim W, Tilly H, Belada D, Feldman T, Illes A, Jacobsen E, Huttmann A, Zinzani P, O'Connor OA, Trepicchio W, Miao H, Rao S, Onsum M, Manley T, **Advani R**. Response To A-CHP By CD30 Expression In The ECHELON-2 Trial. Hematological Oncology Vol. 37 Suppl. 2, 282. Abstract #228. Poster Presentation.

18. Jagadeesh D, Horwitz S, Bartlett NL, **Advani R**, Jacobsen E, Duvic M, Gautman A, Rao S, Onsum M, Fanale M, Kim Y. Response To Brentuximab Vedotin By CD30 Expression: Results From Five Trials In PTCL, CTCL, and B-Cell Lymphomas. Hematological Oncology Vol. 37 Suppl. 2, 470-1. Abstract #438. Poster Presentation.

19. Moskowitz A, **Advani R**, Bartlett N, Vose J, Ramchandren R, Feldman T, LaCasce A, Christian B, Answell S, Moskowitz C, Brown L, Taft D, Ansari S, Zak D, Sacchi M, Manley T, Herrera A. Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study. Blood 134 (1) 238a, 2019. Oral Presentation.

20. Savage K, Horwitz S, **Advani R**, Christensen J, Domingo-Domenech E, Rossi G, Morschhauser F, Alpdogan O, Suh C, Tobinai K, Shustov A, Trneny M, Yuen S, Zinzani P, Truemper L, Illidge T, O'Connor O, Pro B, Little M, Bunn V, Fenton K, Manley T, Iyer S. An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant. Blood 134 (1) 464a, 2019. Oral Presentation.

21. Witzig T, Sokol K, Foss F, Kim W, Jacobsen E, De La Cruz M, Caballero D, **Advani R**, Roncero M, de Ona R, Niebla A, Izquierdo A, Terol M, Domingo-Domenech E, Piris M, Rodriguez

M, Bolognese J, Kessler L, Mishra V, Curry R, Kurman M, Scholz C, Gualberto A. Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study. *Blood* 134 (1) 468a, 2019. Oral Presentation.

22. Steen C, Luca B, Esfahani M, Nabet B, Sworder B, Farshidfar F, Shamardani K, Kurtz D, Liu C, **Advani R**, Natkunam Y, Myklebust J, Diehn M, Gentles A, Newman A, Alizadeh A. An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma. *Blood* 134 (1) 655a, 2019. Oral Presentation.

23. Bannergi R, Allan J, Arnason J, Brown J, **Advani R**, Barnes J, Answell S, O'Brien S, Chavez J, Duell J, David K, Martin P, Joyce R, Charnas R, Ambati S, Adriaens L, Ufkin M, Zhu M, Li J, Gasparini P, Ibrahim A, Jankovic V, Fiaschi N, Aina O, Zhang W, Deering R, Hamon S, Thurston G, Murphy A, Weinreich D, Yancopoulos G, Lowy I, Sternberg D, Topp M. Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL). *Blood* 134 (1) 762a, 2019. Oral Presentation.

24. Garofalo A, Schroers-Martin J, Soo J, Kurtz D, Sworder B, Liu C, Pinsky B, Luikart H, **Advani R**, Natkunam Y, Khush K, Diehn M, Alizadeh A. Deep Sequencing of Viral Cell-Free DNA for Noninvasive Detection of Immunosuppression-Related Lymphoid Malignancies. *Blood* 134 (1) 885a, 2019. Oral Presentation.

25. Hamid M, Rutherford S, Kim S, Bartlett N, Malecek MK, Watkins M, Maddocks K, Bond D, Feldman T, Magarelli G, **Advani R**, Spinner M, Ahmed S, Stephens D, Allen P, Patel K, Tees M, Karmali R, Cheson B, Yazdy M, Strouse C, Pagel J, Ramchandren R. North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma. *Blood* 134 (1) 1553a, 2019. Poster Presentation.

26. Sica RA, Spinner M, Tamaresis J, **Advani R**, Johnston L, Lowsky R, Meyer E, Miklos D, Muffly L, Rezvani A, Shizuru J, Weng W, Negrin R, Arai S. Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents. *Blood* 134 (1) 2022a, 2019. Poster Presentation.

27. Kumar A, Casulo C, **Advani R**, Budde L, Barr P, Batlevi C, Caron P, Constine L, Dandapani S, Drill E, Drullinsky P, Friedberg J, Grieve C, Hamilton A, Hamlin P, Hoppe R, Horwitz S, Matasar M, McCall S, Moskowitz A, Noy A, Palomba M, Schoder H, Straus D, Vemuri S, Yang J, Younes A, Zelenetz A, Yahalom J, Moskowitz C. A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma. *Blood* 134 (1) 2834a, 2019. Poster Presentation.

28. Bartlett N, Straus D, Dlugosz-Danecka M, Alekseev S, Illes Z, Lech-Maranda E, Feldman T, Smolewski P, Savage K, Walewski J, Ramchandren R, Zinzani P, Hutchings M, Connors J, Radford J, Munoz J, Kim W, **Advani R**, Ansell S, Younes A, Gallamini A, Miao H, Liu R, Fenton K, Forero-Torres A, Picardi M. Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin

Lymphoma (cHL): 4-Year Update of the ECHELON-1 Study. Blood 134 (1) 4026a, 2019. Poster Presentation.

29. Orellana-noia V, Isaac K, Wages N, Malecek M, Bartlett N, Voorhees T, Grover N, Hwang S, Bennani N, Hu R, Hill B, Mou E, **Advani R**, Carter J, David K, Ballard H, Svoboda J, Magarelli G, Feldman T, Churnetski M, Cohen J, Evens A, Portell C. Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis. Blood 134 (1) 4027a, 2019. Poster Presentation.

30. Merryman R, Redd R, Nieto Y, Rao U, Byrne M, Bond D, Maddocks K, Ballard H, Svoboda J, Singh A, McGuirk J, Darrah J, Spinner M, **Advani R**, Romancik J, Cohen J, Frigault M, Chen Y, Rahimian M, Joyce R, Shah M, David K, Lynch R, Smith S, Ho V, Armand P, Herrera A. Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma. Blood 134 (1) 4571a, 2019. Poster Presentation.

31. Allen P, Savas H, Evens A, Pro B, Karmali R, Palmer B, Mou E, Bearden J, Scholtens D, Dillehay G, Gordon L, Winter J. Brief Pembrolizumab (PEM) Monotherapy Results In Complete And Near Complete Responses In The Majority Of Untreated Patients With Classical Hodgkin Lymphoma (cHL): A Multicenter Phase 2 PET – Adapted Study of sequential PEM and AVD. Blood 134 (1) 35a, 2019. Oral Presentation.

2020 (16 total)

1. Cheson B, Bartlett N, LaPlant B, Lee H, **Advani R**, Christian B, Deifenbach C, Feldman T, Ansell S. Phase II, multicenter trial of nivolumab (Nivo) and brentuximab vedotin (BV) in patients (Pts) with untreated Hodgkin lymphoma (HL) over the age of 60 years or unable to receive standard ABVD chemotherapy: Results of a study of Academic and Community Cancer Research United (ACCRU) RU051505I. J Clin Oncol 38: 2020 (suppl; abstr 8014). Poster Presentation.

2. Fu K, Yu G, Bi C, Cheng H, Smith L, Naushad J, Link B, Nichols C, Barr P, Kahl B, Stewart D, Barta S, Beaven A, **Advani R**, Martin P, Greiner T, Weisenburger D, Armitage J, Vose J. Mantle cell lymphoma: initial report from the North American Mantle Cell Lymphoma Consortium. J Clin Oncol 38: 2020 (suppl; abstr 8035). Poster Presentation.

3. Picardi M, Straus D, Długosz-Danecka M, Alekseev S, Illes A, Lech-Maranda E, Feldman T, Smolewski P, Savage K, Walewski J, Ramchandren R, Luigi Zinzani P, Hutchings M, Connors J, Radford J, Munoz J, Kim WS, **Advani R**, Ansell S, Younes A, Gallamini A, Miao H, Liu R, Fenton K, ForeroTorres A, Bartlett N. Brentuximab Vedotin With Chemotherapy For Stage III/IV Classical Hodgkin Lymphoma: 4- Year Update Of The ECHELON-1 Study. 25th EHA Congress. Blood. 2020;135(10):735-742. Abstract #S241. Oral Presentation.

4. Brouwer-Visser J, Bannerji R, Allan J, Arnason J, Brown J, **Advani R**, Ansell S, O'Brien S, Duell J, Martin P, Joyce R, Chaudhry A, Ambati S, Ufkin M, Flink D, Zhu M, Li J, Fiaschi N, Zhang

W, Deering R, Hamon S, Thurston G, Murphy A, Weinreich D, Yancopoulos G, Lowy I, Sternberg D, Jankovic V, Topp M. REGN1979 induces transient increase in cytokine levels, T-cell activation, and circulating T-cell reduction, but no sustained effects on T-cells or cytokine release. 25th EHA Congress. Abstract #EP1270. Poster Presentation.

5. Skrypets T, Civallero M, Manni M, Piler S, Weisenburger D, Ko Y, Inghirami G, Bargetzi M, Gabús R, Varela S, Horwitz S, Pavlovsky A, Thieblemont C, De Souza C, Milone J, Kim W, Montoto S, Carson K, Vose J, Federico M, Advani R. Angioimmunoblastic T-cell lymphoma: report on 282 cases from the Prospective International T-Cell Lymphoma Project. 8th Annual Meeting of the Society of Hematologic Oncology (SOHO 2020). Abstract #: TCL-233. Poster Presentation.

6. Radford J, Bartlett N, Straus D, Dlugosz-Danecka M, Alekseev S, Illes A, Lech-Maranda E, Feldman T, Smolewski P, Savage K, Walewski J, Ramchandren R, Zinzani P, Hutchings M, Connors J, Munoz J, Kim W, **Advani R**, Ansell S, Younes A, Gallamini A, Miao H, Liu R, Fenton K, Forero-Torres A, Picardi M. Brentuximab vedotin plus chemotherapy for Stage III/IV classical Hodgkin Lymphoma: 4-year update of the ECHELON-1 study. British Society for Hematology (BSH) 2020 Virtual. Abstract #42139. Poster Presentation.

7. Illidge T, Horwitz S, Iyer S, Bartlett N, Kim W, Belada D, Feldman T, Illes A, Jacobsen E, Huttman A, Zinzani P, O'Connor O, McKay P, Trepicchio W, Miao H, Fenton K, onsum M, Manley T, **Advani R**. Reponse to brentuximab vedotin plus CHP according to CD30 expression in the ECHELON-2 trial. British Society for Hematology (BSH) 2020 Virtual. Abstract #42141. Poster Presentation.

8. Dworkin M, Hiniker S, Von Eyben R, Spinner M, **Advani R**, Lowsky R, Hoppe R. Outcomes of Adult Patients with Lymphoma Treated with Nonmyeloablative Total Lymphoid Irradiation for Stem Cell Transplant (SCT) Conditioning with a Boost to High Risk or Gross Disease. Abstract #3750. 62nd American Society for Radiation Oncology (ASCO) Annual Meeting. Poster Presentation.

9. Bannerji R, Allan J, Arnason J, Brown J, **Advani R**, Ansell S, O'Brien S, Duell J, Martin P, Joyce R, Li J, Flink D, Zhu M, Weinreich D, Yancopoulos G, Sirulnik A, Chaudhry A, Ambati S, Topp M. Odronektamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy. Blood 136 (1) a400, 2020. Oral Presentation.

10. Straus D, Dlugosz-Danecka M, Connors J, Illés A, Picardi M, Lech-Marańda E, Feldman T, Smolewski P, Savage K, Bartlett N, Walewski J, Ramchandren R, Zinzani P, Hutchings M, Munoz J, Kim W, **Advani R**, Ansell S, Younes A, Gallamini A, Liu R, Little M, Fenton K, Fanale M, Radford J. Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study. Blood 136 (1) a2973. Poster Presentation.

11. Orellana-Noia V, Reed D, Sen J, Barlow C, Malecek M, Kahl B, Spinner M, **Advani R**, Voorhees T, Snow A, Grover N, Ayers A, Romancik J, Liu Y, Huntington S, Chavez J, Saeed H, Lazaryan A, Raghunathan V, Spurgeon S, Ollila T, Del Prete C, Olszewski A, Ayers E, Landsburg D, Echalié B, Lee J, Kamdar M, Caimi P, Fu T, Liu J, David K, Alharthy H, Law J, Karmali R, Shah H, Stephens D, Major A, Rojek A, Smith S, Yellala A, Kallam A, Nakhoda S, Khan N, Cohen J, Portell C. CNS Prophylaxis During Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions. *Blood* 136 (1) a478. Oral Presentation.
12. Brouwer-Visser J, Fiaschi N, Deering R, Dhanik A, Cygan K, Zhang W, Jeong S, Pourpe S, Boucher L, Hamon S, Topp M, Bannerji R, Duell J, **Advani R**, Flink D, Chaudhry A, Sirulnik A, Murphy A, Weinreich D, Yancopoulos G, Thurston G, Ambati S, Jankovic V. Baseline Biomarkers of T-Cell Function Correlate with Clinical Responses to Odronextamab (REGN1979), and Loss of CD20 Target Antigen Expression Identified As a Mechanism of Treatment Resistance. *Blood* 136 (1) a2108. Poster Presentation.
13. Rodday A, Parsons S, Scharman C, **Advani R**, Federico M, Friedberg J, Gallamini A, Hodgson D, Hoskin P, Hutchings M, Johnson P, Kelly K, Link B, Radford J, Zinzani P, Cerhan J, Raemaekers J, Evens A. Prognostication for Advanced Stage Hodgkin Lymphoma (HL) in the Modern Era: A Project from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium. *Blood* 36 (1) a2066. Poster Presentation.
14. Horwitz S, O'Connor O, Pro B, Illidge T, Iyer S, **Advani R**, Bartlett N, Christensen J, Morschhauser F, Domingo-Domenech E, Rossi G, Kim W, Feldman T, Menne T, Belada D, Illés A, Tobinai K, Tsukasaki K, Yeh S, Shustov A, Hüttmann A, Savage K, Yuen S, Zinzani P, Miao H, Bunn V, Fenton K, Fanale M, Puhlmann M, Truemper L. The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma. *Blood* 136 (1) a1150. Poster Presentation.
15. Perez G, Hong F, Evens A, Habermann T, **Advani R**, Ansell S, Cheema P, Dy P, O'Brien T, Winter J, Chang J, Cella D, Kahl B, Wagner L. Patient-Reported Outcomes Among Patients with High-Risk Untreated Follicular Lymphoma (FL) Randomized to Bendamustine/Rituximab (BR) or Bendamustine/Rituximab with Bortezomib (BVR) Therapy: Results from the ECOG-ACRIN E2408 Study. *Blood* 136 (1) a2046. Poster Presentation.
16. Marco Picardi, David J. Straus, Monika Długosz-Danecka, Sergey Alekseev Arpad Illes, Ewa Lech-Maranda, Tatyana A. Feldman, Piotr Smolewski, Kerry J. Savage, Jan Walewski, Radhakrishnan Ramchandren, Pier Luigi Zinzani, Martin Hutchings, Joseph M. Connors, John Radford, Javier Munoz, Won-Seong Kim, **Ranjana Advani**, Stephen M. Ansell, Anas Younes, Andrea Gallamini, Harry Miao, Rachel Liu, Keenan Fenton, Andres Forero-Torres, Nancy L. Bartlett. Brentuximab Vedotin with chemotherapy for stage III/IV classical Hodgkin Lymphoma: 4 year update of the ECHELON-1 Study. EHA Library; 293624; EP1135